<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Non‐steroidal anti‐inflammatory drugs for acute low back pain - van der Gaag, WH - 2020 | Cochrane Library</title> <meta content="Non‐steroidal anti‐inflammatory drugs for acute low back pain - van der Gaag, WH - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013581/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Non‐steroidal anti‐inflammatory drugs for acute low back pain - van der Gaag, WH - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013581/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013581" name="dc.identifier" scheme="DOI"/> <meta content="Non‐steroidal anti‐inflammatory drugs for acute low back pain" name="citation_title"/> <meta content="Wendelien H van der Gaag" name="citation_author"/> <meta content="Erasmus Medical Center" name="citation_author_institution"/> <meta content="w.vandergaag@erasmusmc.nl" name="citation_author_email"/> <meta content="Pepijn DDM Roelofs" name="citation_author"/> <meta content="Wendy TM Enthoven" name="citation_author"/> <meta content="Erasmus Medical Center" name="citation_author_institution"/> <meta content="Maurits W van Tulder" name="citation_author"/> <meta content="Bart W Koes" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD013581" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/04/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013581/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013581/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013581/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Pain [*drug therapy]; Anti‐Inflammatory Agents, Non‐Steroidal [adverse effects, *therapeutic use]; Cyclooxygenase 2 Inhibitors [adverse effects, therapeutic use]; Disability Evaluation; Low Back Pain [*drug therapy]; Pain Measurement; Placebos [therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013581&amp;doi=10.1002/14651858.CD013581&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xx9QLps0";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013581\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013581\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013581\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013581\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","zh_HANT","th","pt","ms","hr","fa","fr","pl","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013581",title:"Non\\u2010steroidal anti\\u2010inflammatory drugs for acute low back pain",firstPublishedDate:"Apr 16, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Back and Neck Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013581&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013581';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013581/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013581/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013581%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013581/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013581/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013581/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013581/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013581" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013581/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013581" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013581/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013581/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>20768 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013581" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013581/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013581/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013581/full#CD013581-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013581/full#CD013581-sec-0143"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013581/full#CD013581-sec-0043"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013581/full#CD013581-sec-0044"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013581/full#CD013581-sec-0049"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013581/full#CD013581-sec-0050"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013581/full#CD013581-sec-0074"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013581/full#CD013581-sec-0137"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013581/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013581/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013581/appendices#CD013581-sec-0148"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013581/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013581/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/table_n/CD013581StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/table_n/CD013581StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013581/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013581/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013581/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013581/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013581/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013581/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013581/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Non‐steroidal anti‐inflammatory drugs for acute low back pain</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013581/information#CD013581-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Wendelien H van der Gaag</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013581/information#CD013581-cr-0003">Pepijn DDM Roelofs</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013581/information#CD013581-cr-0004">Wendy TM Enthoven</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013581/information#CD013581-cr-0005">Maurits W van Tulder</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013581/information#CD013581-cr-0006">Bart W Koes</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013581/information/en#CD013581-sec-0159">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 April 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013581/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013581">https://doi.org/10.1002/14651858.CD013581</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013581-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013581-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013581-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013581-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013581-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD013581-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD013581-abs-0005">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013581-abs-0018">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013581-abs-0001" lang="en"> <section id="CD013581-sec-0001"> <h3 class="title" id="CD013581-sec-0001">Background</h3> <p>Acute low back pain (LBP) is a common health problem. Non‐steroidal anti‐inflammatory drugs (NSAIDs) are often used in the treatment of LBP, particularly in people with acute LBP. In 2008, a Cochrane Review was published about the efficacy of NSAIDs for LBP (acute, chronic, and sciatica), identifying a small but significant effect in favour of NSAIDs compared to placebo for short‐term pain reduction and global improvement in participants with acute LBP. This is an update of the previous review, focusing on acute LBP. </p> </section> <section id="CD013581-sec-0002"> <h3 class="title" id="CD013581-sec-0002">Objectives</h3> <p>To assess the effects of NSAIDs compared to placebo and other comparison treatments for acute LBP. </p> </section> <section id="CD013581-sec-0003"> <h3 class="title" id="CD013581-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, PubMed, and two trials registers for randomised controlled trials (RCT) to 7 January 2020. We also screened the reference lists from relevant reviews and included studies. </p> </section> <section id="CD013581-sec-0004"> <h3 class="title" id="CD013581-sec-0004">Selection criteria</h3> <p>We included RCTs that assessed the use of one or more types of NSAIDs compared to placebo (the main comparison) or alternative treatments for acute LBP in adults (≥ 18 years); conducted in both primary and secondary care settings. We assessed the effects of treatment on pain reduction, disability, global improvement, adverse events, and return to work. </p> </section> <section id="CD013581-sec-0005"> <h3 class="title" id="CD013581-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected trials to be included in this review, evaluated the risk of bias, and extracted the data. If appropriate, we performed a meta‐analysis, using a random‐effects model throughout, due to expected variability between studies. We assessed the quality of the evidence using the GRADE approach. We used standard methodological procedures recommended by Cochrane. </p> </section> <section id="CD013581-sec-0006"> <h3 class="title" id="CD013581-sec-0006">Main results</h3> <p>We included 32 trials, with a total of 5356 participants (age range 16 to 78 years). Follow‐up ranged from one day to six months. Studies were conducted across the globe, the majority taking place in Europe and North‐America. Africa and the Eastern Mediterranean region were not represented. We considered seven studies at low risk of bias. Performance and attrition were the most common biases. There was often a lack of information on randomisation procedures and allocation concealment (selection bias); studies were prone to selective reporting bias, since most studies did not register their trials. Almost half of the studies were industry‐funded. </p> <p>There is moderate quality evidence that NSAIDs are slightly more effective in short‐term (≤ 3 weeks) reduction of pain intensity (visual analogue scale (VAS), 0 to 100) than placebo (mean difference (MD) ‐7.29 (95% confidence interval (CI) ‐10.98 to ‐3.61; 4 RCTs, N = 815). There is high quality evidence that NSAIDs are slightly more effective for short‐term improvement in disability (Roland Morris Disability Questionnaire (RMDQ), 0 to 24) than placebo (MD ‐2.02, 95% CI ‐2.89 to ‐1.15; 2 RCTs, N = 471). The magnitude of these effects is small and probably not clinically relevant. There is low quality evidence that NSAIDs are slightly more effective for short‐term global improvement than placebo (risk ratio (RR) 1.40, 95% CI 1.12 to 1.75; 5 RCTs, N = 1201), but there was substantial heterogeneity (I² 52%) between studies. There is very low quality evidence of no clear difference in the proportion of participants experiencing adverse events when using NSAIDs compared to placebo (RR 0.86, 95% CI 0.63 to 1.18; 6 RCTs, N = 1394). There is very low quality evidence of no clear difference between the proportion of participants who could return to work after seven days between those who used NSAIDs and those who used placebo (RR 1.48, 95% CI 0.98 to 2.23; 1 RCT, N = 266). </p> <p>There is low quality evidence of no clear difference in short‐term reduction of pain intensity between those who took selective COX‐2 inhibitor NSAIDs compared to non‐selective NSAIDs (mean change from baseline ‐2.60, 95% CI ‐9.23 to 4.03; 2 RCTs, N = 437). There is moderate quality evidence of conflicting results for short‐term disability improvement between groups (2 RCTs, N = 437). Low quality evidence from one trial (N = 333) reported no clear difference between groups in the proportion of participants experiencing global improvement. There is very low quality evidence of no clear difference in the proportion of participants experiencing adverse events between those who took COX‐2 inhibitors and non‐selective NSAIDs (RR 0.97, 95% CI 0.63 to 1.50; 2 RCTs, N = 444). No data were reported for return to work. </p> </section> <section id="CD013581-sec-0007"> <h3 class="title" id="CD013581-sec-0007">Authors' conclusions</h3> <p>This updated Cochrane Review included 32 trials to evaluate the efficacy of NSAIDs in people with acute LBP. The quality of the evidence ranged from high to very low, thus further research is (very) likely to have an important impact on our confidence in the estimates of effect, and may change the estimates. </p> <p>NSAIDs seemed slightly more effective than placebo for short‐term pain reduction (moderate certainty), disability (high certainty), and global improvement (low certainty), but the magnitude of the effects is small and probably not clinically relevant. </p> <p>There was no clear difference in short‐term pain reduction (low certainty) when comparing selective COX‐2 inhibitors to non‐selective NSAIDs. </p> <p>We found very low evidence of no clear difference in the proportion of participants experiencing adverse events in both the comparison of NSAIDs versus placebo and selective COX‐2 inhibitors versus non‐selective NSAIDs. </p> <p>We were unable to draw conclusions about adverse events and the safety of NSAIDs for longer‐term use, since we only included RCTs with a primary focus on short‐term use of NSAIDs and a short follow‐up. These are not optimal for answering questions about longer‐term or rare adverse events. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013581-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013581-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013581-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013581-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013581-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013581-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013581-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013581-abs-0015">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD013581-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013581-abs-0003">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD013581-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013581-abs-0019">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013581-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013581-abs-0002" lang="en"> <h3>Anti‐inflammatory drugs for acute low back pain</h3> <p><b>Review question</b> </p> <p>We examined the effect of non‐steroidal anti‐inflammatory drugs (NSAIDs), such as diclofenac, ibuprofen, and naproxen, for people with acute low back pain. Acute low back pain is defined as the presence of pain in the back, below the ribs and above the buttocks, for under 12 weeks. We compared NSAIDs to placebo, paracetamol, other NSAIDs, other drugs, and non‐drug treatments. </p> <p><b>Background</b> </p> <p>Acute low back pain is common, and causes pain and disability. Physicians often prescribe NSAIDs to treat acute low back pain. Different types of NSAIDs are available, both over‐the‐counter and as prescription drugs. </p> <p><b>Study characteristics</b> </p> <p>We searched for randomised controlled trials that were published or registered before 7 January 2020. We included 32 trials with 5356 participants. Trial participants were 16 to 78 years old and had acute low back pain. Study length varied from one day to six months. The studies took place in many different countries. More than half of the studies was done in Europe and North‐America. </p> <p><b>Key results</b> </p> <p>NSAIDs were slightly more effective than placebo for pain reduction in the first three weeks. On average, the pain intensity decreased by 7.3 points on a 100‐point scale. This means there was a small difference between the two treatments, but it was not clinically relevant. People receiving NSAIDs also scored 2.0 points better on a 24‐point disability scale than those receiving placebo. This is unlikely to be of real‐world benefit. There was a similar number of side effects between people receiving NSAIDs and people receiving placebo. However, the type of studies that we investigated are not designed to find side effects. Therefore, we should be careful about drawing conclusions based upon these findings. </p> <p>We also compared two different types of NSAIDs; non‐selective NSAIDs versus COX‐2 inhibitors. We found no clear differences in effect. There was also a similar number of reported side effects of the digestive system, such as abdominal pain, nausea, diarrhoea, or stomach symptoms. </p> <p><b>Quality of the evidence</b> </p> <p>There is moderate quality evidence that NSAIDs are slightly more effective than placebo for reducing short‐term pain, and high quality evidence that they are slightly more effective than placebo for reducing disability in acute low back pain. The magnitude of the effect is very small. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013581-sec-0143" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013581-sec-0143"></div> <h3 class="title" id="CD013581-sec-0144">Implications for practice</h3> <section id="CD013581-sec-0144"> <p>For people with acute low back pain (LBP), non‐steroidal anti‐inflammatory drugs (NSAIDs) were found to be slightly better in reducing pain (moderate quality evidence) and disability (high quality evidence) than placebo in the short‐term. However, the magnitude of the effect is small and probably not clinically relevant. There is low quality evidence that there is no clear difference between selective COX‐2 inhibitor NSAIDs and non‐selective NSAIDs in reducing pain in the short‐term. In all cases, potential (gastrointestinal) adverse events should be taken into account. </p> </section> <h3 class="title" id="CD013581-sec-0145">Implications for research</h3> <section id="CD013581-sec-0145"> <p>Almost half of the studies in this review were industry‐sponsored, and often they were relatively old. The quality of the evidence ranged from high to very low. Since acute LBP is a frequent condition and morbidity is high, future research is needed to establish strong, and high‐quality evidence regarding the use of NSAIDs in acute LBP. We encourage researchers to use the previously mentioned preliminary core outcome sets for clinical trials on non‐specific LBP recently developed by an international steering committee, and to report all outcomes that are deemed clinically relevant to acute LBP to improve the comparability of results (<a href="./references#CD013581-bbs2-0100" title="ChiarottoA , BoersM , DeyoRA , BuchbinderR , CorbinTP , CostaLOP , et al. Core outcome measurement instruments for clinical trials in non‐specific low back pain. Pain2018;159(3):481–95. [DOI: 10.1097/j.pain.0000000000001117; PUBMED: 29194127] ">Chiarotto 2018</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013581-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013581-sec-0043"></div> <div class="table" id="CD013581-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">NSAIDs compared to placebo in people with acute low back pain</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>NSAIDs compared to placebo in people with acute low back pain</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (≥ 18 years of age) with acute low back pain<br/> <b>Setting:</b> primary and secondary care settings, mainly general practice and outpatient clinics<br/> <b>Intervention:</b> NSAIDs<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NSAIDs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain intensity</b> </p> <p>VAS (0 to 100; lower = better)</p> <p>Follow<b>‐</b>up: ≤ 3 weeks (range 7 to 15 days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain intensity in the placebo group ranged from 7.9 to 33.9</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain intensity in the NSAID group was</p> <p>7.29 lower (10.98 lower to 3.61 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>815<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MID is 10 points on a 0 to 100 scale</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability</b> </p> <p>RMDQ (0 to 24; lower = better)</p> <p>Follow‐up: ≤ 3 weeks (range 7 to 14 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean disability in the placebo group ranged from 6.0 to 7.3</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean disability in the NSAID group was</p> <p>2.02 lower (2.89 lower to 1.15 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>471<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MID is 2.4 points on a 0 to 24 scale</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of participants experiencing global improvement</b> </p> <p>Various dichotomised Likert scales; lower = better</p> <p>Follow‐up ≤ 3 weeks (range 1 to 15 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.40<br/> (1.12 to 1.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1201<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>367 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>514 per 1000<br/> (412 to 643) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of participants experiencing adverse events</b> </p> <p>Follow‐up range 1 day to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/> (0.63 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1394<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,d,e,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000<br/> (70 to 130) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Return to work</b> (%) </p> <p>Follow‐up: 7 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.48</p> <p>(0.98 to 2.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>266</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>212 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>314 per 1000</p> <p>(208 to 473)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>VAS:</b> visual analogue scale; <b>RMDQ:</b> Roland Morris Disability Questionnaire; <b>RR:</b> risk ratio; <b>RCT</b> : randomised controlled trial; <b>MID</b>: minimal important difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty.</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty.</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty.</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty.</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias. More than 25% of the included participants were from studies with a high risk of bias.<br/> <sup>b</sup>Downgraded one level due to inconsistency. There is moderate to substantial heterogeneity with an I² of 52% and a wide variance in point estimates across studies.<br/> <sup>c</sup>Downgraded one level due to indirectness. Two studies (three treatment arms) included a small percentage of participants with additional sciatic complaints (different population). NSAID tablets, capsules or intramuscular injections were used (different intervention). Treatment time and timing of outcome assessments ranged (differences in outcome), which could make the results less generalisable.<br/> <sup>d</sup>Downgraded one level due to inconsistency. On visual inspection, there is a wide variance in point estimates across studies. Follow‐up duration to measure and report adverse events varied greatly, and was probably too short in a few studies to adequately detect all adverse events.<br/> <sup>e</sup>Downgraded one level due to indirectness. Two studies (three treatment arms) included a small percentage of participants with additional sciatic complaints (different population). Most studies had a relatively short follow‐up time (ranging from 1 day to 2 to 3 weeks), except for one study (follow‐up time 12 weeks). Therefore, it is unclear if the follow‐up time frame was sufficient to measure and report all relevant outcomes regarding adverse events.<br/> <sup>f</sup>Downgraded one level due to imprecision. The total number of events was less than 300.<br/> <sup>g</sup>Downgraded two levels due to imprecision. Only one study was included in the comparison, with a total number of events far less than 300. The 95% CI includes both no effect and the threshold of appreciable benefit. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013581-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Selective COX‐2 inhibitors compared to non‐selective NSAIDs for acute low back pain</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Selective COX‐2 inhibitors compared to non‐selective NSAIDs for acute low back pain</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (≥ 18 years of age) with acute low back pain (LBP)<br/> <b>Setting:</b> primary and secondary care settings, mainly general practice and outpatient clinics<br/> <b>Intervention:</b> selective COX‐2 inhibitors<br/> <b>Comparison:</b> non‐selective NSAIDs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with non‐selective NSAIDs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with COX‐2 inhibitors</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in pain intensity from baseline</b> </p> <p>VAS (0 to 100; lower = better)</p> <p>Follow‐up ≤ 3 weeks (range 7 to 10 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in pain intensity from baseline in the non‐selective NSAID group ranged from 38 to 41 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in pain intensity from baseline in the COX‐2 inhibitors group was 2.60 lower (9.23 lower to 4.03 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>437<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MID is 10 points on a 0 to 100 scale</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability</b> </p> <p>ODI (0 to 50; lower = better)</p> <p>Follow‐up ≤ 3 weeks (range 7 to 10 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>One trial reported a mean difference in disability score of ‐7.00 (95% CI ‐13.15 to ‐0.85) after 10 days, showing a statistically significant and clinically relevant difference in favour of the nimesulide arm. </p> <p>One trial reported a mean decrease in baseline disability of 32% in both the valdecoxib and diclofenac arm at 1 week follow‐up, showing no clear difference between study arms. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>437<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MID is 5 points on a 0 to 50 scale</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants experiencing global improvement</b> </p> <p>% of dichotomized Likert scale</p> <p>Follow‐up ≤ 3 weeks (7 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>One trial reported the percentage of participants who reported their pain relief as 'a lot better' or 'completely better' at 1 week follow‐up, which was similar in both the valdecoxib (80%) and diclofenac (81%) arm, showing no clear difference between study arms. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>333</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of participants experiencing adverse events</b> </p> <p>Follow‐up range 10 to 37 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.63 to 1.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>444<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>248 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>240 per 1000<br/> (156 to 372) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Return to work</b> (%) </p> <p>Follow‐up: N/A</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>VAS:</b> visual analogue scale; <b>ODI:</b> Oswestry Disability Index; <b>RR:</b> risk ratio; <b>RCT</b> : randomised controlled trial; <b>N/A</b> : not available; <b>MID</b>: minimal important difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty.</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty.</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty.</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty.</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias. More than 25% of the included participants were from a study with high risk of bias.<br/> <sup>b</sup>Downgraded one level due to inconsistency. There is moderate to substantial heterogeneity with an I² of 57%, and a wide variance in point estimates.<br/> <sup>c</sup>Downgraded one level due to imprecision. The total number of events was far less than 300, leading to a wide confidence interval. <br/> <sup>d</sup>Downgraded two levels due to imprecision. The total number of events was far less than 300, leading to a wide confidence interval. The 95% confidence interval includes both no effect and the threshold of appreciable benefit or harm. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013581-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013581-sec-0044"></div> <section id="CD013581-sec-0045"> <h3 class="title" id="CD013581-sec-0045">Description of the condition</h3> <p>Low back pain (LBP) is one of the most prevalent health problems worldwide, and still one of the leading causes of years lived with disability, according to the most recently published global burden of disease study (<a href="./references#CD013581-bbs2-0106" title="GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet2017;390(10100):1211‐59. [DOI: 10.1016/S0140‐6736(17)32154‐2] ">GBD 2016</a>). It is usually defined as pain, muscle tension, or stiffness localised below the costal margin and above the inferior gluteal folds (<a href="./references#CD013581-bbs2-0114" title="KoesBW , vanTulderMW , ThomasS . Diagnosis and treatment of low back pain. BMJ 2006 June 17;332(7555):1430‐4. [DOI: 10.1136/bmj.332.7555.1430; PUBMED: 16777886] ">Koes 2006</a>). The lifetime prevalence of non‐specific LBP is estimated at 60% to 70% in industrialised countries (<a href="./references#CD013581-bbs2-0112" title="HoyD , BrooksP , BlythF , BuchbinderR . The epidemiology of low back pain. Best Practice &amp; Research Clinical Rheumatology2010;24:769‐81. [DOI: 10.1016/j.berh.2010.10.002] ">Hoy 2010</a>). This affects personal lives, causing activity limitations and work absence, but also brings with it an economic burden, with high socioeconomic costs (<a href="./references#CD013581-bbs2-0112" title="HoyD , BrooksP , BlythF , BuchbinderR . The epidemiology of low back pain. Best Practice &amp; Research Clinical Rheumatology2010;24:769‐81. [DOI: 10.1016/j.berh.2010.10.002] ">Hoy 2010</a>; <a href="./references#CD013581-bbs2-0116" title="LidgrenL . The bone and joint decade 2000‐2010. Bulletin of the World Health Organization2003;81(9):629. [PUBMED: PMC2572548] ">Lidgren 2003</a>); especially when a chronic state of LBP develops (<a href="./references#CD013581-bbs2-0131" title="SteenstraIA , VerbeekJH , HeymansWM , BongersPM . Prognostic factors for duration of sick leave in patients sick listed with acute low back pain: a systematic review of the literature. Occupational and Environmental Medicine2005;62:851‐60. [DOI: 10.1136/oem.2004.015842] ">Steenstra 2005</a>). In the first six weeks, recovery occurs in a substantial number of participants. However, there is increasing debate about the numbers of recurrent pain episodes and chronicity, since participants continue to report pain after one year (<a href="./references#CD013581-bbs2-0102" title="Costa daLCM , MaherCG , Hancock , MJ , McAuleyJH , HerbertRD , CostaLOP . The prognosis of acute and persistent low‐back pain: a meta‐analysis. Canadian Medical Association Journal2012;184(11):E613‐2. [DOI: 10.1503/cmaj.111271] ">Costa 2012</a>; <a href="./references#CD013581-bbs2-0113" title="ItzCJ , GeurtsJW , vanKleefM , NelemansP . Clinical course of non‐specific low back pain: a systematic review of prospective cohort studies set in primary care.. European Journal of Pain (London, England)2013 Jan;17(1):5‐15. [PUBMED: 22641374] ">Itz 2013</a>; <a href="./references#CD013581-bbs2-0119" title="ManchikantiL , SinghV , FalcoFJE , RamsinM , BenyaminMD , HirschJA . Epidemiology of low back pain in adults. Neuromodulation: Technology at the Neural Interface2014;17(52):3‐10. [DOI: 10.1111/ner.12018] ">Manchikanti 2014</a>; <a href="./references#CD013581-bbs2-0123" title="PengelLH , HerbertRD , MaherCG , RefshaugeKM . Acute low back pain: systematic review of its prognosis. BMJ 2003 Aug 9;327(7410):323. [DOI: 10.1136/bmj.327.7410.323; PUBMED: 12907487] ">Pengel 2003</a>). Current guidelines on the treatment of non‐specific LBP are consistent in their focus on early and gradual activation, patient education, avoiding bedrest, and addressing psychosocial factors to prevent chronicity; and on prescribing analgesic medication for short periods, where necessary, in the case of acute LBP (<a href="./references#CD013581-bbs2-0121" title="OliveiraCB , MaherCG , PintoRZ , TraegerAC , LinCC , ChenotJF , et al. Clinical practice guidelines for the management of non‐specific low back pain in primary care: an updated overview. European Spine Journal2018 Nov;27(11):2791‐2803. [DOI: 10.1007/s00586‐018‐5673‐2] ">Oliveira 2018</a>). </p> </section> <section id="CD013581-sec-0046"> <h3 class="title" id="CD013581-sec-0046">Description of the intervention</h3> <p>As stated above, most guidelines recommend staying active. Better pain control may ease this process, therefore, the use of non‐steroidal anti‐inflammatory drugs (NSAIDs) can be of value. If pain medication is considered, NSAIDs are recommended (<a href="./references#CD013581-bbs2-0121" title="OliveiraCB , MaherCG , PintoRZ , TraegerAC , LinCC , ChenotJF , et al. Clinical practice guidelines for the management of non‐specific low back pain in primary care: an updated overview. European Spine Journal2018 Nov;27(11):2791‐2803. [DOI: 10.1007/s00586‐018‐5673‐2] ">Oliveira 2018</a>). Previously, guidelines recommended various types of analgesics (<a href="./references#CD013581-bbs2-0115" title="KoesBW , vanTulderMW , LinCW , MacedoLG , McAuleyJ , MaherC . An updated overview of clinical guidelines for the management of non‐specific low back pain in primary care. European Spine Journal2010 Dec;19(12):2075‐94. ">Koes 2010</a>). Recently, an updated review on paracetamol for LBP found high‐quality evidence that paracetamol (4 g per day) is no better than placebo for relieving acute LBP (<a href="./references#CD013581-bbs2-0128" title="SaragiottoBT , MachadoGC , Ferreira ML. PinheiroMB , Abdel ShaheedC , MaherCG . Paracetamol for low back pain. Cochrane Database of Systematic Reviews2016, Issue 6. [DOI: 10.1002/14651858.CD012230] ">Saragiotto 2016</a>). In some adapted guidelines, this new evidence is already incorporated, for instance, the National Institute for Health and Care Excellence (NICE) guidelines from the UK (<a href="./references#CD013581-bbs2-0097" title="BernsteinIA , MalikQ , CarvilleS , WardS . Low back pain and sciatica: summary of NICE guidance. BMJ2017;356:i6748. [DOI: 10.1136/bmj.i6748] ">Bernstein 2017</a>). The most recent guidelines from the USA recommend non‐pharmacological treatments first, given that most people with (sub)acute LBP improve over time, regardless of treatment. But if pharmacological treatment is considered, then NSAIDs or muscle relaxants are recommended as first line options (<a href="./references#CD013581-bbs2-0125" title="QaseemA , WiltTJ , McLeanRM , ForcieaMA . Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine2017;166:514‐30. [DOI: 10.7326/M16‐2367] ">Qaseem 2017</a>). In such circumstances, NSAIDs are often recommended because of their known analgesic and anti‐inflammatory effects. However, the drawback is that they are also associated with a variety of potential adverse events, particularly gastrointestinal and cardiovascular effects (<a href="./references#CD013581-bbs2-0099" title="BruneK , PatrignaniP . New insights into the use of currently available non‐steroidal anti‐inflammatory drugs. Journal of Pain Research2015;8:105‐18. [DOI: 10.2147/JPR.S75160] ">Brune 2015</a>). </p> </section> <section id="CD013581-sec-0047"> <h3 class="title" id="CD013581-sec-0047">How the intervention might work</h3> <p>The main therapeutic effects of NSAIDs derive from their ability to inhibit the production of prostaglandins. The first enzyme in the pathway of prostaglandin synthesis is cyclooxygenase (COX). Both COX‐1 and COX‐2 contribute to the production of prostaglandins when inflammation and pain are present, and for autoregulation and homeostasis of the human body. COX‐1 is the dominant source for the production of prostaglandins that are responsible for gastric epithelial protection and haemostasis. COX‐2 is important for prostaglandin synthesis induced by cytokines and stress. NSAIDs inhibit the COX enzyme, and thus block the synthesis of prostaglandins, reducing inflammation, pain, and fever (<a href="./references#CD013581-bbs2-0109" title="GrosserT , SmythE , FitzGeraldGA . Anti‐inflammatory, antipyretic, and analgesic agents; pharmacology of gout. In: BruntonLL , ChabnerBA , KnollmanBC editor(s). Goodman &amp; Gilman's Pharmacological Basis of Therapeutics. 12th Edition. New York: McGraw‐Hill, 2011:962‐77. ">Grosser 2011</a>). Two types of NSAIDs are available: non‐selective NSAIDs that inhibit both COX‐1 and COX‐2 enzymes (e.g. ibuprofen, diclofenac, naproxen); and selective COX‐2 inhibitors that only inhibit the COX‐2 enzyme (e.g. nimesulide, celecoxib). The latter was developed because non‐selective NSAIDs were often associated with gastrointestinal adverse events. Blocking COX‐1 also reduced gastric protection, leading to an increased risk for gastrointestinal complications (e.g. gastric ulcer, perforation, stomach bleeding (<a href="./references#CD013581-bbs2-0130" title="SostresC , GargalloCJ , LanasA . Nonsteroidal anti‐inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Research &amp; Therapy 2013 Jul 24 [Epub ahead of print];15(Suppl 3):S3. [DOI: 10.1186/ar4175; PUBMED: 24267289] ">Sostres 2013</a>)). Selective COX‐2 inhibitors decrease this risk, however they increase the risk for cardiovascular adverse events. For instance, rofecoxib, a selective COX‐2 inhibitor, was withdrawn from the market for this reason. Similar concerns arose around the cardiovascular safety of traditional NSAIDs (<a href="./references#CD013581-bbs2-0101" title="BhalaN , EmbersonJ , MerhiA , AbramsonS , ArberN , BaronJA , et al. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non‐steroidal anti‐inflammatory drugs: meta‐analyses of individual participant data from randomised trials. Lancet2013 Aug;382(9894):769‐79. [DOI: 10.1016/S0140‐6736(13)60900‐9; PUBMED: 23726390] ">CNT Collaboration 2013</a>; <a href="./references#CD013581-bbs2-0132" title="Trelle S , ReichenbachS , WandelS , HildebrandP , TschannenB , VilligerPM , et al. Cardiovascular safety of non‐steroidal anti‐inflammatory drugs: network meta‐analysis. BMJ2011 Jan;342:c7086. [DOI: 10.1136/bmj.c7086; PUBMED: 21224324] ">Trelle 2011</a>; <a href="./references#CD013581-bbs2-0134" title="WalkerC , BiasucciLM . Cardiovascular safety of non‐steroidal anti‐inflammatory drugs revisited. Postgraduate Medicine2018;130(1):55‐71. [DOI: 101.1080/00325481.2018.1412799] ">Walker 2018</a>). There is evidence that this risk is duration‐ and dose‐dependent (<a href="./references#CD013581-bbs2-0124" title="PepineCJ , GurbelPA . Cardiovascular safety of NSAIDs: additional insights after PRECISION and point of view. Clinical Cardiology2017 Dec;40(12):1352‐6. [DOI: 10.1002/clc.22814; PUBMED: 29247518] ">Pepine 2017</a>). Therefore, whenever NSAIDs are prescribed, one should always take into account the risk for gastrointestinal or cardiovascular adverse events (<a href="./references#CD013581-bbs2-0099" title="BruneK , PatrignaniP . New insights into the use of currently available non‐steroidal anti‐inflammatory drugs. Journal of Pain Research2015;8:105‐18. [DOI: 10.2147/JPR.S75160] ">Brune 2015</a>; <a href="./references#CD013581-bbs2-0134" title="WalkerC , BiasucciLM . Cardiovascular safety of non‐steroidal anti‐inflammatory drugs revisited. Postgraduate Medicine2018;130(1):55‐71. [DOI: 101.1080/00325481.2018.1412799] ">Walker 2018</a>), and if possible, choose the shortest duration and lowest effective doses (<a href="./references#CD013581-bbs2-0124" title="PepineCJ , GurbelPA . Cardiovascular safety of NSAIDs: additional insights after PRECISION and point of view. Clinical Cardiology2017 Dec;40(12):1352‐6. [DOI: 10.1002/clc.22814; PUBMED: 29247518] ">Pepine 2017</a>). NSAIDs vary in their degree of COX‐2 selectivity. The choice of the best fitting NSAID further depends on patient characteristics, their medical history, and the type of complaint. </p> </section> <section id="CD013581-sec-0048"> <h3 class="title" id="CD013581-sec-0048">Why it is important to do this review</h3> <p>This Cochrane Review is part of a series on the effect of NSAIDs for LBP, and is an update of a Cochrane Review first published in 2000 (<a href="./references#CD013581-bbs2-0136" title="vanTulderMW , ScholtenRJ , KoesBW , DeyoRA . Non‐steroidal anti‐inflammatory drugs for low back pain. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD000396; CD000396; PUBMED: PMID: 10796356] ">van Tulder 2000</a>). The previous update included 65 randomised controlled trials on acute LBP, chronic LBP, and sciatica (<a href="./references#CD013581-bbs2-0135" title="RoelofsPDDM , DeyoRA , KoesBW , ScholtenRJPM , vanTulderMW . Non‐steroidal anti‐inflammatory drugs for low back pain. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD000396.pub3] ">Roelofs 2008</a>). Due to the high number of trials, we split the review into three separate Cochrane Reviews on the use of NSAIDs for different types of LBP. The response to NSAIDs may differ for acute LBP, compared to chronic LBP or sciatica. The reviews on chronic LBP (<a href="./references#CD013581-bbs2-0104" title="EnthovenWTM , RoelofsPDDM , DeyoRA , vanTulderMW , KoesBW . Non‐steroidal anti‐inflammatory drugs for chronic low back pain. Cochrane Database of Systematic Reviews2016, Issue 2. [DOI: 10.1002/14651858.CD012087] ">Enthoven 2016</a>), and sciatica (<a href="./references#CD013581-bbs2-0126" title="Rasmussen‐BarrE , HeldU , GrootenWJA , RoelofsPDDM , KoesBW , vanTulderMW , et al. Non‐steroidal anti‐inflammatory drugs for sciatica. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD012382] ">Rasmussen‐Barr 2016</a>), have been published. This review focuses on the efficacy of NSAIDs for acute LBP. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013581-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013581-sec-0049"></div> <p>To assess the effects of non‐steroidal anti‐inflammatory drugs compared to placebo and other comparison treatments for acute low back pain. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013581-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013581-sec-0050"></div> <section id="CD013581-sec-0051"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013581-sec-0052"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials, conducted in both primary and secondary care settings. The original protocol of this review included only English, German, and Dutch studies. The present update had no language restrictions. </p> </section> <section id="CD013581-sec-0053"> <h4 class="title">Types of participants</h4> <p>We included subjects aged 18 years or older, treated for acute non‐specific low back pain (LBP). We defined LBP as pain below the costal margin and above the inferior gluteal folds. Acute LBP was defined as having LBP symptoms for less than 12 weeks. Within acute LBP, we included both acute (less than six weeks) and subacute LBP (6 to 12 weeks). If the study authors did not describe the duration of LBP, but LBP was labelled as acute, we also included the study. If a study included mixed populations (like acute or subacute and chronic LBP), we only included the study if they presented data for acute LBP separately. If a minor part of the study population (&lt; 10%) experienced pain radiating to one or both legs to the knee, or a flare‐up (acute exacerbations of chronic LBP), we included the study and performed a sensitivity analysis at a later stage, if applicable. We excluded studies on subjects with chronic LBP, flare‐ups, or sciatica, as well as studies that included participants with LBP caused by specific pathological entities, such as infection, neoplasm, metastasis, osteoporosis, rheumatoid arthritis, or fractures. </p> </section> <section id="CD013581-sec-0054"> <h4 class="title">Types of interventions</h4> <p>We included trials that assessed one or more types of non‐steroidal anti‐inflammatory drugs (NSAID). Additional interventions were allowed if there was a contrast for NSAIDs in the trial. For example, studies comparing NSAIDs plus muscle relaxants versus muscle relaxants alone would be included, while studies comparing NSAIDs plus muscle relaxants versus NSAIDs alone were not. We also excluded studies if they combined NSAIDs with other drugs, making it difficult to distinguish the actual effect of the NSAID, e.g. a study comparing NSAIDs plus muscle relaxants versus paracetamol would be excluded. We included studies that compared NSAIDs to another type of NSAID. We excluded a study if it compared an NSAID to the same NSAID with the mode of delivery as the only difference, or if different NSAIDs were used in the same group, and no distinction was made in the analysis. </p> <p>We clustered comparisons of NSAIDs versus reference treatments into the following categories: </p> <p> <ul id="CD013581-list-0001"> <li> <p>NSAIDs versus placebo (the main comparison)</p> </li> <li> <p>Selective COX‐2 inhibitors versus non‐selective NSAIDs</p> </li> <li> <p>NSAIDs versus paracetamol</p> </li> <li> <p>NSAIDs versus other drug treatment</p> </li> <li> <p>NSAIDs versus non‐drug treatment</p> </li> </ul> </p> <p>The NSAID arm could include both selective and non‐selective NSAIDs, except for the comparison of selective COX‐2 inhibitors versus non‐selective NSAIDs, where this was specified. </p> </section> <section id="CD013581-sec-0055"> <h4 class="title">Types of outcome measures</h4> <p>As outcome measures, we used the four primary outcomes that were already defined in the protocol and previous version of the Cochrane review (<a href="./references#CD013581-bbs2-0135" title="RoelofsPDDM , DeyoRA , KoesBW , ScholtenRJPM , vanTulderMW . Non‐steroidal anti‐inflammatory drugs for low back pain. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD000396.pub3] ">Roelofs 2008</a>). We added adverse events as a fifth primary outcome. These outcomes are described below. We set the minimal duration of follow‐up at one day, with at least one outcome measured in the first three weeks. We divided the timing of outcome assessment into two main categories: </p> <p>1) Short‐term follow‐up: ranging from one day to three weeks. If there were more outcome assessments around this time point, we used the strategy of including outcomes closest to three weeks. </p> <p>2) Long‐term follow‐up: ranging from longer than three and up to 12 weeks. If there were more outcome assessments around this time point, we used the strategy of including outcomes closest to twelve weeks. </p> <section id="CD013581-sec-0056"> <h5 class="title">Primary outcomes</h5> <p>Primary outcome measures were:</p> <p>1) pain intensity (e.g. Visual Analogue Scale (VAS) or Numerical Rating Scale (NRS))</p> <p>2) back pain‐specific functional status (e.g. Roland Morris Disability Questionnaire (RMDQ), Oswestry Disability Index (ODI)) </p> <p>3) global measure (e.g. overall improvement, proportion of participants recovered)</p> <p>4) adverse events (proportion of participants experiencing adverse events)</p> <p>5) return to work (e.g. return to work status, number of days off work)</p> <p>We evaluated pain intensity and disability as continuous outcomes. We considered a between‐group difference of more than 10% of the scale (e.g. 10 points on a 0 to 100 scale) to be clinically relevant. A mean difference smaller than this was considered not clinically relevant. For the global measure of improvement, we used dichotomous outcomes; if there were categories in range of improvement, we counted categories such as 'almost recovered' and 'completely recovered', 'good' and 'very good or excellent', and 'a lot' to 'complete recovery' responses as recovered. For adverse events and return to work, we used dichotomous outcomes, usually proportion of participants. </p> </section> <section id="CD013581-sec-0057"> <h5 class="title">Secondary outcomes</h5> <p>There were no secondary outcomes.</p> </section> </section> </section> <section id="CD013581-sec-0058"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013581-sec-0059"> <h4 class="title">Electronic searches</h4> <p>We identified RCTs that met our inclusion criteria by searching the following databases, with no language restrictions, to 7 January 2020: </p> <p> <ul id="CD013581-list-0002"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL, 2020, Issue 1) in the Cochrane Library; includes the Back and Neck Group Trials Register; CRS Web (searched 7 January 2020); </p> </li> <li> <p>MEDLINE Ovid Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE(R) Daily and MEDLINE(R) (1946 to 7 January 2020); </p> </li> <li> <p>Embase (1980 to 2020 Week 01);</p> </li> <li> <p><a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">PubMed</a> (1946 to January 2016); </p> </li> <li> <p><a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> (searched 7 January 2020); </p> </li> <li> <p><a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a> (searched 7 January 2020). </p> </li> </ul> </p> <p>We conducted searches in May 2012 (for publications between June 2007 and May 2012), and repeated them annually until January 2020. Search strategies are presented in <a href="./appendices#CD013581-sec-0149">Appendix 1</a>, <a href="./appendices#CD013581-sec-0150">Appendix 2</a>, <a href="./appendices#CD013581-sec-0151">Appendix 3</a>, <a href="./appendices#CD013581-sec-0152">Appendix 4</a>. We searched PubMed in 2015 and 2016 for studies not in MEDLINE, using the strategy recommended by <a href="https://archie.cochrane.org/sections/documents/view?document=z1306101836064269684285014955473%26format=REVMAN#REF-Duffy-2014" target="_blank">Duffy 2014</a>. We began searching MEDLINE Ovid (Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE(R) Daily, and MEDLINE(R)) in 2017 because it allowed us to search several MEDLINE databases in one search. In 2017, we began searching CENTRAL and the Cochrane Back and Neck (CBN) Group Trials Register in CRS Web; previously they were searched in CRS standalone. An experienced information specialist developed the strategies following the updated methods guideline of the CBN and the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (the <i>Handbook</i> (<a href="./references#CD013581-bbs2-0105" title="FurlanAD , MalmivaaraA , ChouR , MaherCG , DeyoRA , SchoeneM , et al. Editorial Board of the Cochrane Back and Neck Group. 2015 Updated method guideline for systematic reviews in the Cochrane Back and Neck Group. Spine2015;40(21):1660‐73. [DOI: 10.1097/BRS.0000000000001061; PUBMED: 26208232] ">Furlan 2015</a>; <a href="./references#CD013581-bbs2-0111" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>)). </p> </section> <section id="CD013581-sec-0060"> <h4 class="title">Searching other resources</h4> <p>We screened the reference lists of all included trials, as well as (systematic) reviews on NSAIDs for acute LBP. We also reassessed the studies on acute low back pain included in the previous version of this review (<a href="./references#CD013581-bbs2-0135" title="RoelofsPDDM , DeyoRA , KoesBW , ScholtenRJPM , vanTulderMW . Non‐steroidal anti‐inflammatory drugs for low back pain. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD000396.pub3] ">Roelofs 2008</a>). </p> </section> </section> <section id="CD013581-sec-0061"> <h3 class="title" id="CD013581-sec-0061">Data collection and analysis</h3> <section id="CD013581-sec-0062"> <h4 class="title">Selection of studies</h4> <p>Two review authors (BK and PR, PR and WG, or WG and WE) independently screened all search results. We excluded clearly ineligible studies based on title and abstract. We retrieved full‐text articles for all remaining studies, and two review authors independently conducted the screening for inclusion. We resolved disagreements via consensus, and consulted a third review author (WG, WE or PR) in case of uncertainty, or if disagreements persisted. </p> </section> <section id="CD013581-sec-0063"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (WG and PR) independently extracted the data using a standardized data extraction form provided by the CBN. We extracted data on: </p> <p> <ul id="CD013581-list-0003"> <li> <p>study characteristics: type of study and randomisation, population, setting, description of interventions, and reference treatments, follow‐up time, trial registration, funding </p> </li> <li> <p>characteristics of participants: number of participants, gender, mean age, duration of current symptoms, inclusion and exclusion criteria </p> </li> <li> <p>primary outcomes and any relevant additional information</p> </li> </ul> </p> <p>We extracted follow‐up data at several time points, and defined an outcome assessment as relevant if it was measured between one day and 12 weeks of follow‐up. We contacted corresponding authors for further information if potentially relevant information was missing or not available, for data extraction due to a different format. We resolved any disagreement through consensus. </p> </section> <section id="CD013581-sec-0064"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (WG and WE, or WG and PR) independently assessed the risk of bias of the included studies using a stepwise approach. First, we used the thirteen criteria recommended by <a href="./references#CD013581-bbs2-0105" title="FurlanAD , MalmivaaraA , ChouR , MaherCG , DeyoRA , SchoeneM , et al. Editorial Board of the Cochrane Back and Neck Group. 2015 Updated method guideline for systematic reviews in the Cochrane Back and Neck Group. Spine2015;40(21):1660‐73. [DOI: 10.1097/BRS.0000000000001061; PUBMED: 26208232] ">Furlan 2015</a>, described in <a href="#CD013581-tbl-0003">Table 1</a> and <a href="#CD013581-tbl-0004">Table 2</a>. Since this review evaluated the efficacy of specific medication for acute LBP, namely NSAIDs, we added an additional criterion concerning funding or sponsorship. We separately scored these fourteen criteria as yes, no, or unsure, and reported these in the 'Risk of bias' tables, including the rationale for our decision. In cases of unsure judgement of the risk of bias, we attempted to contact corresponding authors of newly included trials for extra information. We did not contact authors of previously included trials, since earlier attempts to contact these authors for the previous version of this review were unsuccessful. </p> <div class="table" id="CD013581-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sources of risk of bias</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias domain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Source of Bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Possible answers</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) Was the method of randomisation adequate?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2) Was the treatment allocation concealed?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(3) Was the participant blinded to the intervention?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(4) Was the careprovider blinded to the intervention?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Detection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(5) Was the outcome assessor blinded to the intervention?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Attrition</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(6) Was the dropout rate described and acceptable?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Attrition</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(7) Were all randomised participants analysed in the group<br/> to which they were allocated? </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reporting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(8) Are reports of the study free of suggestion of selective<br/> outcome reporting? </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(9) Were the groups similar at baseline regarding the most<br/> important prognostic indicators? </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(10) Were co‐interventions avoided or similar?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(11) Was the compliance acceptable in all groups?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Detection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(12) Was the timing of the outcome assessment similar in<br/> all groups? </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(13) Are other sources of potential bias unlikely?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><a href="./references#CD013581-bbs2-0105" title="FurlanAD , MalmivaaraA , ChouR , MaherCG , DeyoRA , SchoeneM , et al. Editorial Board of the Cochrane Back and Neck Group. 2015 Updated method guideline for systematic reviews in the Cochrane Back and Neck Group. Spine2015;40(21):1660‐73. [DOI: 10.1097/BRS.0000000000001061; PUBMED: 26208232] ">Furlan 2015</a> </p> </div> </div> <div class="table" id="CD013581-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Criteria for a judgement of 'yes' for the sources of risk of bias</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A random (unpredictable) assignment sequence. Examples of adequate methods are coin toss (for studies with 2 groups), rolling a dice (for studies with 2 or more groups), drawing of balls of different colours, drawing of ballots with the study group labels from a dark bag, computer‐generated random sequence, pre‐ordered sealed envelopes, sequentially‐ordered vials, telephone call to a central office, and preordered list of treatment assignments. </p> <p>Examples of inadequate methods are: alternation, birth date, social insurance or social security number, date in which they are invited to participate in the study, and hospital registration number. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assignment generated by an independent person not responsible for determining the eligibility of the participants. This person has no information about the persons included in the trial and has no influence on the assignment sequence or on the decision about eligibility of the participant. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index and control groups are indistinguishable for the participants, or if the success of blinding was tested among the participants and it was successful. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index and control groups are indistinguishable for the careproviders, or if the success of blinding was tested among the careproviders and it was successful. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequacy of blinding should be assessed for each primary outcome separately. This item should be scored 'yes' if the success of blinding was tested among the outcome assessors and it was successful or:<br/> • for participant‐reported outcomes in which the participant is the outcome assessor (e.g. pain, disability): the blinding procedure is adequate for outcome assessors if participant blinding is scored 'yes' </p> <p>• for outcome criteria assessed during scheduled visit and that supposes a contact between participants and outcome assessors (e.g. clinical examination): the blinding procedure is adequate if participants are blinded, and the treatment or adverse effects of the treatment cannot be noticed during clinical examination<br/> • for outcome criteria that do not suppose a contact with participants (e.g. radiography, magnetic resonance imaging): the blinding procedure is adequate if the treatment or adverse effects of the treatment cannot be noticed when assessing the main outcome </p> <p>• for outcome criteria that are clinical or therapeutic events that will be determined by the interaction between participants and careproviders (e.g. co‐interventions, hospitalisation length, treatment failure), in which the careprovider is the outcome assessor: the blinding procedure is adequate for outcome assessors if item '4' (caregivers) is scored 'yes'<br/> • for outcome criteria that are assessed from data from the medical forms: the blinding procedure is adequate if the treatment or adverse effects of the treatment cannot be noticed on the extracted data </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The number of participants who were included in the study but did not complete the observation period or were not included in the analysis must be described and reasons given. If the percentage of withdrawals and dropouts does not exceed 20% for short‐term follow‐up and 30% for long‐term follow‐up, and does not lead to substantial bias, a 'yes' is scored. (N.B. these percentages are arbitrary, not supported by literature). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All randomised participants are reported and analysed in the group to which they were allocated by randomisation for the most important moments of effect measurement (minus missing values) irrespective of non‐compliance and co‐interventions. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All the results from all prespecified outcomes have been adequately reported in the published report of the trial. This information is either obtained by comparing the protocol and the report, or in the absence of a protocol, by assessing that the published report includes enough information to make this judgement. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Groups have to be similar at baseline regarding demographic factors, duration and severity of complaints, percentage of participants with neurological symptoms, and value of main outcome measure(s). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If there were no co‐interventions, or if they were similar between the index and control groups. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The review author determines if the compliance with the interventions is acceptable, based on the reported intensity, duration, number, and frequency of sessions for both the index intervention and control intervention(s). For example, physiotherapy treatment is usually administered for several sessions; therefore, it is necessary to assess how many sessions each participant attended. For single‐session interventions (e.g. surgery), this item is irrelevant. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Timing of outcome assessment should be identical for all intervention groups and for all primary outcome measures. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other types of biases. For example:<br/> • When the outcome measures were not valid. There should be evidence from a previous or present scientific study that the primary outcome can be considered valid in the context of the present. </p> <p>• Industry‐sponsored trials. The conflict of interest (COI) statement should explicitly state that the researchers have had full possession of the trial process from planning to reporting without funders with potential COI having any possibility to interfere in the process. If, for example, the statistical analyses have been done by a funder with a potential COI, usually 'unsure' is scored. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Published by <a href="./references#CD013581-bbs2-0105" title="FurlanAD , MalmivaaraA , ChouR , MaherCG , DeyoRA , SchoeneM , et al. Editorial Board of the Cochrane Back and Neck Group. 2015 Updated method guideline for systematic reviews in the Cochrane Back and Neck Group. Spine2015;40(21):1660‐73. [DOI: 10.1097/BRS.0000000000001061; PUBMED: 26208232] ">Furlan 2015</a>; these instructions were adapted from <a href="./references#CD013581-bbs2-0133" title="vanTulderM , FurlanA , BombardierC , BouterL . Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine2003;28(12):1290‐9. ">van Tulder 2003</a>, <a href="./references#CD013581-bbs2-0098" title="BoutronI , MoherD , TugwellP , GiraudeauB , PoiraudeauS , NizardR , et al. A checklist to evaluate a report of a non pharmacological trial (CLEAR NPT) was developed using consensus. Journal of Clinical Epidemiology2005;58:1233‐40. ">Boutron 2005</a>, and the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013581-bbs2-0111" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </div> </div> <p>Each of these fourteen criteria corresponds to a specific type of bias at the domain level. Therefore, as a second step, we assessed the risk of bias at domain level: selection bias (criteria 1, 2, 9), performance bias (criteria 3, 4, 10, 11), detection (or measurement) bias (criteria 5, 12), attrition bias (criteria 6, 7), reporting bias (criteria 8), and other (potential) biases (criteria 13, 14). We resolved disagreements by consensus, and consulted a third review author (PR or WE) if disagreements persisted. </p> </section> <section id="CD013581-sec-0065"> <h4 class="title">Measures of treatment effect</h4> <p>Following the recommendations in the <i>Handbook</i> (<a href="./references#CD013581-bbs2-0111" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), we analysed dichotomous outcomes by calculating the risk ratio (RR). We analysed continuous outcomes by calculating the mean difference (MD) when the same instrument was used to measure outcomes, or the standardized mean difference (SMD) when different instruments were used. We expressed the uncertainty with 95% confidence intervals (CI). </p> </section> <section id="CD013581-sec-0066"> <h4 class="title">Unit of analysis issues</h4> <p>We included cross‐over trials if the data from the first phase (until the cross‐over) were available, to aid comparability. Cluster‐randomized trials were analysed based on the level of allocation, for example, a cluster of participants. </p> <p>Some of the included studies had more than two study arms. To avoid unit of analysis error, we split the control group to prevent overestimation of the number of participants for the same intervention. For example, in the <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a> and <a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a> studies, we divided the placebo group into two subgroups, by dividing the number of events and number of cases by two for dichotomous outcomes, or by dividing the sample size by two, and assuming similar mean and standard deviations reported for continuous outcomes in both subgroups. </p> </section> <section id="CD013581-sec-0067"> <h4 class="title">Dealing with missing data</h4> <p>For trials that were included in the previous review: data that were not reported in the study, nor added in the previous review after consultation of the study authors, were considered missing for this update. In case of unclear or mixed duration or location of back pain, with no subgroup analyses presented, we moved the study to 'Studies awaiting classification', while we tried to contact the authors. In a future update, these studies could either be moved to 'Included' or 'Excluded' studies, depending on the trial author response. </p> <p>For new trials: in case of missing data, we e‐mailed the corresponding author. Additional data provided by authors were used in the analyses. If data were not described in the text, but were shown in graphs, two review authors (PR and WG) collected the data from the graphs by estimation. If needed, we recalculated data to provide standard deviations. We performed the calculations according to the <i>Handbook</i> (<a href="./references#CD013581-bbs2-0111" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> <section id="CD013581-sec-0068"> <h4 class="title">Assessment of heterogeneity</h4> <p>Statistical heterogeneity was assessed with the I² statistic. Values of I² below 40% suggested no important heterogeneity, above 75% suggested considerable heterogeneity. If values of I² were between 40% and 75%, moderate to substantial heterogeneity could be present (<a href="./references#CD013581-bbs2-0105" title="FurlanAD , MalmivaaraA , ChouR , MaherCG , DeyoRA , SchoeneM , et al. Editorial Board of the Cochrane Back and Neck Group. 2015 Updated method guideline for systematic reviews in the Cochrane Back and Neck Group. Spine2015;40(21):1660‐73. [DOI: 10.1097/BRS.0000000000001061; PUBMED: 26208232] ">Furlan 2015</a>; <a href="./references#CD013581-bbs2-0111" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We performed visual inspection of the forest plot and the overlap of confidence intervals. If the I² value was below 40%, we pooled the results; if it was above 75%, we did not pool. For values between 40% and 75%, we based the decision for pooling on the evaluation of the heterogeneity. Clinical heterogeneity was assessed for all included studies that reported similar outcomes. We judged the studies on the setting, population source of the participants, and the intervention. For the latter, we took variations in the type of NSAIDs that were used, dosage, mode of delivery, and duration of treatment into account. If studies were clinically too heterogeneous, we did not pool them. If pooling was feasible, we used a random‐effects model throughout this review, due to expected variability between studies (e.g. differences in populations and interventions as described above). </p> </section> <section id="CD013581-sec-0069"> <h4 class="title">Assessment of reporting biases</h4> <p>According to CBN, publication bias should be examined when at least ten studies are included in the meta‐analysis (<a href="./references#CD013581-bbs2-0105" title="FurlanAD , MalmivaaraA , ChouR , MaherCG , DeyoRA , SchoeneM , et al. Editorial Board of the Cochrane Back and Neck Group. 2015 Updated method guideline for systematic reviews in the Cochrane Back and Neck Group. Spine2015;40(21):1660‐73. [DOI: 10.1097/BRS.0000000000001061; PUBMED: 26208232] ">Furlan 2015</a>). No comparisons included more than six trials, therefore, it was not possible to construct a funnel plot or to draw conclusions concerning publication bias. There were no language restrictions to prevent reporting bias due to language. </p> </section> <section id="CD013581-sec-0070"> <h4 class="title">Data synthesis</h4> <p>We assessed the overall quality of the evidence for each outcome using the GRADE approach, as recommended in the <i>Handbook,</i> and adapted in the CBN's updated method guidelines (<a href="./references#CD013581-bbs2-0105" title="FurlanAD , MalmivaaraA , ChouR , MaherCG , DeyoRA , SchoeneM , et al. Editorial Board of the Cochrane Back and Neck Group. 2015 Updated method guideline for systematic reviews in the Cochrane Back and Neck Group. Spine2015;40(21):1660‐73. [DOI: 10.1097/BRS.0000000000001061; PUBMED: 26208232] ">Furlan 2015</a>; <a href="./references#CD013581-bbs2-0107" title="AtkinsD , BestD , BrissPA , EcclesM , Falck‐YtterY , FlottorpS , et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJJune 2004;328(7454):1490. ">GRADE Working Group 2004</a>; <a href="./references#CD013581-bbs2-0110" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [DOI: 10.1136/bmj.39489.470347.AD] ">Guyatt 2008</a>; <a href="./references#CD013581-bbs2-0111" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>; <a href="./appendices#CD013581-sec-0156">Appendix 5</a>). We determined the quality of evidence for each outcome based on five domains: limitations in study design and implementation (risk of bias), inconsistency (heterogeneity), indirectness (inability to generalise), imprecision (insufficient or imprecise data), and publication bias. We judged these five domains for all studies that measured a particular outcome and could be included in a meta‐analysis. The quality of the evidence for a specific outcome could be reduced by one or more levels, depending on the performance of the studies against these five factors. For the considerations used to define the level of evidence, refer to <a href="./appendices#CD013581-sec-0156">Appendix 5</a>. The overall quality of the evidence for each outcome is the result of the combination of this assessment of all domains. </p> <p>The GRADEpro GDT enabled us to import data from Review Manager 5.3 to create the 'Summary of findings' tables for the main comparison (<a href="./references#CD013581-bbs2-0108" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 31 January 2019. Hamilton (ON): McMaster University (developed by Evidence Prime). ">GRADEpro GDT</a>; <a href="./references#CD013581-bbs2-0127" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> <section id="CD013581-sec-0071"> <h5 class="title">'Summary of findings' tables</h5> <p>We considered 'NSAIDs versus placebo' our main comparison. We added a second 'Summary of findings' table for 'Selective COX‐2 inhibitors versus non‐selective NSAIDs', since we considered this a clinically important comparison. We considered all five primary outcome measures important, and as such, we presented all of them in the 'Summary of findings' tables. We presented the outcomes in the short‐term (follow‐up ≤ 3 weeks), which was deemed most relevant in the case of acute LBP, except for the reporting of adverse events, which had no limitations in follow‐up time. </p> </section> </section> <section id="CD013581-sec-0072"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned subgroup analyses on the analysis of NSAIDs versus non‐drug treatment (one subgroup for physiotherapy and spinal manipulation, and one subgroup for bedrest), but these were not applicable, due to lack of available data. A subgroup analysis of selective versus non‐selective NSAIDs was planned but not completed, due to lack of data. </p> </section> <section id="CD013581-sec-0073"> <h4 class="title">Sensitivity analysis</h4> <p>We planned two sensitivity analyses for each comparison. In the first sensitivity analysis, we excluded studies with a final judgement of a high risk of bias from the analysis. The second sensitivity analysis included the studies with solely acute LBP participants. We left studies with a case‐mix of participants with acute LBP and a small subgroup of the study population (&lt; 10%) with additional sciatic or flare‐up complaints out of this analysis. We could only perform both sensitivity analyses in a few comparisons, most often for NSAIDs versus placebo. In some comparisons this was not possible because all studies were judged as having a high risk of bias, or available data were lacking. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013581-sec-0074" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013581-sec-0074"></div> <section id="CD013581-sec-0075"> <h3 class="title">Description of studies</h3> <section id="CD013581-sec-0076"> <h4 class="title">Results of the search</h4> <p>For this update, we identified 5786 references through database and trial registry searches (<a href="#CD013581-fig-0001">Figure 1</a>). After removing duplicates, we screened 4680 titles and abstracts, and subsequently assessed 96 full‐text publications. In total, we included 32 publications in the present update: 26 studies that focused on acute low back pain (LBP) from the previous review (<a href="./references#CD013581-bbs2-0001" title="AghababianRV , VolturoGA , HeifetzIN . Comparison of diflunisal and naproxen in the management of acute low back pain. Clinical Therapeutics1986;9(Suppl C):47‐51. ">Aghababian 1986</a>; <a href="./references#CD013581-bbs2-0002" title="AgrifoglioE , BenvenuttiM , GattoP , AlbaneseL , ChrubinoP , MarinoniEC , et al. Aceclofenac: a new NSAID in the treatment of acute lumbago. Multicentre single blind study vs. diclofenac. Acta Therapeutica1994;20:33‐43. ">Agrifoglio 1994</a>; <a href="./references#CD013581-bbs2-0003" title="AmlieE , WeberH , HolmeI . Treatment of acute low back pain with piroxicam: results of a double‐blind placebo‐controlled trial. Spine1987;12:473‐6. ">Amlie 1987</a>; <a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0005" title="BakshiR , ThumbN , BröllH , KleinG , MayrhoferF , RainerF , et al. Treatment of acute lumbosacral back pain with diclofenac resinate: results of a double‐blind comparative trial versus piroxicam. Drug Investigation1994;8:288‐93. ">Bakshi 1994</a>; <a href="./references#CD013581-bbs2-0006" title="BrownFL , BodisonS , DixonJ , DavisW , NowoslawskiJ . Comparison of diflunisal and acetaminophen with codeine in the treatment of initial or recurrent acute low back pain. Clinical Therapeutics1986;9(Suppl C):52‐8. ">Brown 1986</a>; <a href="./references#CD013581-bbs2-0007" title="ColbergK , HettichM , SigmundR , DegnerFL . The efficacy and tolerability of an 8‐day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Current Medical Research and Opinion1996;13:363‐77. ">Colberg 1996</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0010" title="HosieGAC . The topical NSAID, felbinac, versus oral ibuprofen: a comparison of efficacy in the treatment of acute lower back injury. British Journal of Clinical Research1993;4:5‐17. ">Hosie 1993</a>; <a href="./references#CD013581-bbs2-0011" title="InnesGD , CroskerryP , WorthingtonJ , BeveridgeR , JonesD . Ketorolac versus acetaminophen‐codeine in the emergency department treatment of acute low back pain. Journal of Emergency Medicine1998;16(4):549‐56. ">Innes 1998</a>; <a href="./references#CD013581-bbs2-0012" title="JaffeG . A double‐blind, between‐patient comparison of alclofenac ('Prinalgin' ) and indomethacin in the treatment of low back pain and sciatica. Current Medical Research and Opinion1974;2:424‐9. ">Jaffe 1974</a>; <a href="./references#CD013581-bbs2-0013" title="LaceyPH , DoddGD , ShannonDJ . A double‐blind placebo controlled study of piroxicam in the management of acute musculoskeletal disorders. European Journal of Rheumatology and Inflammation1984;7:95‐104. ">Lacey 1984</a>; <a href="./references#CD013581-bbs2-0014" title="Metscher B. Kubler U. Jahnel‐KrachtH . Dexketoprofen‐trometamol and tramadol in acute lumbago [Dexketoprofen‐Trometamol und Tramadol bei akuter Lumbago]. Fortschritte der Medizin. Originalien2001;118(4):147‐51. ">Metscher 2001</a>; <a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a>; <a href="./references#CD013581-bbs2-0017" title="OravaS . Medical treatment of acute low back pain. Diflunisal compared with indomethacin in acute lumbago. International Journal of Clinical Research1986;6:45‐51. ">Orava 1986</a>; <a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a>; <a href="./references#CD013581-bbs2-0020" title="PostacchiniF , FacchiniM , PalieriP . Efficacy of various forms of conservative treatment in low back pain: a comparative study. Neuro‐Orthopedics1988;6:28‐35. ">Postacchini 1988</a>; <a href="./references#CD013581-bbs2-0021" title="SchattenkirchnerM , MilachowskiKA . A double‐blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clinical Rheumatology2003;22(2):127‐35. ">Schattenkirchner 2003</a>; <a href="./references#CD013581-bbs2-0023" title="StratzT . Intramuscular etofenamate in the treatment of acute lumbago. Effectiveness and tolerance in comparison with intramuscular diclofenac‐Na. Fortschritte der Medizin1990;108:264‐6. ">Stratz 1990</a>; <a href="./references#CD013581-bbs2-0024" title="SzpalskiM , PotyS , HayezJP , DebaizeJP . Objective assessment of trunk function in patients with acute low back pain treated with Tenoxicam. A prospective controlled study. Neuro‐orthopedics1990;10:41‐7. ">Szpalski 1990</a>; <a href="./references#CD013581-bbs2-0025" title="SzpalskiM , HayezJP . Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain: a double blind placebo‐controlled study. British Journal of Rheumatology1994;33:74‐8. ">Szpalski 1994</a>; <a href="./references#CD013581-bbs2-0026" title="VidemanT , HeikkilaJ , PartanenT . Double‐blind parallel study of meptazinol versus diflunisal in the treatment of lumbago. Current Medical Research and Opinion1984;9:246‐52. ">Videman 1984</a>; <a href="./references#CD013581-bbs2-0028" title="WaterworthRF , HunterIA . An open study of diflunisal, conservative and manipulative therapy in the management of acute mechanical low back pain. New Zealand Medical Journal1985;May:372‐5. ">Waterworth 1985</a>; <a href="./references#CD013581-bbs2-0029" title="WieselSW , CucklerJM , DelucaF , JonesF , ZeideMS , RothmanRH . Acute low back pain: an objective analysis of conservative therapy. Spine1980;5:324‐30. ">Wiesel 1980</a>; <a href="./references#CD013581-bbs2-0030" title="XimenesA , RoblesM , SandsG , VinuezaR . Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. Clinical Journal of Pain2007;23(3):244‐50. ">Ximenes 2007</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>); and six new publications (<a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0015" title="MikiK , IkemotoT , HayashiK , AraiY , SekiguchiM , ShiK , et al. Randomized open‐label non‐inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain. Journal of Orthopaedic Science 2018 Oct 3;23(3):483‐7. [PUBMED: PMID: 30292383] ">Miki 2018</a>; <a href="./references#CD013581-bbs2-0018" title="PlaplerPG , ScheinbergMA , EcclissatoCC , Bocchi de OliveiraMF , AmazonasRB . Double‐blind, randomized, double‐dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain. Drug Design, Development and Therapy2016;10:1987‐93. ">Plapler 2016</a>; <a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>). </p> <div class="figure" id="CD013581-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD013581-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>There are 16 studies still awaiting classification. We contacted the authors of these studies to ask for clarification, unless we were unable to find any currently active contact information. The reasons for not being classified were: an unclear or mixed duration of pain (<a href="./references#CD013581-bbs2-0077" title="AokiT , KurokiY , KageyamaT , IrimajiriS , MizushimaY , YamamotoK . Multicentre double‐blind comparison of piroxicam and indomethacin in the treatment of lumbar diseases. European Journal of Rheumatology and Inflammation1983;6:247‐52. ">Aoki 1983</a>; <a href="./references#CD013581-bbs2-0079" title="BorghiB , AuriniL , WhitePF , TognùA , RossiB , FiniG , et al. Treatment of recent onset low back pain with periradicular injections of meloxicam: a randomized, double blind, placebo controlled cross‐over study. Minerva Anestesiologica2018 May;84(5):590‐8. ">Borghi 2018</a>; <a href="./references#CD013581-bbs2-0080" title="DavoliL , CiottiG , BiondiM , PasseriM . Piroxicam‐beta‐cyclodextrin in the treatment of low‐back pain. Controlled study vs etodolac. Current Therapeutic Research, Clinical and Experimental1989;46:940‐7. ">Davoli 1989</a>; <a href="./references#CD013581-bbs2-0081" title="FamaeyJP , BruhwylerJ , GeczyJ , VandekerckhoveK , AppelboomT . Open controlled randomized multicenter comparison of nimesulide and diclofenac in the treatment of subacute and chronic low back pain. Journal of Clinical Research1998;1:219‐38. ">Famaey 1998</a>; <a href="./references#CD013581-bbs2-0082" title="HingoraniK , BiswasAK . Double‐blind controlled trial comparing oxyphenbutazone and indomethacin in the treatment of acute low back pain. British Journal of Clinical Practice1970;24:120‐3. ">Hingorani 1970</a>; <a href="./references#CD013581-bbs2-0083" title="HingoraniK , TempletonJS . A comparative trial of azapropazone and ketoprofen in the treatment of acute backache. Current Medical Research and Opinion1975;3:407‐12. ">Hingorani 1975</a>; <a href="./references#CD013581-bbs2-0084" title="JacobsJH , GraysonMF . Trial of anti‐inflammatory agent (indomethacin) in low back pain with and without radicular involvement. British Medical Journal1968;3:158‐60. ">Jacobs 1968</a>; <a href="./references#CD013581-bbs2-0088" title="SweetmanBJ , BaigA , ParsonsDL . Mefenamic acid, chlormezanone‐paracetamol, ethoheptazine‐aaspirin‐meprobamate: a comparative study in acute low back pain. British Journal of Clinical Practice1987;41:619‐24. ">Sweetman 1987</a>; <a href="./references#CD013581-bbs2-0090" title="WaikakulS , SoparatK . Effectiveness and safety of loxoprofen compared with naproxen in nonsurgical low back pain: a parallel study. Clinical Drug Investigation1995;10:59‐63. ">Waikakul 1995</a>; <a href="./references#CD013581-bbs2-0091" title="WaikakulS , DanputipongP , SoparatK . Topical analgesics, indomethacin plaster and diclofenac emulgel for low back pain: a parallel study. Journal of the Medical Association of Thailand1996;79:486‐90. ">Waikakul 1996</a>; <a href="./references#CD013581-bbs2-0092" title="ZolotovskayaIA , DavydkinIL . Effect of nonsteroidal anti‐inflammatory drugs on the indicators of cardiovascular risk in patients with acute nonspecific back pain [Russian]. Terapevticheskii Arkhiv2015;87(12):18‐25. ">Zolotovskaya 2015</a>); an unclear or mixed location of pain (<a href="./references#CD013581-bbs2-0078" title="BasmajianJV . Acute back pain and spasm: a controlled multicenter trial of combined analgesic and antispasm agents. Spine1989;14:438‐9. ">Basmajian 1989</a>; <a href="./references#CD013581-bbs2-0085" title="MilgromC , FinestoneA , LevB , WienerM , FlomanY . Overexertional lumbar and thoracic back pain among recruits: a prospective study of risk factors and treatment regimens. Journal of Speech Disorders1993;6:187‐93. ">Milgrom 1993</a>; <a href="./references#CD013581-bbs2-0087" title="PredelHG , Ebel‐BitounC , LangeR , WeiserT . A randomized, placebo‐ and active‐controlled, multi‐country, multi‐center parallel group trial to evaluate the efficacy and safety of a fixed‐dose combination of 400 mg ibuprofen and 100 mg caffeine compared with ibuprofen 400 mg and placebo in patients with acute lower back or neck pain. Journal of Pain Research2019;12:2771‐83. ">Predel 2019</a>); the use of different non‐steroidal anti‐inflammatory drugs (NSAID) in one treatment arm that was not specified (<a href="./references#CD013581-bbs2-0086" title="NCT01374269 . Improvement in pain, function and HRQoL (Health Related Quality of Life) in subacute low back pain: a controlled clinical trial of exercise versus NSAIDs. clinicaltrials.gov/ct2/show/study/NCT01374269 (first posted 15 June 2011). ">NCT01374269</a>); or a completed pilot study for which we are awaiting the results (<a href="./references#CD013581-bbs2-0089" title="TCTR20141027001 . A single‐blind randomized controlled trial of AVS023 poly‐herbal formula for Acute low back pain: a pilot study. apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20141027001 (first registered 27 October 2014). ">TCTR20141027001</a>). Usually, there was no subgroup analysis presented, or the reported data were insufficient to be used in our analyses. By retrieving more information from the authors, we aimed to clarify if subgroup analyses would be possible in a future update. Further details of the studies can be found in the '<a href="./references#CD013581-sec-0167" title="">Characteristics of studies awaiting classification</a>' table. </p> <p>There were four ongoing studies recruiting participants, thus no results were available for this review (<a href="./references#CD013581-bbs2-0093" title="CTRI/2018/11/016371 . A comparative study of the efficacy and tolerability of fixed dose combination of etoricoxib and thiocolchicoside and thiocolchicoside alone in patients with painful muscle spasm. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2018/11/016371 (first registered 16 November 2018 ). ">CTRI/2018/11/016371</a>; <a href="./references#CD013581-bbs2-0094" title="NCT03861611 . A comparison of NSAIDs for acute, non‐radicular low back pain. A randomized trial. clinicaltrials.gov/ct2/show/NCT03861611 (first posted 4 March 2019). ">NCT03861611</a>; <a href="./references#CD013581-bbs2-0095" title="NCT04111315 . Efficacy of metamizole versus ibuprofen and a short educational intervention versus standard care in acute and subacute low back pain: a randomized, factorial trial. clinicaltrials.gov/ct2/show/NCT04111315 (first posted 1 October 2019). ">NCT04111315</a>; <a href="./references#CD013581-bbs2-0096" title="TCTR20151118003 . Efficacy of Ayurved SIRIRAJ SAHATTHARA recipe, in patient with acute low back pain, the open‐label randomized controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20151118003 (first registered 17 November 2015). ">TCTR20151118003</a>). Further details can be found in the '<a href="./references#CD013581-sec-0168" title="">Characteristics of ongoing studies</a>' table. </p> </section> <section id="CD013581-sec-0077"> <h4 class="title">Included studies</h4> <p>We included 32 trials with a total of 5356 participants (sample size ranged from 30 to 372). Ages of included participants ranged from 16 to 78 years; one trial had no age limits, but did not specify the age range of the back pain subgroup (<a href="./references#CD013581-bbs2-0013" title="LaceyPH , DoddGD , ShannonDJ . A double‐blind placebo controlled study of piroxicam in the management of acute musculoskeletal disorders. European Journal of Rheumatology and Inflammation1984;7:95‐104. ">Lacey 1984</a>). All of the included studies were published in English, except for one which was in German (<a href="./references#CD013581-bbs2-0014" title="Metscher B. Kubler U. Jahnel‐KrachtH . Dexketoprofen‐trometamol and tramadol in acute lumbago [Dexketoprofen‐Trometamol und Tramadol bei akuter Lumbago]. Fortschritte der Medizin. Originalien2001;118(4):147‐51. ">Metscher 2001</a>). The studies were conducted in Germany (six studies), USA (four studies), UK (three studies), Finland (three studies), Belgium (two studies), Italy (two studies), Brazil, Norway, Austria, France, Australia, Canada, Japan, South‐Korea, New Zealand and Russia (one study each). One study was conducted in three European countries (Belgium, Germany, Poland), while one study took place in nine Latin‐American countries (Brazil, Venezuela, Ecuador, Argentina, Chile, Mexico, Colombia, Costa Rica, and Peru). Settings were most often general practice or outpatient clinics. In some cases, the setting was the emergency department or an occupational health centre. For further details of the studies refer to the '<a href="./references#CD013581-sec-0165" title="">Characteristics of included studies</a>' table. </p> <p>Comparisons were as follows:</p> <p> <ul id="CD013581-list-0004"> <li> <p>nine trials compared one or more types of NSAIDs with a placebo (<a href="./references#CD013581-bbs2-0003" title="AmlieE , WeberH , HolmeI . Treatment of acute low back pain with piroxicam: results of a double‐blind placebo‐controlled trial. Spine1987;12:473‐6. ">Amlie 1987</a>; <a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0013" title="LaceyPH , DoddGD , ShannonDJ . A double‐blind placebo controlled study of piroxicam in the management of acute musculoskeletal disorders. European Journal of Rheumatology and Inflammation1984;7:95‐104. ">Lacey 1984</a>; <a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a>; <a href="./references#CD013581-bbs2-0020" title="PostacchiniF , FacchiniM , PalieriP . Efficacy of various forms of conservative treatment in low back pain: a comparative study. Neuro‐Orthopedics1988;6:28‐35. ">Postacchini 1988</a>; <a href="./references#CD013581-bbs2-0025" title="SzpalskiM , HayezJP . Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain: a double blind placebo‐controlled study. British Journal of Rheumatology1994;33:74‐8. ">Szpalski 1994</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>); </p> </li> <li> <p>three trials compared one or more types of NSAIDs with paracetamol (<a href="./references#CD013581-bbs2-0015" title="MikiK , IkemotoT , HayashiK , AraiY , SekiguchiM , ShiK , et al. Randomized open‐label non‐inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain. Journal of Orthopaedic Science 2018 Oct 3;23(3):483‐7. [PUBMED: PMID: 30292383] ">Miki 2018</a>; <a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a>; <a href="./references#CD013581-bbs2-0029" title="WieselSW , CucklerJM , DelucaF , JonesF , ZeideMS , RothmanRH . Acute low back pain: an objective analysis of conservative therapy. Spine1980;5:324‐30. ">Wiesel 1980</a>); </p> </li> <li> <p>seventeen trials compared different types of NSAIDs (<a href="./references#CD013581-bbs2-0001" title="AghababianRV , VolturoGA , HeifetzIN . Comparison of diflunisal and naproxen in the management of acute low back pain. Clinical Therapeutics1986;9(Suppl C):47‐51. ">Aghababian 1986</a>; <a href="./references#CD013581-bbs2-0002" title="AgrifoglioE , BenvenuttiM , GattoP , AlbaneseL , ChrubinoP , MarinoniEC , et al. Aceclofenac: a new NSAID in the treatment of acute lumbago. Multicentre single blind study vs. diclofenac. Acta Therapeutica1994;20:33‐43. ">Agrifoglio 1994</a>; <a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0005" title="BakshiR , ThumbN , BröllH , KleinG , MayrhoferF , RainerF , et al. Treatment of acute lumbosacral back pain with diclofenac resinate: results of a double‐blind comparative trial versus piroxicam. Drug Investigation1994;8:288‐93. ">Bakshi 1994</a>; <a href="./references#CD013581-bbs2-0007" title="ColbergK , HettichM , SigmundR , DegnerFL . The efficacy and tolerability of an 8‐day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Current Medical Research and Opinion1996;13:363‐77. ">Colberg 1996</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0010" title="HosieGAC . The topical NSAID, felbinac, versus oral ibuprofen: a comparison of efficacy in the treatment of acute lower back injury. British Journal of Clinical Research1993;4:5‐17. ">Hosie 1993</a>; <a href="./references#CD013581-bbs2-0012" title="JaffeG . A double‐blind, between‐patient comparison of alclofenac ('Prinalgin' ) and indomethacin in the treatment of low back pain and sciatica. Current Medical Research and Opinion1974;2:424‐9. ">Jaffe 1974</a>; <a href="./references#CD013581-bbs2-0017" title="OravaS . Medical treatment of acute low back pain. Diflunisal compared with indomethacin in acute lumbago. International Journal of Clinical Research1986;6:45‐51. ">Orava 1986</a>; <a href="./references#CD013581-bbs2-0018" title="PlaplerPG , ScheinbergMA , EcclissatoCC , Bocchi de OliveiraMF , AmazonasRB . Double‐blind, randomized, double‐dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain. Drug Design, Development and Therapy2016;10:1987‐93. ">Plapler 2016</a>; <a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a>; <a href="./references#CD013581-bbs2-0021" title="SchattenkirchnerM , MilachowskiKA . A double‐blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clinical Rheumatology2003;22(2):127‐35. ">Schattenkirchner 2003</a>; <a href="./references#CD013581-bbs2-0023" title="StratzT . Intramuscular etofenamate in the treatment of acute lumbago. Effectiveness and tolerance in comparison with intramuscular diclofenac‐Na. Fortschritte der Medizin1990;108:264‐6. ">Stratz 1990</a>; <a href="./references#CD013581-bbs2-0029" title="WieselSW , CucklerJM , DelucaF , JonesF , ZeideMS , RothmanRH . Acute low back pain: an objective analysis of conservative therapy. Spine1980;5:324‐30. ">Wiesel 1980</a>; <a href="./references#CD013581-bbs2-0030" title="XimenesA , RoblesM , SandsG , VinuezaR . Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. Clinical Journal of Pain2007;23(3):244‐50. ">Ximenes 2007</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>); two of these trials compared selective COX‐2 inhibitors with non‐selective NSAIDs (<a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a>; <a href="./references#CD013581-bbs2-0030" title="XimenesA , RoblesM , SandsG , VinuezaR . Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. Clinical Journal of Pain2007;23(3):244‐50. ">Ximenes 2007</a>); </p> </li> <li> <p>four trials compared one or more types of NSAIDs with other drugs (<a href="./references#CD013581-bbs2-0006" title="BrownFL , BodisonS , DixonJ , DavisW , NowoslawskiJ . Comparison of diflunisal and acetaminophen with codeine in the treatment of initial or recurrent acute low back pain. Clinical Therapeutics1986;9(Suppl C):52‐8. ">Brown 1986</a>; <a href="./references#CD013581-bbs2-0011" title="InnesGD , CroskerryP , WorthingtonJ , BeveridgeR , JonesD . Ketorolac versus acetaminophen‐codeine in the emergency department treatment of acute low back pain. Journal of Emergency Medicine1998;16(4):549‐56. ">Innes 1998</a>; <a href="./references#CD013581-bbs2-0014" title="Metscher B. Kubler U. Jahnel‐KrachtH . Dexketoprofen‐trometamol and tramadol in acute lumbago [Dexketoprofen‐Trometamol und Tramadol bei akuter Lumbago]. Fortschritte der Medizin. Originalien2001;118(4):147‐51. ">Metscher 2001</a>; <a href="./references#CD013581-bbs2-0026" title="VidemanT , HeikkilaJ , PartanenT . Double‐blind parallel study of meptazinol versus diflunisal in the treatment of lumbago. Current Medical Research and Opinion1984;9:246‐52. ">Videman 1984</a>); </p> </li> <li> <p>seven trials compared one or more types of NSAIDs with non‐drug treatment (<a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a>; <a href="./references#CD013581-bbs2-0020" title="PostacchiniF , FacchiniM , PalieriP . Efficacy of various forms of conservative treatment in low back pain: a comparative study. Neuro‐Orthopedics1988;6:28‐35. ">Postacchini 1988</a>; <a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a>; <a href="./references#CD013581-bbs2-0024" title="SzpalskiM , PotyS , HayezJP , DebaizeJP . Objective assessment of trunk function in patients with acute low back pain treated with Tenoxicam. A prospective controlled study. Neuro‐orthopedics1990;10:41‐7. ">Szpalski 1990</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>; <a href="./references#CD013581-bbs2-0028" title="WaterworthRF , HunterIA . An open study of diflunisal, conservative and manipulative therapy in the management of acute mechanical low back pain. New Zealand Medical Journal1985;May:372‐5. ">Waterworth 1985</a>). </p> </li> </ul> </p> <p>Three studies had multiple groups of NSAID treatment, comparing two different types of NSAIDs to other treatment (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0029" title="WieselSW , CucklerJM , DelucaF , JonesF , ZeideMS , RothmanRH . Acute low back pain: an objective analysis of conservative therapy. Spine1980;5:324‐30. ">Wiesel 1980</a>). Comparators in the group of other drugs were acetaminophen with codeine, tramadol hydrochloride, and meptazinol. Comparators in the group of non‐drug treatment were spinal manipulation, physiotherapy, bedrest, heat wrap, and motion style acupuncture treatment. </p> <p>The duration of follow‐up ranged from one day to six months. Most studies only reported short‐term results (follow‐up one day to three weeks). We defined long‐term follow‐up as longer than three weeks and up to 12 weeks. Only five trials had a follow‐up duration longer than three weeks (<a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0015" title="MikiK , IkemotoT , HayashiK , AraiY , SekiguchiM , ShiK , et al. Randomized open‐label non‐inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain. Journal of Orthopaedic Science 2018 Oct 3;23(3):483‐7. [PUBMED: PMID: 30292383] ">Miki 2018</a>; <a href="./references#CD013581-bbs2-0020" title="PostacchiniF , FacchiniM , PalieriP . Efficacy of various forms of conservative treatment in low back pain: a comparative study. Neuro‐Orthopedics1988;6:28‐35. ">Postacchini 1988</a>; <a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>).Of these five trials, <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a> reported that they completed assessments at 12 weeks, but they did not report the data; <a href="./references#CD013581-bbs2-0020" title="PostacchiniF , FacchiniM , PalieriP . Efficacy of various forms of conservative treatment in low back pain: a comparative study. Neuro‐Orthopedics1988;6:28‐35. ">Postacchini 1988</a> only reported a combination score of improvement in pain, disability, and spinal mobility (all three combined in one 'global measure') at two months; <a href="./references#CD013581-bbs2-0015" title="MikiK , IkemotoT , HayashiK , AraiY , SekiguchiM , ShiK , et al. Randomized open‐label non‐inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain. Journal of Orthopaedic Science 2018 Oct 3;23(3):483‐7. [PUBMED: PMID: 30292383] ">Miki 2018</a> only presented a mean pain difference score between groups at four weeks. <a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a> presented long‐term outcomes at four weeks, but in both study arms, they allowed participants to pursue other treatments of their choice once they completed the intervention treatment session (reportedly due to ethical reasons). This implies the results after the first follow‐up at 30 minutes may be difficult to interpret or generalize. <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a> presented long‐term follow‐up outcomes (84 days) while maintaining the intervention groups throughout the follow‐up period. </p> <p>In four studies, a part of the study population had sciatic complaints or a flare‐up of chronic back complaints (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0005" title="BakshiR , ThumbN , BröllH , KleinG , MayrhoferF , RainerF , et al. Treatment of acute lumbosacral back pain with diclofenac resinate: results of a double‐blind comparative trial versus piroxicam. Drug Investigation1994;8:288‐93. ">Bakshi 1994</a>; <a href="./references#CD013581-bbs2-0012" title="JaffeG . A double‐blind, between‐patient comparison of alclofenac ('Prinalgin' ) and indomethacin in the treatment of low back pain and sciatica. Current Medical Research and Opinion1974;2:424‐9. ">Jaffe 1974</a>; <a href="./references#CD013581-bbs2-0017" title="OravaS . Medical treatment of acute low back pain. Diflunisal compared with indomethacin in acute lumbago. International Journal of Clinical Research1986;6:45‐51. ">Orava 1986</a>); in one study, none of the screened people were excluded, despite the strict exclusion criteria (<a href="./references#CD013581-bbs2-0018" title="PlaplerPG , ScheinbergMA , EcclissatoCC , Bocchi de OliveiraMF , AmazonasRB . Double‐blind, randomized, double‐dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain. Drug Design, Development and Therapy2016;10:1987‐93. ">Plapler 2016</a>); one study used a very selected population of young male army trainees (<a href="./references#CD013581-bbs2-0029" title="WieselSW , CucklerJM , DelucaF , JonesF , ZeideMS , RothmanRH . Acute low back pain: an objective analysis of conservative therapy. Spine1980;5:324‐30. ">Wiesel 1980</a>). One study used an inadequate dosage of the reference medication (<a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>). </p> <p>Fourteen studies were industry‐sponsored. The pharmaceutical companies that funded the studies were most often the developer of the study drug (<a href="./references#CD013581-bbs2-0001" title="AghababianRV , VolturoGA , HeifetzIN . Comparison of diflunisal and naproxen in the management of acute low back pain. Clinical Therapeutics1986;9(Suppl C):47‐51. ">Aghababian 1986</a>; <a href="./references#CD013581-bbs2-0003" title="AmlieE , WeberH , HolmeI . Treatment of acute low back pain with piroxicam: results of a double‐blind placebo‐controlled trial. Spine1987;12:473‐6. ">Amlie 1987</a>; <a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0005" title="BakshiR , ThumbN , BröllH , KleinG , MayrhoferF , RainerF , et al. Treatment of acute lumbosacral back pain with diclofenac resinate: results of a double‐blind comparative trial versus piroxicam. Drug Investigation1994;8:288‐93. ">Bakshi 1994</a>; <a href="./references#CD013581-bbs2-0006" title="BrownFL , BodisonS , DixonJ , DavisW , NowoslawskiJ . Comparison of diflunisal and acetaminophen with codeine in the treatment of initial or recurrent acute low back pain. Clinical Therapeutics1986;9(Suppl C):52‐8. ">Brown 1986</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0010" title="HosieGAC . The topical NSAID, felbinac, versus oral ibuprofen: a comparison of efficacy in the treatment of acute lower back injury. British Journal of Clinical Research1993;4:5‐17. ">Hosie 1993</a>; <a href="./references#CD013581-bbs2-0011" title="InnesGD , CroskerryP , WorthingtonJ , BeveridgeR , JonesD . Ketorolac versus acetaminophen‐codeine in the emergency department treatment of acute low back pain. Journal of Emergency Medicine1998;16(4):549‐56. ">Innes 1998</a>; <a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a>; <a href="./references#CD013581-bbs2-0018" title="PlaplerPG , ScheinbergMA , EcclissatoCC , Bocchi de OliveiraMF , AmazonasRB . Double‐blind, randomized, double‐dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain. Drug Design, Development and Therapy2016;10:1987‐93. ">Plapler 2016</a>; <a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a>; <a href="./references#CD013581-bbs2-0021" title="SchattenkirchnerM , MilachowskiKA . A double‐blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clinical Rheumatology2003;22(2):127‐35. ">Schattenkirchner 2003</a>; <a href="./references#CD013581-bbs2-0030" title="XimenesA , RoblesM , SandsG , VinuezaR . Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. Clinical Journal of Pain2007;23(3):244‐50. ">Ximenes 2007</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>). One study, with spinal manipulation as a comparison was funded by two organisations for manual therapy (<a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>). A few studies clearly stated they were funded by sponsors that did not have any influence on data collection, management, analysis, and reports (<a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>); by a hospital foundation (<a href="./references#CD013581-bbs2-0028" title="WaterworthRF , HunterIA . An open study of diflunisal, conservative and manipulative therapy in the management of acute mechanical low back pain. New Zealand Medical Journal1985;May:372‐5. ">Waterworth 1985</a>); a national association for musculoskeletal pain studies (<a href="./references#CD013581-bbs2-0015" title="MikiK , IkemotoT , HayashiK , AraiY , SekiguchiM , ShiK , et al. Randomized open‐label non‐inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain. Journal of Orthopaedic Science 2018 Oct 3;23(3):483‐7. [PUBMED: PMID: 30292383] ">Miki 2018</a>); or that they received an unrestricted grant (<a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>). The remaining fourteen studies did not mention their funding sources. </p> <p>For declarations of (and potential conflicts of) interest: one author of a study with motion‐style acupuncture treatment as a comparison was supported by an Asian medicine institute (<a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a>); one study was written by a paid consultant and co‐authored by employees of the health sciences institute of a pharmaceutical company (<a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a>); one study received statistical help from an employee of a pharmaceutical company (<a href="./references#CD013581-bbs2-0013" title="LaceyPH , DoddGD , ShannonDJ . A double‐blind placebo controlled study of piroxicam in the management of acute musculoskeletal disorders. European Journal of Rheumatology and Inflammation1984;7:95‐104. ">Lacey 1984</a>); one study received editorial support (<a href="./references#CD013581-bbs2-0030" title="XimenesA , RoblesM , SandsG , VinuezaR . Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. Clinical Journal of Pain2007;23(3):244‐50. ">Ximenes 2007</a>). One study was funded by a local pharmaceutical company that was involved in study design, protocol development, obtaining and evaluating the data, and writing the manuscript together with the authors, and all authors received grants and consulting fees for this (<a href="./references#CD013581-bbs2-0018" title="PlaplerPG , ScheinbergMA , EcclissatoCC , Bocchi de OliveiraMF , AmazonasRB . Double‐blind, randomized, double‐dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain. Drug Design, Development and Therapy2016;10:1987‐93. ">Plapler 2016</a>). </p> </section> <section id="CD013581-sec-0078"> <h4 class="title">Excluded studies</h4> <p>We described the reasons for excluding studies in the '<a href="./references#CD013581-sec-0166" title="">Characteristics of excluded studies</a>' table. There were four main categories: </p> <p> <ul id="CD013581-list-0005"> <li> <p>Not a randomised controlled trial (RCT; e.g. no intervention, a clinical series, case report, review or commentary (<a href="./references#CD013581-bbs2-0035" title="AnayaA , PlantmasonL , DhaliwalG . Back attack. Journal of General Internal Medicine2014;29(1):255‐9. ">Anaya 2014</a>; <a href="./references#CD013581-bbs2-0036" title="Arul PrakasamKC , SalmanP , SenthilkumarN . Comparative assessment of analgesic effect of different NSAID's in the management of low back pain. International Journal of PharmTech Research2011;3(3):1260‐4. ">Arul Prakasam 2011</a>; <a href="./references#CD013581-bbs2-0041" title="BuchbinderR . Topical NSAIDs provide effective relief of acute musculoskeletal pain compared to placebo, with no increase in risk of adverse effects. Evidence‐Based Medicine2010;15(6):177‐8. ">Buchbinder 2010</a>; <a href="./references#CD013581-bbs2-0046" title="DayRO , GrahamGG . Therapeutics: non‐steroidal anti‐inflammatory drugs (NSAIDs). BMJ (Online)2013;346:f3195. [DOI: 10.1136/bmj.f3195] ">Day 2013</a>; <a href="./references#CD013581-bbs2-0070" title="ShikherimovRK . The use of nimesulide in the treatment of acute low back pain [Russian] [Применение нимесулида в терапии острой боли в нижней частиспины]. Zhurnal Nevrologii i Psikhiatrii Imeni S S2016;116(5):28‐32. ">Shikhkerimov 2016</a>; <a href="./references#CD013581-bbs2-0075" title="UberallMA , EssnerU , Muller‐SchwefeGH . 2‐week efficacy and tolerability of flupirtine MR and diclofenac in patients with acute low/back pain – results of a post‐hoc subgroup analysis of patient‐level data from four non‐interventional studies [German] [2‐Wochen‐Wirksamkeit und ‐Verträglichkeit von Flupirtin MR und Diclofenac bei akuten Kreuz‐/Rückenschmerzen]. MMW Fortschritte der Medizin2013 Dec;155 Suppl 4:115‐23. ">von Uberall 2013</a>; <a href="./references#CD013581-bbs2-0076" title="YastrebovDN , ShpaginMV , ArtifexoSB . Pathophysiological substantiation of epidural administration of Tenoxicam in dorsalgia treatment. Sovremennye Tehnologii v Medicine2012;1:133‐6. ">Yastrebov 2012</a>)); </p> </li> <li> <p>Not acute LBP (i.e. LBP was of longer duration, or it did not concern LBP in general (<a href="./references#CD013581-bbs2-0038" title="BlazekM , KeszthelyiB , VarhelyiM , KorosiO . Comparative study of biarison and voltaren in acute lumbar pain and lumbo‐ischialgia. Therapia Hungarica (English Edition)1986;34:163‐6. ">Blazek 1986</a>; <a href="./references#CD013581-bbs2-0042" title="ChrubasikS , ModelA , BlackA , PollakS . A randomized double‐blind pilot study comparing Doloteffin and Vioxx in the treatment of low back pain. Rheumatology (Oxford)2003;42(1):141‐8. ">Chrubasik 2003</a>; <a href="./references#CD013581-bbs2-0043" title="CoatsTL , BorensteinDG , NangiaNK , BrownMT . Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo‐controlled trial. Clinical Therapeutics2004;26(8):1249‐60. ">Coats 2004</a>; <a href="./references#CD013581-bbs2-0049" title="DriessensM , FamaeyJP , OrloffS , ChochradI , CleppeD , BrabanterG , et al. Efficacy and tolerability of sustained‐release ibuprofen in the treatment of patients with chronic back pain. Current Therapeutic Research, Clinical and Experimental1994;55:1283‐92. ">Driessens 1994</a>; <a href="./references#CD013581-bbs2-0051" title="EvansDP , BurkeMS , NewcombeRG . Medicines of choice in low back pain. Current Medical Research and Opinion1980;6:540‐7. ">Evans 1980</a>; <a href="./references#CD013581-bbs2-0058" title="IngpenML . A controlled clinical trial of sustained‐action dextropropoxyphene hydrochloride. British Journal of Clinical Practice1969;23:113‐5. ">Ingpen 1969</a>; <a href="./references#CD013581-bbs2-0063" title="MatsumoS , KanedaK , NoharaY . Clinical evaluation of Ketoprofen (Orudis) in lumbago: a double‐blind comparison with diclofenac sodium. British Journal of Clinical Practice1981;35(7‐8):266. [PUBMED: PMID 6459111] ">Matsumo 1981</a>; <a href="./references#CD013581-bbs2-0064" title="MuckleDS . Flurbiprofen for the treatment of soft tissue trauma. American Journal of Medicine1986;80:76‐80. ">Muckle 1986</a>; <a href="./references#CD013581-bbs2-0069" title="ShellWE , CharuvastraEH , DewoodMA , MayLA , BulliasDH , SilverDS . A double‐blind controlled trial of a single dose naproxen and an amino acid medical food theramine for the treatment of low back pain. American Journal of Therapeutics2012;19(2):108‐14. ">Shell 2012</a>; <a href="./references#CD013581-bbs2-0071" title="SiegmethW , SiebererW . A comparison of the short‐term effects of ibuprofen and diclofenac in spondylosis. Journal of International Medical Research1978;6:369‐74. ">Siegmeth 1978</a>)); </p> </li> <li> <p>NSAIDs were not evaluated separately (e.g. NSAIDs were added for blinding purposes only, or the comparison group only involved the mode of administration (<a href="./references#CD013581-bbs2-0033" title="AllegriniA , NuzzoL , PavoneD , Tavella‐ScaringiA , GiangrecoD , BucciM , et al. Efficacy and safety of piroxicam patch versus piroxicam cream in patients with lumbar osteoarthritis: A randomized, placebo‐controlled study. Arzneimittel‐Forschung/Drug Research2009;59(8):403‐9. ">Allegrini 2009</a>; <a href="./references#CD013581-bbs2-0034" title="AltanL , Kasapoglu AksoyM , Kösegil ÖztürkE . Efficacy of diclofenac &amp; thiocolchioside gel phonophoresis comparison with ultrasound therapy on acute low back pain; a prospective, double‐blind, randomized clinical study. Ultrasonics2019 Jan;91:201‐5. ">Altan 2019</a>; <a href="./references#CD013581-bbs2-0037" title="BerryH , HutchinsonDR . Tizanidine and ibuprofen in acute low‐back pain: results of a double‐blind multicentre study in general practice. Journal of International Medical Research1988;16:83‐91. ">Berry 1988</a>; <a href="./references#CD013581-bbs2-0039" title="BorensteinDG , LacksS , WieselSW . Cyclobenzaprine and naproxen versus naproxen alone in the treatment of acute low back pain and muscle spasm. Clinical Therapeutics1990;12:125‐31. ">Borenstein 1990</a>; <a href="./references#CD013581-bbs2-0040" title="BruggemannG , KoehlerCO , KochEM . Results of a double‐blind study of diclofenac + vitamin B1, B6, B12 versus diclofenac in patients with acute pain of the lumbar vertebrae. A multicenter study. Klinische Wochenschrift1990;68:116‐20. ">Bruggemann 1990</a>; <a href="./references#CD013581-bbs2-0044" title="CohenMM , SmitV , AndrianopoulosN , Ben‐MeirM , TaylorDM , ParkerSJ , et al. Acupuncture for analgesia in the emergency department: a multicentre, randomised, equivalence and non‐inferiority trial. Medical Journal of Australia2017;206(11):494‐9. ">Cohen 2017</a>; <a href="./references#CD013581-bbs2-0045" title="CostantinoC , MarangioE , CoruzziG . Mesotherapy versus systemic therapy in the treatment of acute low back pain: a randomized trial. Evidence‐Based Complementary and Alternative Medicine: eCAM2011;2011:317183. ">Costantino 2011</a>; <a href="./references#CD013581-bbs2-0047" title="DehghanM , FarahbodF . The efficacy of thermotherapy and cryotherapy on pain relief in patients with acute low back pain, a clinical trial study. Journal of Clinical and Diagnostic Research2014;8(9):LC01‐4. ">Dehghan 2014</a>; <a href="./references#CD013581-bbs2-0048" title="DehghanM , FarahbodF . Evaluation of the therapeutic effect of oral gabapentin on the severity of acute low back pain [Persian]. Scientific Journal of Kurdistan University of Medical Sciences2015;20(1):97‐104. ">Dehghan 2015</a>; <a href="./references#CD013581-bbs2-0052" title="FriedmanBW , DymAA , DavittM , HoldenL , SolorzanoC , EssesD , et al. Naproxen with cyclobenzaprine, oxycodone/acetaminophen, or placebo for treating acute low back pain: a randomized clinical trial. JAMA2015;314(15):1572‐80. [DOI: 10.1001/jama.2015.13043] ">Friedman 2015</a>; <a href="./references#CD013581-bbs2-0053" title="FriedmanBW , IrizarryE , SolorzanoC , KhankelN , ZapataJ , ZiasE , et al. Diazepam is no better than placebo when added to naproxen for acute low back pain. Annals of Emergency Medicine2017 Aug;70(2):169‐76. [DOI: 10.1016/j.annemergmed.2016.10.002] ">Friedman 2016</a>; <a href="./references#CD013581-bbs2-0054" title="FriedmanBW , CisewskiD , IrizarryE , DavittM , SolorzanoC , NasseryA , et al. A randomized, double‐blind, placebo‐controlled trial of Naproxen with or without Orphenadrine or Methocarbamol for acute low back pain. Annals of Emergency Medicine2018;71(3):348‐56. ">Friedman 2018</a>; <a href="./references#CD013581-bbs2-0055" title="GellerM , MibielliMA , NunesCP , daFonsecaAS , GoldbergSW , OliveiraL . Comparison of the action of diclofenac alone versus diclofenac plus B vitamins on mobility in patients with low back pain. Journal of Drug Assessment2016;5(1):1‐3. ">Geller 2016</a>; <a href="./references#CD013581-bbs2-0056" title="GórskaJ . Effects of back pain treatment with tizanidine [Polish]. Ortopedia, Traumatologia, Rehabilitacja2005;7(3):306‐9. ">Górska 2005</a>; <a href="./references#CD013581-bbs2-0057" title="IlicKV , Sefik‐BukilicaM , JankovicS , Vujasinovic‐StuparN . Efficacy and safety of two generic copies of nimesulide in patients with low back pain or knee osteoarthritis. Reumatismo2009;61(1):27‐33. ">Ilic 2009</a>; <a href="./references#CD013581-bbs2-0059" title="IRCT2013052213146N2 . Compare between non‐steroidal anti‐inflammatory drugs and different frequencies of pulse low level laser therapy in acute low back pain. en.irct.ir/trial/13065 (first registered 15 December 2013). ">IRCT2013052213146N2</a>; <a href="./references#CD013581-bbs2-0060" title="KuhlweinA , MeyerHJ , KoehlerCO . Reduced diclofenac administration by B vitamins: results of a randomized double‐blind study with reduced daily doses of diclofenac (75 mg diclofenac versus 75 mg diclofenac plus B vitamins) in acute lumbar vertebral syndromes. Klinische Wochenschrift1990;68:107‐15. ">Kuhlwein 1990</a>; <a href="./references#CD013581-bbs2-0062" title="ListratV , DougadosM , ChevalierX , KramerF , AmorB . Comparison of the analgesic effect of tenoxicam after oral or intramuscular administration. Drug Investigation1990;2(Suppl 3):51‐2. [DOI: 10.1007/BF03258217] ">Listrat 1990</a>; <a href="./references#CD013581-bbs2-0065" title="OstojicP , RadunovicG , LazovicM , Tomanovic‐VujadinovicS . Ibuprofen plus paracetamol versus ibuprofen in acute low back pain: a randomized open label multicenter clinical study. Acta Reumatologica Portuguesa2017;42(1):18‐25. ">Ostojic 2017</a>; <a href="./references#CD013581-bbs2-0072" title="StarkJ , PetrofskyJ , BerkL , BainsG , ChenS , DoyleG . Continuous low‐level heat wrap therapy relieves low back pain and reduces muscle stiffness.. Physician &amp; Sportsmedicine2014;42(4):39‐48. ">Stark 2014</a>; <a href="./references#CD013581-bbs2-0073" title="VetterG , BruggemannG , LettkoM , SchwiegerG , AsbachH , BiermannW , et al. Shortening diclofenac therapy by B vitamins. Results of a randomized double‐blind study, diclofenac 50 mg versus diclofenac 50 mg plus B vitamins, in painful spinal diseases with degenerative changes. Zeitschrift fur Rheumatologie1988;47:351‐62. ">Vetter 1988</a>; <a href="./references#CD013581-bbs2-0074" title="VoicuVA , MircioiuC , PlesaC , JingaM , BalabanV , SanduloviciR , et al. Effect of a new synergistic combination of low doses of acetylsalicylic acid, caffeine, acetaminophen, and chlorpheniramine in acute low back pain. Frontiers in Pharmacology2019;10:607. ">Voicu 2019</a>)); </p> </li> <li> <p>Other reasons (e.g. no (or insufficient) study results were available because we did not find the original study results (<a href="./references#CD013581-bbs2-0066" title="PenaM . Etodolac: analgesic effects in musculoskeletal and postoperative pain. Rheumatology International1990;10(Suppl):9‐16. ">Pena 1990</a>), the study terminated early (<a href="./references#CD013581-bbs2-0067" title="SchreijenbergM , LuijsterburgPA , VanTrierYD , RizopoulosD , KoopmanschapMA , VoogtL , et al. Efficacy of paracetamol, diclofenac and advice for acute low back pain in general practice: design of a randomized controlled trial (PACE Plus). BMC Musculoskeletal Disorders2017;18(1):56. ">Schreijenberg 2017</a>); or the duration of follow‐up was less than one day (<a href="./references#CD013581-bbs2-0050" title="EkenC , SerinkenM , ElicabukH , UyanikE , ErdalM . Intravenous paracetamol versus dexketoprofen versus morphine in acute mechanical low back pain in the emergency department: a randomised double‐blind controlled trial. Emergency Medicine Journal2014;31(3):177‐81. ">Eken 2014</a>; <a href="./references#CD013581-bbs2-0061" title="LeeHKH , TingSM , LauFL . A randomised control trial comparing the efficacy of tramadol and paracetamol against ketorolac and paracetamol in the management of musculoskeletal pain in the emergency department. Hong Kong Journal of Emergency Medicine.January 2008;15(1):5‐11. ">Lee 2008</a>; <a href="./references#CD013581-bbs2-0068" title="SerinkenM , EkenC , TunayK , GolcukY . Ketoprofen gel improves low back pain in addition to IV dexketoprofen: a randomized placebo‐controlled trial. American Journal of Emergency Medicine2016;34(8):1458‐61. ">Serinken 2016</a>)). </p> </li> </ul> </p> </section> </section> <section id="CD013581-sec-0079"> <h3 class="title">Risk of bias in included studies</h3> <p>We presented the assessment of the risk of bias of included studies at the domain level in <a href="#CD013581-fig-0002">Figure 2</a> and <a href="#CD013581-fig-0003">Figure 3</a>. Domains included selection, performance, detection, attrition, reporting, and other biases. After final assessment at the domain level, we determined there were seven studies with an overall judgement of low risk of bias (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0011" title="InnesGD , CroskerryP , WorthingtonJ , BeveridgeR , JonesD . Ketorolac versus acetaminophen‐codeine in the emergency department treatment of acute low back pain. Journal of Emergency Medicine1998;16(4):549‐56. ">Innes 1998</a>; <a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a>; <a href="./references#CD013581-bbs2-0025" title="SzpalskiM , HayezJP . Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain: a double blind placebo‐controlled study. British Journal of Rheumatology1994;33:74‐8. ">Szpalski 1994</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>). </p> <div class="figure" id="CD013581-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary per domain: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD013581-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary per domain: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> </div> <div class="figure" id="CD013581-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph per domain: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies" data-id="CD013581-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph per domain: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD013581-sec-0080"> <h4 class="title">Allocation</h4> <p>Of the 32 included studies, 12 reported an adequate randomisation procedure (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0011" title="InnesGD , CroskerryP , WorthingtonJ , BeveridgeR , JonesD . Ketorolac versus acetaminophen‐codeine in the emergency department treatment of acute low back pain. Journal of Emergency Medicine1998;16(4):549‐56. ">Innes 1998</a>; <a href="./references#CD013581-bbs2-0015" title="MikiK , IkemotoT , HayashiK , AraiY , SekiguchiM , ShiK , et al. Randomized open‐label non‐inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain. Journal of Orthopaedic Science 2018 Oct 3;23(3):483‐7. [PUBMED: PMID: 30292383] ">Miki 2018</a>; <a href="./references#CD013581-bbs2-0018" title="PlaplerPG , ScheinbergMA , EcclissatoCC , Bocchi de OliveiraMF , AmazonasRB . Double‐blind, randomized, double‐dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain. Drug Design, Development and Therapy2016;10:1987‐93. ">Plapler 2016</a>; <a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a>; <a href="./references#CD013581-bbs2-0021" title="SchattenkirchnerM , MilachowskiKA . A double‐blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clinical Rheumatology2003;22(2):127‐35. ">Schattenkirchner 2003</a>; <a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>; <a href="./references#CD013581-bbs2-0030" title="XimenesA , RoblesM , SandsG , VinuezaR . Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. Clinical Journal of Pain2007;23(3):244‐50. ">Ximenes 2007</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>). Ten studies adequately concealed treatment allocation (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0015" title="MikiK , IkemotoT , HayashiK , AraiY , SekiguchiM , ShiK , et al. Randomized open‐label non‐inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain. Journal of Orthopaedic Science 2018 Oct 3;23(3):483‐7. [PUBMED: PMID: 30292383] ">Miki 2018</a>; <a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a>; <a href="./references#CD013581-bbs2-0021" title="SchattenkirchnerM , MilachowskiKA . A double‐blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clinical Rheumatology2003;22(2):127‐35. ">Schattenkirchner 2003</a>; <a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>; <a href="./references#CD013581-bbs2-0030" title="XimenesA , RoblesM , SandsG , VinuezaR . Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. Clinical Journal of Pain2007;23(3):244‐50. ">Ximenes 2007</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>). The majority of studies did not report the method of randomisation or allocation concealment, thus, we scored these studies as unclear risk on both items. </p> <p>Two‐thirds of the studies showed similar characteristics at baseline (<a href="./references#CD013581-bbs2-0002" title="AgrifoglioE , BenvenuttiM , GattoP , AlbaneseL , ChrubinoP , MarinoniEC , et al. Aceclofenac: a new NSAID in the treatment of acute lumbago. Multicentre single blind study vs. diclofenac. Acta Therapeutica1994;20:33‐43. ">Agrifoglio 1994</a>; <a href="./references#CD013581-bbs2-0003" title="AmlieE , WeberH , HolmeI . Treatment of acute low back pain with piroxicam: results of a double‐blind placebo‐controlled trial. Spine1987;12:473‐6. ">Amlie 1987</a>; <a href="./references#CD013581-bbs2-0005" title="BakshiR , ThumbN , BröllH , KleinG , MayrhoferF , RainerF , et al. Treatment of acute lumbosacral back pain with diclofenac resinate: results of a double‐blind comparative trial versus piroxicam. Drug Investigation1994;8:288‐93. ">Bakshi 1994</a>; <a href="./references#CD013581-bbs2-0007" title="ColbergK , HettichM , SigmundR , DegnerFL . The efficacy and tolerability of an 8‐day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Current Medical Research and Opinion1996;13:363‐77. ">Colberg 1996</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0010" title="HosieGAC . The topical NSAID, felbinac, versus oral ibuprofen: a comparison of efficacy in the treatment of acute lower back injury. British Journal of Clinical Research1993;4:5‐17. ">Hosie 1993</a>; <a href="./references#CD013581-bbs2-0011" title="InnesGD , CroskerryP , WorthingtonJ , BeveridgeR , JonesD . Ketorolac versus acetaminophen‐codeine in the emergency department treatment of acute low back pain. Journal of Emergency Medicine1998;16(4):549‐56. ">Innes 1998</a>; <a href="./references#CD013581-bbs2-0015" title="MikiK , IkemotoT , HayashiK , AraiY , SekiguchiM , ShiK , et al. Randomized open‐label non‐inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain. Journal of Orthopaedic Science 2018 Oct 3;23(3):483‐7. [PUBMED: PMID: 30292383] ">Miki 2018</a>; <a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a>; <a href="./references#CD013581-bbs2-0017" title="OravaS . Medical treatment of acute low back pain. Diflunisal compared with indomethacin in acute lumbago. International Journal of Clinical Research1986;6:45‐51. ">Orava 1986</a>; <a href="./references#CD013581-bbs2-0018" title="PlaplerPG , ScheinbergMA , EcclissatoCC , Bocchi de OliveiraMF , AmazonasRB . Double‐blind, randomized, double‐dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain. Drug Design, Development and Therapy2016;10:1987‐93. ">Plapler 2016</a>; <a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a>; <a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a>; <a href="./references#CD013581-bbs2-0025" title="SzpalskiM , HayezJP . Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain: a double blind placebo‐controlled study. British Journal of Rheumatology1994;33:74‐8. ">Szpalski 1994</a>; <a href="./references#CD013581-bbs2-0026" title="VidemanT , HeikkilaJ , PartanenT . Double‐blind parallel study of meptazinol versus diflunisal in the treatment of lumbago. Current Medical Research and Opinion1984;9:246‐52. ">Videman 1984</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>; <a href="./references#CD013581-bbs2-0028" title="WaterworthRF , HunterIA . An open study of diflunisal, conservative and manipulative therapy in the management of acute mechanical low back pain. New Zealand Medical Journal1985;May:372‐5. ">Waterworth 1985</a>; <a href="./references#CD013581-bbs2-0030" title="XimenesA , RoblesM , SandsG , VinuezaR . Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. Clinical Journal of Pain2007;23(3):244‐50. ">Ximenes 2007</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>). The other studies either did not report baseline characteristics, or did not provide enough details to compare them. Several studies reported that baseline characteristics were similar, however, they did not provide details of the actual baseline characteristics for the acute LBP subgroup. We scored these as unclear risk of bias. </p> <p>Overall, we determined 12 studies to have a low risk of selection bias (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0011" title="InnesGD , CroskerryP , WorthingtonJ , BeveridgeR , JonesD . Ketorolac versus acetaminophen‐codeine in the emergency department treatment of acute low back pain. Journal of Emergency Medicine1998;16(4):549‐56. ">Innes 1998</a>; <a href="./references#CD013581-bbs2-0015" title="MikiK , IkemotoT , HayashiK , AraiY , SekiguchiM , ShiK , et al. Randomized open‐label non‐inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain. Journal of Orthopaedic Science 2018 Oct 3;23(3):483‐7. [PUBMED: PMID: 30292383] ">Miki 2018</a>; <a href="./references#CD013581-bbs2-0018" title="PlaplerPG , ScheinbergMA , EcclissatoCC , Bocchi de OliveiraMF , AmazonasRB . Double‐blind, randomized, double‐dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain. Drug Design, Development and Therapy2016;10:1987‐93. ">Plapler 2016</a>; <a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a>; <a href="./references#CD013581-bbs2-0021" title="SchattenkirchnerM , MilachowskiKA . A double‐blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clinical Rheumatology2003;22(2):127‐35. ">Schattenkirchner 2003</a>; <a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>; <a href="./references#CD013581-bbs2-0030" title="XimenesA , RoblesM , SandsG , VinuezaR . Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. Clinical Journal of Pain2007;23(3):244‐50. ">Ximenes 2007</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>). </p> </section> <section id="CD013581-sec-0081"> <h4 class="title">Blinding</h4> <section id="CD013581-sec-0082"> <h5 class="title">Performance bias</h5> <p>Fifteen studies adequately blinded participants (<a href="./references#CD013581-bbs2-0003" title="AmlieE , WeberH , HolmeI . Treatment of acute low back pain with piroxicam: results of a double‐blind placebo‐controlled trial. Spine1987;12:473‐6. ">Amlie 1987</a>; <a href="./references#CD013581-bbs2-0005" title="BakshiR , ThumbN , BröllH , KleinG , MayrhoferF , RainerF , et al. Treatment of acute lumbosacral back pain with diclofenac resinate: results of a double‐blind comparative trial versus piroxicam. Drug Investigation1994;8:288‐93. ">Bakshi 1994</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0010" title="HosieGAC . The topical NSAID, felbinac, versus oral ibuprofen: a comparison of efficacy in the treatment of acute lower back injury. British Journal of Clinical Research1993;4:5‐17. ">Hosie 1993</a>; <a href="./references#CD013581-bbs2-0011" title="InnesGD , CroskerryP , WorthingtonJ , BeveridgeR , JonesD . Ketorolac versus acetaminophen‐codeine in the emergency department treatment of acute low back pain. Journal of Emergency Medicine1998;16(4):549‐56. ">Innes 1998</a>; <a href="./references#CD013581-bbs2-0013" title="LaceyPH , DoddGD , ShannonDJ . A double‐blind placebo controlled study of piroxicam in the management of acute musculoskeletal disorders. European Journal of Rheumatology and Inflammation1984;7:95‐104. ">Lacey 1984</a>; <a href="./references#CD013581-bbs2-0017" title="OravaS . Medical treatment of acute low back pain. Diflunisal compared with indomethacin in acute lumbago. International Journal of Clinical Research1986;6:45‐51. ">Orava 1986</a>; <a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a>; <a href="./references#CD013581-bbs2-0023" title="StratzT . Intramuscular etofenamate in the treatment of acute lumbago. Effectiveness and tolerance in comparison with intramuscular diclofenac‐Na. Fortschritte der Medizin1990;108:264‐6. ">Stratz 1990</a>; <a href="./references#CD013581-bbs2-0025" title="SzpalskiM , HayezJP . Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain: a double blind placebo‐controlled study. British Journal of Rheumatology1994;33:74‐8. ">Szpalski 1994</a>; <a href="./references#CD013581-bbs2-0026" title="VidemanT , HeikkilaJ , PartanenT . Double‐blind parallel study of meptazinol versus diflunisal in the treatment of lumbago. Current Medical Research and Opinion1984;9:246‐52. ">Videman 1984</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>). Twelve trials adequately blinded careproviders (<a href="./references#CD013581-bbs2-0003" title="AmlieE , WeberH , HolmeI . Treatment of acute low back pain with piroxicam: results of a double‐blind placebo‐controlled trial. Spine1987;12:473‐6. ">Amlie 1987</a>; <a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0005" title="BakshiR , ThumbN , BröllH , KleinG , MayrhoferF , RainerF , et al. Treatment of acute lumbosacral back pain with diclofenac resinate: results of a double‐blind comparative trial versus piroxicam. Drug Investigation1994;8:288‐93. ">Bakshi 1994</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0010" title="HosieGAC . The topical NSAID, felbinac, versus oral ibuprofen: a comparison of efficacy in the treatment of acute lower back injury. British Journal of Clinical Research1993;4:5‐17. ">Hosie 1993</a>; <a href="./references#CD013581-bbs2-0011" title="InnesGD , CroskerryP , WorthingtonJ , BeveridgeR , JonesD . Ketorolac versus acetaminophen‐codeine in the emergency department treatment of acute low back pain. Journal of Emergency Medicine1998;16(4):549‐56. ">Innes 1998</a>; <a href="./references#CD013581-bbs2-0013" title="LaceyPH , DoddGD , ShannonDJ . A double‐blind placebo controlled study of piroxicam in the management of acute musculoskeletal disorders. European Journal of Rheumatology and Inflammation1984;7:95‐104. ">Lacey 1984</a>; <a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a>; <a href="./references#CD013581-bbs2-0021" title="SchattenkirchnerM , MilachowskiKA . A double‐blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clinical Rheumatology2003;22(2):127‐35. ">Schattenkirchner 2003</a>; <a href="./references#CD013581-bbs2-0025" title="SzpalskiM , HayezJP . Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain: a double blind placebo‐controlled study. British Journal of Rheumatology1994;33:74‐8. ">Szpalski 1994</a>; <a href="./references#CD013581-bbs2-0026" title="VidemanT , HeikkilaJ , PartanenT . Double‐blind parallel study of meptazinol versus diflunisal in the treatment of lumbago. Current Medical Research and Opinion1984;9:246‐52. ">Videman 1984</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>). Thirteen studies adequately blinded outcome assessors (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0006" title="BrownFL , BodisonS , DixonJ , DavisW , NowoslawskiJ . Comparison of diflunisal and acetaminophen with codeine in the treatment of initial or recurrent acute low back pain. Clinical Therapeutics1986;9(Suppl C):52‐8. ">Brown 1986</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0010" title="HosieGAC . The topical NSAID, felbinac, versus oral ibuprofen: a comparison of efficacy in the treatment of acute lower back injury. British Journal of Clinical Research1993;4:5‐17. ">Hosie 1993</a>; <a href="./references#CD013581-bbs2-0011" title="InnesGD , CroskerryP , WorthingtonJ , BeveridgeR , JonesD . Ketorolac versus acetaminophen‐codeine in the emergency department treatment of acute low back pain. Journal of Emergency Medicine1998;16(4):549‐56. ">Innes 1998</a>; <a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a>; <a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a>; <a href="./references#CD013581-bbs2-0025" title="SzpalskiM , HayezJP . Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain: a double blind placebo‐controlled study. British Journal of Rheumatology1994;33:74‐8. ">Szpalski 1994</a>; <a href="./references#CD013581-bbs2-0026" title="VidemanT , HeikkilaJ , PartanenT . Double‐blind parallel study of meptazinol versus diflunisal in the treatment of lumbago. Current Medical Research and Opinion1984;9:246‐52. ">Videman 1984</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>). The remaining studies either (i) had inadequate blinding of participants, careproviders, and outcome assessors (scored at high risk); or (ii) provided insufficient details to determine adequacy of blinding (scored as unclear risk). In two studies, blinding of careproviders was not possible, since they had to perform either real or sham spinal manipulation; however, in both studies, the outcome assessors were blinded (<a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>). </p> <p>Regarding co‐interventions: we allowed paracetamol as rescue medication. No other analgesics or anti‐inflammatory drugs were allowed. Five studies allowed the use of paracetamol as rescue medication (<a href="./references#CD013581-bbs2-0003" title="AmlieE , WeberH , HolmeI . Treatment of acute low back pain with piroxicam: results of a double‐blind placebo‐controlled trial. Spine1987;12:473‐6. ">Amlie 1987</a>; <a href="./references#CD013581-bbs2-0014" title="Metscher B. Kubler U. Jahnel‐KrachtH . Dexketoprofen‐trometamol and tramadol in acute lumbago [Dexketoprofen‐Trometamol und Tramadol bei akuter Lumbago]. Fortschritte der Medizin. Originalien2001;118(4):147‐51. ">Metscher 2001</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>), whereas in one study, the use of rescue medication terminated trial participation (<a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>). In one study, all participants received 1g of paracetamol four times a day (<a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>). Three studies prescribed bedrest to all participants (<a href="./references#CD013581-bbs2-0024" title="SzpalskiM , PotyS , HayezJP , DebaizeJP . Objective assessment of trunk function in patients with acute low back pain treated with Tenoxicam. A prospective controlled study. Neuro‐orthopedics1990;10:41‐7. ">Szpalski 1990</a>; <a href="./references#CD013581-bbs2-0025" title="SzpalskiM , HayezJP . Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain: a double blind placebo‐controlled study. British Journal of Rheumatology1994;33:74‐8. ">Szpalski 1994</a>; <a href="./references#CD013581-bbs2-0029" title="WieselSW , CucklerJM , DelucaF , JonesF , ZeideMS , RothmanRH . Acute low back pain: an objective analysis of conservative therapy. Spine1980;5:324‐30. ">Wiesel 1980</a>). We scored 14 studies that avoided co‐interventions at low risk of bias (<a href="./references#CD013581-bbs2-0001" title="AghababianRV , VolturoGA , HeifetzIN . Comparison of diflunisal and naproxen in the management of acute low back pain. Clinical Therapeutics1986;9(Suppl C):47‐51. ">Aghababian 1986</a>; <a href="./references#CD013581-bbs2-0003" title="AmlieE , WeberH , HolmeI . Treatment of acute low back pain with piroxicam: results of a double‐blind placebo‐controlled trial. Spine1987;12:473‐6. ">Amlie 1987</a>; <a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0005" title="BakshiR , ThumbN , BröllH , KleinG , MayrhoferF , RainerF , et al. Treatment of acute lumbosacral back pain with diclofenac resinate: results of a double‐blind comparative trial versus piroxicam. Drug Investigation1994;8:288‐93. ">Bakshi 1994</a>; <a href="./references#CD013581-bbs2-0006" title="BrownFL , BodisonS , DixonJ , DavisW , NowoslawskiJ . Comparison of diflunisal and acetaminophen with codeine in the treatment of initial or recurrent acute low back pain. Clinical Therapeutics1986;9(Suppl C):52‐8. ">Brown 1986</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0010" title="HosieGAC . The topical NSAID, felbinac, versus oral ibuprofen: a comparison of efficacy in the treatment of acute lower back injury. British Journal of Clinical Research1993;4:5‐17. ">Hosie 1993</a>; <a href="./references#CD013581-bbs2-0014" title="Metscher B. Kubler U. Jahnel‐KrachtH . Dexketoprofen‐trometamol and tramadol in acute lumbago [Dexketoprofen‐Trometamol und Tramadol bei akuter Lumbago]. Fortschritte der Medizin. Originalien2001;118(4):147‐51. ">Metscher 2001</a>; <a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a>; <a href="./references#CD013581-bbs2-0021" title="SchattenkirchnerM , MilachowskiKA . A double‐blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clinical Rheumatology2003;22(2):127‐35. ">Schattenkirchner 2003</a>; <a href="./references#CD013581-bbs2-0023" title="StratzT . Intramuscular etofenamate in the treatment of acute lumbago. Effectiveness and tolerance in comparison with intramuscular diclofenac‐Na. Fortschritte der Medizin1990;108:264‐6. ">Stratz 1990</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>; <a href="./references#CD013581-bbs2-0028" title="WaterworthRF , HunterIA . An open study of diflunisal, conservative and manipulative therapy in the management of acute mechanical low back pain. New Zealand Medical Journal1985;May:372‐5. ">Waterworth 1985</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>). We scored one study at high risk of bias because they did not restrict co‐interventions after the first follow‐up at 30 minutes, and participants could choose between inpatient and outpatient treatment, which influenced the amount of additional treatment for each participant (<a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a>). We scored the remaining studies as unclear risk of bias. </p> <p>Most studies provided insufficient information on compliance, therefore, we scored them as unclear risk of bias. Four studies either reported that compliance was acceptable or provided details regarding compliance (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0023" title="StratzT . Intramuscular etofenamate in the treatment of acute lumbago. Effectiveness and tolerance in comparison with intramuscular diclofenac‐Na. Fortschritte der Medizin1990;108:264‐6. ">Stratz 1990</a>). </p> <p>Overall, we determined twelve studies to be at low risk of performance bias (<a href="./references#CD013581-bbs2-0003" title="AmlieE , WeberH , HolmeI . Treatment of acute low back pain with piroxicam: results of a double‐blind placebo‐controlled trial. Spine1987;12:473‐6. ">Amlie 1987</a>; <a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0005" title="BakshiR , ThumbN , BröllH , KleinG , MayrhoferF , RainerF , et al. Treatment of acute lumbosacral back pain with diclofenac resinate: results of a double‐blind comparative trial versus piroxicam. Drug Investigation1994;8:288‐93. ">Bakshi 1994</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0010" title="HosieGAC . The topical NSAID, felbinac, versus oral ibuprofen: a comparison of efficacy in the treatment of acute lower back injury. British Journal of Clinical Research1993;4:5‐17. ">Hosie 1993</a>; <a href="./references#CD013581-bbs2-0011" title="InnesGD , CroskerryP , WorthingtonJ , BeveridgeR , JonesD . Ketorolac versus acetaminophen‐codeine in the emergency department treatment of acute low back pain. Journal of Emergency Medicine1998;16(4):549‐56. ">Innes 1998</a>; <a href="./references#CD013581-bbs2-0013" title="LaceyPH , DoddGD , ShannonDJ . A double‐blind placebo controlled study of piroxicam in the management of acute musculoskeletal disorders. European Journal of Rheumatology and Inflammation1984;7:95‐104. ">Lacey 1984</a>; <a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a>; <a href="./references#CD013581-bbs2-0025" title="SzpalskiM , HayezJP . Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain: a double blind placebo‐controlled study. British Journal of Rheumatology1994;33:74‐8. ">Szpalski 1994</a>; <a href="./references#CD013581-bbs2-0026" title="VidemanT , HeikkilaJ , PartanenT . Double‐blind parallel study of meptazinol versus diflunisal in the treatment of lumbago. Current Medical Research and Opinion1984;9:246‐52. ">Videman 1984</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>). </p> </section> <section id="CD013581-sec-0083"> <h5 class="title">Detection bias</h5> <p>The majority of studies adequately reported the timing of outcome assessments, and this timing was similar in most cases; therefore, we scored 28 studies at low risk of bias. Four studies either did not report clearly on the timing of the outcome assessment (and we scored them as unclear risk of bias (<a href="./references#CD013581-bbs2-0006" title="BrownFL , BodisonS , DixonJ , DavisW , NowoslawskiJ . Comparison of diflunisal and acetaminophen with codeine in the treatment of initial or recurrent acute low back pain. Clinical Therapeutics1986;9(Suppl C):52‐8. ">Brown 1986</a>; <a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a>)); or they had different timing of outcome assessment between participants (and we scored them at high risk of bias (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0023" title="StratzT . Intramuscular etofenamate in the treatment of acute lumbago. Effectiveness and tolerance in comparison with intramuscular diclofenac‐Na. Fortschritte der Medizin1990;108:264‐6. ">Stratz 1990</a>)). This domain also concerned the adequate blinding of the outcome assessor, which we listed above (see Performance bias; we scored 13 trials at low risk). </p> <p>Overall, we determined twelve studies to have a low risk of detection bias (<a href="./references#CD013581-bbs2-0006" title="BrownFL , BodisonS , DixonJ , DavisW , NowoslawskiJ . Comparison of diflunisal and acetaminophen with codeine in the treatment of initial or recurrent acute low back pain. Clinical Therapeutics1986;9(Suppl C):52‐8. ">Brown 1986</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0010" title="HosieGAC . The topical NSAID, felbinac, versus oral ibuprofen: a comparison of efficacy in the treatment of acute lower back injury. British Journal of Clinical Research1993;4:5‐17. ">Hosie 1993</a>; <a href="./references#CD013581-bbs2-0011" title="InnesGD , CroskerryP , WorthingtonJ , BeveridgeR , JonesD . Ketorolac versus acetaminophen‐codeine in the emergency department treatment of acute low back pain. Journal of Emergency Medicine1998;16(4):549‐56. ">Innes 1998</a>; <a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a>; <a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a>; <a href="./references#CD013581-bbs2-0025" title="SzpalskiM , HayezJP . Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain: a double blind placebo‐controlled study. British Journal of Rheumatology1994;33:74‐8. ">Szpalski 1994</a>; <a href="./references#CD013581-bbs2-0026" title="VidemanT , HeikkilaJ , PartanenT . Double‐blind parallel study of meptazinol versus diflunisal in the treatment of lumbago. Current Medical Research and Opinion1984;9:246‐52. ">Videman 1984</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>). </p> </section> </section> <section id="CD013581-sec-0084"> <h4 class="title">Incomplete outcome data</h4> <p>We scored most studies at low risk of bias concerning dropout rates. However, three studies did not adequately report dropouts and we scored them as unclear risk of bias (<a href="./references#CD013581-bbs2-0013" title="LaceyPH , DoddGD , ShannonDJ . A double‐blind placebo controlled study of piroxicam in the management of acute musculoskeletal disorders. European Journal of Rheumatology and Inflammation1984;7:95‐104. ">Lacey 1984</a>; <a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a>; <a href="./references#CD013581-bbs2-0029" title="WieselSW , CucklerJM , DelucaF , JonesF , ZeideMS , RothmanRH . Acute low back pain: an objective analysis of conservative therapy. Spine1980;5:324‐30. ">Wiesel 1980</a>); five studies reported substantial drop‐out rates or clear differences between groups, and we scored them at high risk of bias (<a href="./references#CD013581-bbs2-0001" title="AghababianRV , VolturoGA , HeifetzIN . Comparison of diflunisal and naproxen in the management of acute low back pain. Clinical Therapeutics1986;9(Suppl C):47‐51. ">Aghababian 1986</a>; <a href="./references#CD013581-bbs2-0015" title="MikiK , IkemotoT , HayashiK , AraiY , SekiguchiM , ShiK , et al. Randomized open‐label non‐inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain. Journal of Orthopaedic Science 2018 Oct 3;23(3):483‐7. [PUBMED: PMID: 30292383] ">Miki 2018</a>; <a href="./references#CD013581-bbs2-0018" title="PlaplerPG , ScheinbergMA , EcclissatoCC , Bocchi de OliveiraMF , AmazonasRB . Double‐blind, randomized, double‐dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain. Drug Design, Development and Therapy2016;10:1987‐93. ">Plapler 2016</a>; <a href="./references#CD013581-bbs2-0020" title="PostacchiniF , FacchiniM , PalieriP . Efficacy of various forms of conservative treatment in low back pain: a comparative study. Neuro‐Orthopedics1988;6:28‐35. ">Postacchini 1988</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>). Twelve studies performed an intention‐to‐treat (ITT) analysis and we scored them at low risk of bias (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0005" title="BakshiR , ThumbN , BröllH , KleinG , MayrhoferF , RainerF , et al. Treatment of acute lumbosacral back pain with diclofenac resinate: results of a double‐blind comparative trial versus piroxicam. Drug Investigation1994;8:288‐93. ">Bakshi 1994</a>; <a href="./references#CD013581-bbs2-0007" title="ColbergK , HettichM , SigmundR , DegnerFL . The efficacy and tolerability of an 8‐day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Current Medical Research and Opinion1996;13:363‐77. ">Colberg 1996</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0021" title="SchattenkirchnerM , MilachowskiKA . A double‐blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clinical Rheumatology2003;22(2):127‐35. ">Schattenkirchner 2003</a>; <a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a>; <a href="./references#CD013581-bbs2-0025" title="SzpalskiM , HayezJP . Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain: a double blind placebo‐controlled study. British Journal of Rheumatology1994;33:74‐8. ">Szpalski 1994</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>; <a href="./references#CD013581-bbs2-0030" title="XimenesA , RoblesM , SandsG , VinuezaR . Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. Clinical Journal of Pain2007;23(3):244‐50. ">Ximenes 2007</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>). The remaining trials either did not report (unclear risk of bias), or did not perform an ITT analysis (high risk of bias). </p> <p>Overall, we determined ten studies to have a low risk of attrition bias (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0005" title="BakshiR , ThumbN , BröllH , KleinG , MayrhoferF , RainerF , et al. Treatment of acute lumbosacral back pain with diclofenac resinate: results of a double‐blind comparative trial versus piroxicam. Drug Investigation1994;8:288‐93. ">Bakshi 1994</a>; <a href="./references#CD013581-bbs2-0007" title="ColbergK , HettichM , SigmundR , DegnerFL . The efficacy and tolerability of an 8‐day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Current Medical Research and Opinion1996;13:363‐77. ">Colberg 1996</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0021" title="SchattenkirchnerM , MilachowskiKA . A double‐blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clinical Rheumatology2003;22(2):127‐35. ">Schattenkirchner 2003</a>; <a href="./references#CD013581-bbs2-0025" title="SzpalskiM , HayezJP . Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain: a double blind placebo‐controlled study. British Journal of Rheumatology1994;33:74‐8. ">Szpalski 1994</a>; <a href="./references#CD013581-bbs2-0030" title="XimenesA , RoblesM , SandsG , VinuezaR . Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. Clinical Journal of Pain2007;23(3):244‐50. ">Ximenes 2007</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>). </p> </section> <section id="CD013581-sec-0085"> <h4 class="title">Selective reporting</h4> <p>Three RCTs registered their study protocol in an accessible clinical trial registry, published it, or made their study protocol available on request (<a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>). We scored registered trials at low risk for reporting bias. If there was no study protocol, we scored the risk of bias as unclear. We scored two studies at high risk of bias for selective reporting: <a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a> had a study protocol available, but several outcomes of the primary treatment groups were not compared, and they did not report the results of two comparison groups; and <a href="./references#CD013581-bbs2-0020" title="PostacchiniF , FacchiniM , PalieriP . Efficacy of various forms of conservative treatment in low back pain: a comparative study. Neuro‐Orthopedics1988;6:28‐35. ">Postacchini 1988</a> reported they intended to recruit a control group of untreated participants, but did not include this group in the final analyses because not enough participants agreed to enrol in this group, and most of them were lost to follow‐up. They reported this in the discussion section, but not in the methods section. </p> <p>Therefore, we determined only three studies at low risk for the domain of reporting bias (<a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>). </p> </section> <section id="CD013581-sec-0086"> <h4 class="title">Other potential sources of bias</h4> <p>We did not find any other potential sources of bias. Therefore, we determined all studies to be at low risk for the domain of other potential sources of bias. </p> <section id="CD013581-sec-0087"> <h5 class="title">Summary</h5> <p>To summarise, the most common sources of bias were due to insufficient information, for instance, on the method of randomisation, allocation concealment (selection bias), and blinding (performance and detection bias). Often, there was no information available as to whether they performed an ITT analysis (attrition bias). Most did not register their study protocols, which increases the risk for selective reporting (reporting bias). Lastly, it remains unclear if there was publication bias. </p> </section> </section> </section> <section id="CD013581-sec-0088"> <h3 class="title" id="CD013581-sec-0088">Effects of interventions</h3> <p>See: <a href="./full#CD013581-tbl-0001"><b>Summary of findings for the main comparison</b> NSAIDs compared to placebo in people with acute low back pain</a>; <a href="./full#CD013581-tbl-0002"><b>Summary of findings 2</b> Selective COX‐2 inhibitors compared to non‐selective NSAIDs for acute low back pain</a> </p> <p>We used a random‐effects model to pool results throughout this review, assuming some between‐study variation, when taking into account the differences in population, types and frequency of NSAIDs used, follow‐up duration, and the country where the trial was performed. This approach provided us with a slightly more conservative estimate of the 95% confidence interval (CI). We planned subgroup analyses, but we could not conduct these due to lack of available data. </p> <section id="CD013581-sec-0089"> <h4 class="title">1. NSAIDs compared to placebo</h4> <p>See <a href="./full#CD013581-tbl-0001">summary of findings Table for the main comparison</a> for this comparison. </p> <p>Nine studies compared NSAIDs with placebo (<a href="./references#CD013581-bbs2-0003" title="AmlieE , WeberH , HolmeI . Treatment of acute low back pain with piroxicam: results of a double‐blind placebo‐controlled trial. Spine1987;12:473‐6. ">Amlie 1987</a>; <a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0013" title="LaceyPH , DoddGD , ShannonDJ . A double‐blind placebo controlled study of piroxicam in the management of acute musculoskeletal disorders. European Journal of Rheumatology and Inflammation1984;7:95‐104. ">Lacey 1984</a>; <a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a>; <a href="./references#CD013581-bbs2-0020" title="PostacchiniF , FacchiniM , PalieriP . Efficacy of various forms of conservative treatment in low back pain: a comparative study. Neuro‐Orthopedics1988;6:28‐35. ">Postacchini 1988</a>; <a href="./references#CD013581-bbs2-0025" title="SzpalskiM , HayezJP . Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain: a double blind placebo‐controlled study. British Journal of Rheumatology1994;33:74‐8. ">Szpalski 1994</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>), two of which compared two different NSAIDs with placebo (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>). Diclofenac was the most common NSAID evaluated (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0020" title="PostacchiniF , FacchiniM , PalieriP . Efficacy of various forms of conservative treatment in low back pain: a comparative study. Neuro‐Orthopedics1988;6:28‐35. ">Postacchini 1988</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>). Other studies evaluated ibuprofen (two studies), piroxicam, dipyrone, and tenoxicam. We considered four studies at low risk of bias (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0025" title="SzpalskiM , HayezJP . Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain: a double blind placebo‐controlled study. British Journal of Rheumatology1994;33:74‐8. ">Szpalski 1994</a>). Follow‐up ranged from one day to two months. Treatment duration ranged from one day to four weeks. Most often, tablets or capsules were used as the mode of delivery, except for <a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>, which used intramuscular injections, and <a href="./references#CD013581-bbs2-0025" title="SzpalskiM , HayezJP . Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain: a double blind placebo‐controlled study. British Journal of Rheumatology1994;33:74‐8. ">Szpalski 1994</a>, which started with an intramuscular injection followed by capsules. <a href="./references#CD013581-bbs2-0020" title="PostacchiniF , FacchiniM , PalieriP . Efficacy of various forms of conservative treatment in low back pain: a comparative study. Neuro‐Orthopedics1988;6:28‐35. ">Postacchini 1988</a> compared diclofenac tablets to an anti‐edema gel that functioned as a placebo. </p> <p>One study added a placebo for blinding purposes only, and did not report results for the comparison of NSAID versus placebo (<a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a>). One study only reported a combination score of improvement in pain, disability, and spinal mobility, which showed no significant differences between NSAID and placebo after three weeks and two months (<a href="./references#CD013581-bbs2-0020" title="PostacchiniF , FacchiniM , PalieriP . Efficacy of various forms of conservative treatment in low back pain: a comparative study. Neuro‐Orthopedics1988;6:28‐35. ">Postacchini 1988</a>). One study closed the placebo arm early, after an interim analysis showing superiority of both treatment arms (diclofenac or spinal manipulation) compared to placebo (<a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>). They presented data of the combined group of both active treatment arms compared to placebo, without providing a subgroup analysis of diclofenac versus placebo, hence, these data could not be used in this comparison. </p> <section id="CD013581-sec-0090"> <h5 class="title">Primary outcomes</h5> <section id="CD013581-sec-0091"> <h6 class="title">Pain intensity</h6> <p>Four studies (five treatment arms, N = 815) reported on short‐term pain reduction from baseline (visual analogue scale (VAS) 0 to 100) and provided data at a time point relevant for our review that could be pooled (<a href="./references#CD013581-bbs2-0003" title="AmlieE , WeberH , HolmeI . Treatment of acute low back pain with piroxicam: results of a double‐blind placebo‐controlled trial. Spine1987;12:473‐6. ">Amlie 1987</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0025" title="SzpalskiM , HayezJP . Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain: a double blind placebo‐controlled study. British Journal of Rheumatology1994;33:74‐8. ">Szpalski 1994</a>). One study reported on pain intensity at a maximum of six hours follow‐up only, and was excluded from the comparison (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>). NSAIDs reduced pain intensity more than placebo (mean difference (MD) ‐7.29, 95% CI ‐10.98 to ‐3.61; I² 35%; <a href="./references#CD013581-fig-0007" title="">Analysis 1.1</a>; <a href="#CD013581-fig-0004">Figure 4</a>). The magnitude of the effect is small and probably not clinically relevant. The quality of this evidence is moderate; we downgraded the evidence one level due to risk of bias. </p> <div class="figure" id="CD013581-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.1 Pain intensity on 100‐mm VAS. Follow‐up ≤ 3 weeks." data-id="CD013581-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.1 Pain intensity on 100‐mm VAS. Follow‐up ≤ 3 weeks. </p> </div> </div> </div> </section> <section id="CD013581-sec-0092"> <h6 class="title">Disability</h6> <p>Two studies (three treatment arms, N = 471) reported on short‐term change in disability from baseline (Roland Morris Disability Questionnaire (RMDQ) 0 to 24 scale) during three weeks follow‐up (<a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>). NSAIDs reduced disability more than placebo (MD ‐2.02, 95% CI ‐2.89 to ‐1.15; I² 0%; <a href="./references#CD013581-fig-0008" title="">Analysis 1.2</a>; <a href="#CD013581-fig-0005">Figure 5</a>). The difference is small and probably not clinically relevant. The quality of this evidence is high; we did not downgrade the evidence. </p> <div class="figure" id="CD013581-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.2 Disability (RMDQ 0 to 24). Follow‐up ≤ 3 weeks." data-id="CD013581-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.2 Disability (RMDQ 0 to 24). Follow‐up ≤ 3 weeks. </p> </div> </div> </div> </section> <section id="CD013581-sec-0093"> <h6 class="title">Global improvement</h6> <p>Five studies (seven treatment arms, N = 1201) reported on the proportion of participants experiencing global improvement (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0013" title="LaceyPH , DoddGD , ShannonDJ . A double‐blind placebo controlled study of piroxicam in the management of acute musculoskeletal disorders. European Journal of Rheumatology and Inflammation1984;7:95‐104. ">Lacey 1984</a>; <a href="./references#CD013581-bbs2-0025" title="SzpalskiM , HayezJP . Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain: a double blind placebo‐controlled study. British Journal of Rheumatology1994;33:74‐8. ">Szpalski 1994</a>). There was a greater likelihood that those who received NSAIDs experienced global improvement over those who took placebo (risk ratio (RR) 1.40, 95% CI 1.12 to 1.75; I² 52%; <a href="./references#CD013581-fig-0009" title="">Analysis 1.3</a>; <a href="#CD013581-fig-0006">Figure 6</a>). The effect size is probably not clinically relevant. The heterogeneity could not be explained, but some differences existed between the studies: different cutoff points to define improvement; different scales and types of outcome measures; varied timing of outcome assessments (ranged from two days to two weeks); and different modes of delivery. The quality of this evidence is low; we downgraded the evidence two levels due to inconsistency and indirectness. </p> <div class="figure" id="CD013581-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.3 Proportion of participants experiencing global improvement. Follow‐up ≤ 3 weeks." data-id="CD013581-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.3 Proportion of participants experiencing global improvement. Follow‐up ≤ 3 weeks. </p> </div> </div> </div> </section> <section id="CD013581-sec-0094"> <h6 class="title">Adverse events</h6> <p>Six studies (eight treatment arms, N = 1394) reported on the proportion of participants experiencing adverse events (<a href="./references#CD013581-bbs2-0003" title="AmlieE , WeberH , HolmeI . Treatment of acute low back pain with piroxicam: results of a double‐blind placebo‐controlled trial. Spine1987;12:473‐6. ">Amlie 1987</a>; <a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0013" title="LaceyPH , DoddGD , ShannonDJ . A double‐blind placebo controlled study of piroxicam in the management of acute musculoskeletal disorders. European Journal of Rheumatology and Inflammation1984;7:95‐104. ">Lacey 1984</a>; <a href="./references#CD013581-bbs2-0025" title="SzpalskiM , HayezJP . Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain: a double blind placebo‐controlled study. British Journal of Rheumatology1994;33:74‐8. ">Szpalski 1994</a>). The results between the NSAID and placebo groups were inconclusive for experiencing adverse events (RR 0.86, 95% CI 0.63 to 1.18; I² 0%; <a href="./references#CD013581-fig-0010" title="">Analysis 1.4</a>). The quality of this evidence is very low; we downgraded the evidence three levels due to risk of bias, inconsistency, indirectness, and imprecision. </p> </section> <section id="CD013581-sec-0095"> <h6 class="title">Return to work</h6> <p>One study (N = 266) reported data on return to work (<a href="./references#CD013581-bbs2-0003" title="AmlieE , WeberH , HolmeI . Treatment of acute low back pain with piroxicam: results of a double‐blind placebo‐controlled trial. Spine1987;12:473‐6. ">Amlie 1987</a>). The results for return to work were inconclusive between the NSAID and placebo groups (RR 1.48; 95% CI 0.98 to 2.23); the difference was not clinically relevant. The quality of this evidence is very low; we downgraded the evidence three levels due to risk of bias (one level), and imprecision (two levels). </p> </section> </section> <section id="CD013581-sec-0096"> <h5 class="title">Long‐term follow‐up &amp; sensitivity analyses</h5> <p>Two studies provided long‐term follow‐up data. <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a> showed no significant differences between NSAIDs and placebo on the mean pain score, mean disability score, and mean global perceived effect score after 12 weeks. <a href="./references#CD013581-bbs2-0020" title="PostacchiniF , FacchiniM , PalieriP . Efficacy of various forms of conservative treatment in low back pain: a comparative study. Neuro‐Orthopedics1988;6:28‐35. ">Postacchini 1988</a> used a combination score of improvement in pain, disability, and spinal mobility, which showed no significant differences between NSAIDs and placebo after two and six months. </p> <p>We performed one sensitivity analysis for pain intensity; removing the studies at high risk of bias did not change the results (<a href="./references#CD013581-bbs2-0003" title="AmlieE , WeberH , HolmeI . Treatment of acute low back pain with piroxicam: results of a double‐blind placebo‐controlled trial. Spine1987;12:473‐6. ">Amlie 1987</a>; <a href="./references#CD013581-bbs2-0013" title="LaceyPH , DoddGD , ShannonDJ . A double‐blind placebo controlled study of piroxicam in the management of acute musculoskeletal disorders. European Journal of Rheumatology and Inflammation1984;7:95‐104. ">Lacey 1984</a>). </p> <p>We performed two sensitivity analyses for global improvement; removing the study at high risk of bias did not change the result (<a href="./references#CD013581-bbs2-0013" title="LaceyPH , DoddGD , ShannonDJ . A double‐blind placebo controlled study of piroxicam in the management of acute musculoskeletal disorders. European Journal of Rheumatology and Inflammation1984;7:95‐104. ">Lacey 1984</a>). Removing studies with mixed participant population increased the heterogeneity, and the result was no longer statistically significant (RR 1.29, 95% CI 0.97 to 1.72; I² 58%; <a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0013" title="LaceyPH , DoddGD , ShannonDJ . A double‐blind placebo controlled study of piroxicam in the management of acute musculoskeletal disorders. European Journal of Rheumatology and Inflammation1984;7:95‐104. ">Lacey 1984</a>). </p> <p>We performed two sensitivity analyses for adverse events; (i) removing the studies at high risk of bias (<a href="./references#CD013581-bbs2-0003" title="AmlieE , WeberH , HolmeI . Treatment of acute low back pain with piroxicam: results of a double‐blind placebo‐controlled trial. Spine1987;12:473‐6. ">Amlie 1987</a>; <a href="./references#CD013581-bbs2-0013" title="LaceyPH , DoddGD , ShannonDJ . A double‐blind placebo controlled study of piroxicam in the management of acute musculoskeletal disorders. European Journal of Rheumatology and Inflammation1984;7:95‐104. ">Lacey 1984</a>), and (ii) removing studies with a mixed participant population (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0013" title="LaceyPH , DoddGD , ShannonDJ . A double‐blind placebo controlled study of piroxicam in the management of acute musculoskeletal disorders. European Journal of Rheumatology and Inflammation1984;7:95‐104. ">Lacey 1984</a>). This did not change the results in either analyses. </p> <p>We did not conduct sensitivity analyses for the other outcomes.</p> </section> </section> <section id="CD013581-sec-0097"> <h4 class="title">2. Selective COX‐2 inhibitors compared to non‐selective NSAIDs</h4> <p>See <a href="./full#CD013581-tbl-0002">summary of findings Table 2</a> for this comparison. </p> <p>Seventeen studies compared NSAIDs to other NSAIDs (<a href="./references#CD013581-bbs2-0001" title="AghababianRV , VolturoGA , HeifetzIN . Comparison of diflunisal and naproxen in the management of acute low back pain. Clinical Therapeutics1986;9(Suppl C):47‐51. ">Aghababian 1986</a>; <a href="./references#CD013581-bbs2-0002" title="AgrifoglioE , BenvenuttiM , GattoP , AlbaneseL , ChrubinoP , MarinoniEC , et al. Aceclofenac: a new NSAID in the treatment of acute lumbago. Multicentre single blind study vs. diclofenac. Acta Therapeutica1994;20:33‐43. ">Agrifoglio 1994</a>; <a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0005" title="BakshiR , ThumbN , BröllH , KleinG , MayrhoferF , RainerF , et al. Treatment of acute lumbosacral back pain with diclofenac resinate: results of a double‐blind comparative trial versus piroxicam. Drug Investigation1994;8:288‐93. ">Bakshi 1994</a>; <a href="./references#CD013581-bbs2-0007" title="ColbergK , HettichM , SigmundR , DegnerFL . The efficacy and tolerability of an 8‐day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Current Medical Research and Opinion1996;13:363‐77. ">Colberg 1996</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0010" title="HosieGAC . The topical NSAID, felbinac, versus oral ibuprofen: a comparison of efficacy in the treatment of acute lower back injury. British Journal of Clinical Research1993;4:5‐17. ">Hosie 1993</a>; <a href="./references#CD013581-bbs2-0012" title="JaffeG . A double‐blind, between‐patient comparison of alclofenac ('Prinalgin' ) and indomethacin in the treatment of low back pain and sciatica. Current Medical Research and Opinion1974;2:424‐9. ">Jaffe 1974</a>; <a href="./references#CD013581-bbs2-0017" title="OravaS . Medical treatment of acute low back pain. Diflunisal compared with indomethacin in acute lumbago. International Journal of Clinical Research1986;6:45‐51. ">Orava 1986</a>; <a href="./references#CD013581-bbs2-0018" title="PlaplerPG , ScheinbergMA , EcclissatoCC , Bocchi de OliveiraMF , AmazonasRB . Double‐blind, randomized, double‐dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain. Drug Design, Development and Therapy2016;10:1987‐93. ">Plapler 2016</a>; <a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a>; <a href="./references#CD013581-bbs2-0021" title="SchattenkirchnerM , MilachowskiKA . A double‐blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clinical Rheumatology2003;22(2):127‐35. ">Schattenkirchner 2003</a>; <a href="./references#CD013581-bbs2-0023" title="StratzT . Intramuscular etofenamate in the treatment of acute lumbago. Effectiveness and tolerance in comparison with intramuscular diclofenac‐Na. Fortschritte der Medizin1990;108:264‐6. ">Stratz 1990</a>; <a href="./references#CD013581-bbs2-0029" title="WieselSW , CucklerJM , DelucaF , JonesF , ZeideMS , RothmanRH . Acute low back pain: an objective analysis of conservative therapy. Spine1980;5:324‐30. ">Wiesel 1980</a>; <a href="./references#CD013581-bbs2-0030" title="XimenesA , RoblesM , SandsG , VinuezaR . Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. Clinical Journal of Pain2007;23(3):244‐50. ">Ximenes 2007</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>), two of which compared a selective COX‐2 inhibitor to a non‐selective NSAID (<a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a>; <a href="./references#CD013581-bbs2-0030" title="XimenesA , RoblesM , SandsG , VinuezaR . Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. Clinical Journal of Pain2007;23(3):244‐50. ">Ximenes 2007</a>). We considered four studies at low risk of bias (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>). Diclofenac was the most common NSAID used for comparison (<a href="./references#CD013581-bbs2-0002" title="AgrifoglioE , BenvenuttiM , GattoP , AlbaneseL , ChrubinoP , MarinoniEC , et al. Aceclofenac: a new NSAID in the treatment of acute lumbago. Multicentre single blind study vs. diclofenac. Acta Therapeutica1994;20:33‐43. ">Agrifoglio 1994</a>; <a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0005" title="BakshiR , ThumbN , BröllH , KleinG , MayrhoferF , RainerF , et al. Treatment of acute lumbosacral back pain with diclofenac resinate: results of a double‐blind comparative trial versus piroxicam. Drug Investigation1994;8:288‐93. ">Bakshi 1994</a>; <a href="./references#CD013581-bbs2-0007" title="ColbergK , HettichM , SigmundR , DegnerFL . The efficacy and tolerability of an 8‐day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Current Medical Research and Opinion1996;13:363‐77. ">Colberg 1996</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0021" title="SchattenkirchnerM , MilachowskiKA . A double‐blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clinical Rheumatology2003;22(2):127‐35. ">Schattenkirchner 2003</a>; <a href="./references#CD013581-bbs2-0023" title="StratzT . Intramuscular etofenamate in the treatment of acute lumbago. Effectiveness and tolerance in comparison with intramuscular diclofenac‐Na. Fortschritte der Medizin1990;108:264‐6. ">Stratz 1990</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>). The other types of NSAIDs used were naproxen, ibuprofen, indomethacin, diflunisal, meloxicam, lornoxicam, aceclofenac, felbinac, ketorolac‐trometamol, etofenamat, dexketoprofen, and phenylbutazone. The latter NSAID (phenylbutazone) was withdrawn from the market for safety reasons. Follow‐up time ranged from one day to two weeks; this was similar for treatment duration. Most often, NSAIDs were used in the form of tablets or capsules, except for <a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>, <a href="./references#CD013581-bbs2-0023" title="StratzT . Intramuscular etofenamate in the treatment of acute lumbago. Effectiveness and tolerance in comparison with intramuscular diclofenac‐Na. Fortschritte der Medizin1990;108:264‐6. ">Stratz 1990</a>, and <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>, which used intramuscular injections; <a href="./references#CD013581-bbs2-0007" title="ColbergK , HettichM , SigmundR , DegnerFL . The efficacy and tolerability of an 8‐day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Current Medical Research and Opinion1996;13:363‐77. ">Colberg 1996</a>, which started with either an intramuscular diclofenac injection or an intravascular meloxicam injection followed by tablets; and <a href="./references#CD013581-bbs2-0010" title="HosieGAC . The topical NSAID, felbinac, versus oral ibuprofen: a comparison of efficacy in the treatment of acute lower back injury. British Journal of Clinical Research1993;4:5‐17. ">Hosie 1993</a>, which compared ibuprofen capsules with a felbinac foam. </p> <p>For further information on the results of the fifteen studies comparing non‐selective NSAIDs to each other, refer to the subheading 'Non‐selective versus non‐selective NSAIDs' below. When focusing on the two studies that compared selective COX‐2 inhibitors versus non‐selective NSAIDs, <a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a> compared nimesulide to ibuprofen (10 days) in a double‐blind, double‐dummy concept, and we considered it at low risk of bias. <a href="./references#CD013581-bbs2-0030" title="XimenesA , RoblesM , SandsG , VinuezaR . Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. Clinical Journal of Pain2007;23(3):244‐50. ">Ximenes 2007</a> compared valdecoxib versus diclofenac (7 days) in a double‐blind but not double‐dummy concept, and we considered it at high risk of bias. </p> <section id="CD013581-sec-0098"> <h5 class="title">Primary outcomes</h5> <section id="CD013581-sec-0099"> <h6 class="title">Pain intensity</h6> <p>Two studies (N = 437) reported on short‐term pain reduction from baseline (<a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a>; <a href="./references#CD013581-bbs2-0030" title="XimenesA , RoblesM , SandsG , VinuezaR . Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. Clinical Journal of Pain2007;23(3):244‐50. ">Ximenes 2007</a>). The I² statistic was 57%, indicating moderate to substantial statistical heterogeneity. On a clinical level, these studies were sufficiently comparable to pool results. The pooled mean change in pain intensity score from baseline was ‐2.60 (95% CI ‐9.23 to 4.03), indicating no clear difference in pain reduction (<a href="./references#CD013581-fig-0011" title="">Analysis 2.1</a>). The quality of this evidence is low; we downgraded the evidence two levels due to risk of bias and inconsistency. </p> </section> <section id="CD013581-sec-0100"> <h6 class="title">Disability</h6> <p>Both studies (N = 437) used the Oswestry Disability Index (0 to 50 scale). <a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a> reported a substantial improvement in mean disability score within both groups at 10‐day follow‐up. Nimesulide reduced disability more than ibuprofen (MD ‐7.00, 95% CI ‐13.15 to ‐0.85); this amount was clinically relevant. <a href="./references#CD013581-bbs2-0030" title="XimenesA , RoblesM , SandsG , VinuezaR . Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. Clinical Journal of Pain2007;23(3):244‐50. ">Ximenes 2007</a> reported similar improvement in both groups at one‐week follow‐up, with a mean decrease in baseline disability of 32% in both the valdecoxib and diclofenac arm, and no clear difference between study arms. The quality of this evidence is moderate; we downgraded the evidence one level due to risk of bias. </p> </section> <section id="CD013581-sec-0101"> <h6 class="title">Global improvement</h6> <p><a href="./references#CD013581-bbs2-0030" title="XimenesA , RoblesM , SandsG , VinuezaR . Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. Clinical Journal of Pain2007;23(3):244‐50. ">Ximenes 2007</a> (N = 333) reported that at day 7, the percentage of participants reporting pain relief as 'a lot' or 'complete' was 80% in the valdecoxib arm versus 81% in the diclofenac arm, showing no clear difference between study arms. The quality of this evidence is low; we downgraded the evidence two levels due to risk of bias and imprecision. <a href="./references#CD013581-bbs2-0019" title="PohjolainenT , JekunenA , AutioL , VuorelaH . Treatment of acute low back pain with the COX‐2‐selective anti‐inflammatory drug nimesulide: results of a randomized, double‐blind comparative trial versus ibuprofen. Spine2000;25(12):1579‐85. ">Pohjolainen 2000</a> did not report data on global improvement. </p> </section> <section id="CD013581-sec-0102"> <h6 class="title">Adverse events</h6> <p>Both studies (N = 444) reported on the proportion of participants experiencing adverse events. There was no clear difference between the treatment arms (RR 0.97, 95% CI 0.63 to 1.50; I² 22%; <a href="./references#CD013581-fig-0012" title="">Analysis 2.2</a>). The quality of this evidence is very low; we downgraded the evidence three levels due to risk of bias (one level), and imprecision (two levels). Both studies reported on the proportion of participants experiencing gastrointestinal adverse events. The results were inconclusive (RR 0.60, 95% CI 0.33 to 1.09; I² 14%; <a href="./references#CD013581-fig-0013" title="">Analysis 2.3</a>). </p> </section> <section id="CD013581-sec-0103"> <h6 class="title">Return to work</h6> <p>There were no data reported for this outcome.</p> </section> </section> <section id="CD013581-sec-0104"> <h5 class="title">Long‐term follow‐up &amp; sensitivity analyses</h5> <p>There was no long‐term follow‐up for either study.</p> <p>We performed a sensitivity analysis removing the study with high risk of bias (<a href="./references#CD013581-bbs2-0030" title="XimenesA , RoblesM , SandsG , VinuezaR . Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. Clinical Journal of Pain2007;23(3):244‐50. ">Ximenes 2007</a>) from the results for pain intensity, adverse events, and gastrointestinal adverse events (<a href="./references#CD013581-fig-0011" title="">Analysis 2.1</a>; <a href="./references#CD013581-fig-0012" title="">Analysis 2.2</a>; <a href="./references#CD013581-fig-0013" title="">Analysis 2.3</a>). This did not change the overall results and conclusion. </p> <p>We did not perform the second sensitivity analysis since the studies did not include mixed participant populations. </p> </section> </section> <section id="CD013581-sec-0105"> <h4 class="title">3. Non‐selective versus non‐selective NSAIDs</h4> <p>As previously mentioned, fifteen studies compared a non‐selective NSAID to another non‐selective NSAID (<a href="./references#CD013581-bbs2-0001" title="AghababianRV , VolturoGA , HeifetzIN . Comparison of diflunisal and naproxen in the management of acute low back pain. Clinical Therapeutics1986;9(Suppl C):47‐51. ">Aghababian 1986</a>; <a href="./references#CD013581-bbs2-0002" title="AgrifoglioE , BenvenuttiM , GattoP , AlbaneseL , ChrubinoP , MarinoniEC , et al. Aceclofenac: a new NSAID in the treatment of acute lumbago. Multicentre single blind study vs. diclofenac. Acta Therapeutica1994;20:33‐43. ">Agrifoglio 1994</a>; <a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0005" title="BakshiR , ThumbN , BröllH , KleinG , MayrhoferF , RainerF , et al. Treatment of acute lumbosacral back pain with diclofenac resinate: results of a double‐blind comparative trial versus piroxicam. Drug Investigation1994;8:288‐93. ">Bakshi 1994</a>; <a href="./references#CD013581-bbs2-0007" title="ColbergK , HettichM , SigmundR , DegnerFL . The efficacy and tolerability of an 8‐day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Current Medical Research and Opinion1996;13:363‐77. ">Colberg 1996</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0010" title="HosieGAC . The topical NSAID, felbinac, versus oral ibuprofen: a comparison of efficacy in the treatment of acute lower back injury. British Journal of Clinical Research1993;4:5‐17. ">Hosie 1993</a>; <a href="./references#CD013581-bbs2-0012" title="JaffeG . A double‐blind, between‐patient comparison of alclofenac ('Prinalgin' ) and indomethacin in the treatment of low back pain and sciatica. Current Medical Research and Opinion1974;2:424‐9. ">Jaffe 1974</a>; <a href="./references#CD013581-bbs2-0017" title="OravaS . Medical treatment of acute low back pain. Diflunisal compared with indomethacin in acute lumbago. International Journal of Clinical Research1986;6:45‐51. ">Orava 1986</a>; <a href="./references#CD013581-bbs2-0018" title="PlaplerPG , ScheinbergMA , EcclissatoCC , Bocchi de OliveiraMF , AmazonasRB . Double‐blind, randomized, double‐dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain. Drug Design, Development and Therapy2016;10:1987‐93. ">Plapler 2016</a>; <a href="./references#CD013581-bbs2-0021" title="SchattenkirchnerM , MilachowskiKA . A double‐blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clinical Rheumatology2003;22(2):127‐35. ">Schattenkirchner 2003</a>; <a href="./references#CD013581-bbs2-0023" title="StratzT . Intramuscular etofenamate in the treatment of acute lumbago. Effectiveness and tolerance in comparison with intramuscular diclofenac‐Na. Fortschritte der Medizin1990;108:264‐6. ">Stratz 1990</a>; <a href="./references#CD013581-bbs2-0029" title="WieselSW , CucklerJM , DelucaF , JonesF , ZeideMS , RothmanRH . Acute low back pain: an objective analysis of conservative therapy. Spine1980;5:324‐30. ">Wiesel 1980</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>), three of which we considered at low risk of bias (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>). Diclofenac was used as a comparison drug in nine studies (<a href="./references#CD013581-bbs2-0002" title="AgrifoglioE , BenvenuttiM , GattoP , AlbaneseL , ChrubinoP , MarinoniEC , et al. Aceclofenac: a new NSAID in the treatment of acute lumbago. Multicentre single blind study vs. diclofenac. Acta Therapeutica1994;20:33‐43. ">Agrifoglio 1994</a>; <a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0005" title="BakshiR , ThumbN , BröllH , KleinG , MayrhoferF , RainerF , et al. Treatment of acute lumbosacral back pain with diclofenac resinate: results of a double‐blind comparative trial versus piroxicam. Drug Investigation1994;8:288‐93. ">Bakshi 1994</a>; <a href="./references#CD013581-bbs2-0007" title="ColbergK , HettichM , SigmundR , DegnerFL . The efficacy and tolerability of an 8‐day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Current Medical Research and Opinion1996;13:363‐77. ">Colberg 1996</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0021" title="SchattenkirchnerM , MilachowskiKA . A double‐blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clinical Rheumatology2003;22(2):127‐35. ">Schattenkirchner 2003</a>; <a href="./references#CD013581-bbs2-0023" title="StratzT . Intramuscular etofenamate in the treatment of acute lumbago. Effectiveness and tolerance in comparison with intramuscular diclofenac‐Na. Fortschritte der Medizin1990;108:264‐6. ">Stratz 1990</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>), and was compared to many different NSAIDs: aceclofenac (twice), dipyrone, piroxicam, meloxicam, ibuprofen, etofenamat, lornoxicam, and dexketoprofen. Other NSAIDs used in comparisons were ibuprofen (twice), diflunisal (twice), indomethacin (twice), naproxen, aspirin, ketorolac‐trometamol, phenylbutazone (off the market), and felbinac foam. We will descriptively summarise the results of these studies below. </p> <section id="CD013581-sec-0106"> <h5 class="title">Primary outcomes</h5> <section id="CD013581-sec-0107"> <h6 class="title">Pain intensity</h6> <p>Two studies reported on pain intensity at a maximum of six hours follow‐up only; we excluded them from this comparison (<a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>). </p> <p>Thirteen studies (N = 1823) reported data on pain intensity at a relevant time point. Ten studies showed no clear difference in pain relief on different scales (either 4‐ or 5‐point ordinal scales, 100‐mm VAS, 11‐point numeric rating scale (NRS), or pain point calculations) after three to eight days (<a href="./references#CD013581-bbs2-0002" title="AgrifoglioE , BenvenuttiM , GattoP , AlbaneseL , ChrubinoP , MarinoniEC , et al. Aceclofenac: a new NSAID in the treatment of acute lumbago. Multicentre single blind study vs. diclofenac. Acta Therapeutica1994;20:33‐43. ">Agrifoglio 1994</a>; <a href="./references#CD013581-bbs2-0005" title="BakshiR , ThumbN , BröllH , KleinG , MayrhoferF , RainerF , et al. Treatment of acute lumbosacral back pain with diclofenac resinate: results of a double‐blind comparative trial versus piroxicam. Drug Investigation1994;8:288‐93. ">Bakshi 1994</a>; <a href="./references#CD013581-bbs2-0007" title="ColbergK , HettichM , SigmundR , DegnerFL . The efficacy and tolerability of an 8‐day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Current Medical Research and Opinion1996;13:363‐77. ">Colberg 1996</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0010" title="HosieGAC . The topical NSAID, felbinac, versus oral ibuprofen: a comparison of efficacy in the treatment of acute lower back injury. British Journal of Clinical Research1993;4:5‐17. ">Hosie 1993</a>; <a href="./references#CD013581-bbs2-0012" title="JaffeG . A double‐blind, between‐patient comparison of alclofenac ('Prinalgin' ) and indomethacin in the treatment of low back pain and sciatica. Current Medical Research and Opinion1974;2:424‐9. ">Jaffe 1974</a>; <a href="./references#CD013581-bbs2-0017" title="OravaS . Medical treatment of acute low back pain. Diflunisal compared with indomethacin in acute lumbago. International Journal of Clinical Research1986;6:45‐51. ">Orava 1986</a>; <a href="./references#CD013581-bbs2-0018" title="PlaplerPG , ScheinbergMA , EcclissatoCC , Bocchi de OliveiraMF , AmazonasRB . Double‐blind, randomized, double‐dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain. Drug Design, Development and Therapy2016;10:1987‐93. ">Plapler 2016</a>; <a href="./references#CD013581-bbs2-0023" title="StratzT . Intramuscular etofenamate in the treatment of acute lumbago. Effectiveness and tolerance in comparison with intramuscular diclofenac‐Na. Fortschritte der Medizin1990;108:264‐6. ">Stratz 1990</a>; <a href="./references#CD013581-bbs2-0029" title="WieselSW , CucklerJM , DelucaF , JonesF , ZeideMS , RothmanRH . Acute low back pain: an objective analysis of conservative therapy. Spine1980;5:324‐30. ">Wiesel 1980</a>). </p> <p>Two studies explored acelofenac and diclofenac. <a href="./references#CD013581-bbs2-0021" title="SchattenkirchnerM , MilachowskiKA . A double‐blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clinical Rheumatology2003;22(2):127‐35. ">Schattenkirchner 2003</a> (N = 227) reported that aceclofenac reduced pain intensity more than diclofenac; the results were statistically significant but not clinically relevant (between‐group difference of 5.5 on 100‐mm VAS). <a href="./references#CD013581-bbs2-0002" title="AgrifoglioE , BenvenuttiM , GattoP , AlbaneseL , ChrubinoP , MarinoniEC , et al. Aceclofenac: a new NSAID in the treatment of acute lumbago. Multicentre single blind study vs. diclofenac. Acta Therapeutica1994;20:33‐43. ">Agrifoglio 1994</a> (N = 100) found no clear difference between the two NSAIDs. </p> <p><a href="./references#CD013581-bbs2-0001" title="AghababianRV , VolturoGA , HeifetzIN . Comparison of diflunisal and naproxen in the management of acute low back pain. Clinical Therapeutics1986;9(Suppl C):47‐51. ">Aghababian 1986</a> (N = 56) reported that 100% of those who took diflunisal reported none or mild pain after two weeks compared to 88% of those who took naproxen, but no significance tests were reported, and the difference was not clinically relevant. </p> <p><a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a> (N = 220) reported a sum of pain intensity differences from baseline to day six of 4.2 for those who took lornoxicam versus 3.8 for those who took diclofenac, a statistically significant but not clinically relevant difference. </p> <p>The quality of this evidence is moderate; we downgraded the evidence one level due to risk of bias. </p> </section> <section id="CD013581-sec-0108"> <h6 class="title">Disability</h6> <p>Five studies (N = 1006) reported data on disability at a relevant time point, four of which showed no clear difference in disability or functional status between groups, measured with either the RMDQ (<a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>), or a 4‐point ordinal scale (<a href="./references#CD013581-bbs2-0012" title="JaffeG . A double‐blind, between‐patient comparison of alclofenac ('Prinalgin' ) and indomethacin in the treatment of low back pain and sciatica. Current Medical Research and Opinion1974;2:424‐9. ">Jaffe 1974</a>; <a href="./references#CD013581-bbs2-0017" title="OravaS . Medical treatment of acute low back pain. Diflunisal compared with indomethacin in acute lumbago. International Journal of Clinical Research1986;6:45‐51. ">Orava 1986</a>). </p> <p>One study showed that aceclofenac reduced pain more than diclofenac by a between‐group difference of 4.5% on the 100‐point Quebec Back Pain Disability Score; the trail authors stated the results were statistically significant but not clinically relevant (<a href="./references#CD013581-bbs2-0021" title="SchattenkirchnerM , MilachowskiKA . A double‐blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clinical Rheumatology2003;22(2):127‐35. ">Schattenkirchner 2003</a>). </p> <p>The quality of this evidence is moderate; we downgraded the evidence one level due to risk of bias. </p> </section> <section id="CD013581-sec-0109"> <h6 class="title">Global improvement</h6> <p>Seven studies (N = 987) reported data on the proportion of participants who experienced global improvement, five of which showed similar improvement between groups, with no statistically significant or clinically relevant differences (<a href="./references#CD013581-bbs2-0001" title="AghababianRV , VolturoGA , HeifetzIN . Comparison of diflunisal and naproxen in the management of acute low back pain. Clinical Therapeutics1986;9(Suppl C):47‐51. ">Aghababian 1986</a>; <a href="./references#CD013581-bbs2-0005" title="BakshiR , ThumbN , BröllH , KleinG , MayrhoferF , RainerF , et al. Treatment of acute lumbosacral back pain with diclofenac resinate: results of a double‐blind comparative trial versus piroxicam. Drug Investigation1994;8:288‐93. ">Bakshi 1994</a>; <a href="./references#CD013581-bbs2-0007" title="ColbergK , HettichM , SigmundR , DegnerFL . The efficacy and tolerability of an 8‐day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Current Medical Research and Opinion1996;13:363‐77. ">Colberg 1996</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0023" title="StratzT . Intramuscular etofenamate in the treatment of acute lumbago. Effectiveness and tolerance in comparison with intramuscular diclofenac‐Na. Fortschritte der Medizin1990;108:264‐6. ">Stratz 1990</a>). </p> <p><a href="./references#CD013581-bbs2-0002" title="AgrifoglioE , BenvenuttiM , GattoP , AlbaneseL , ChrubinoP , MarinoniEC , et al. Aceclofenac: a new NSAID in the treatment of acute lumbago. Multicentre single blind study vs. diclofenac. Acta Therapeutica1994;20:33‐43. ">Agrifoglio 1994</a> (N = 100) reported that 87% of those who took aceclofenac reported global improvement versus 79% of participants who took diclofenac; a statistically significant but not clinically relevant difference. </p> <p><a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a> (N = 174) reported that 32% of those who received dipyrone intramuscular injections were completely recovered after two days versus 12% of the participants who received diclofenac intramuscular injections; a statistically and clinically relevant difference. </p> <p>The quality of this evidence is moderate; we downgraded the evidence one level due to risk of bias. </p> </section> <section id="CD013581-sec-0110"> <h6 class="title">Adverse events</h6> <p>Fourteen studies (N = 2337) reported data on adverse events, 11 of which showed no clear difference between treatments in the proportion of participants experiencing adverse events (<a href="./references#CD013581-bbs2-0001" title="AghababianRV , VolturoGA , HeifetzIN . Comparison of diflunisal and naproxen in the management of acute low back pain. Clinical Therapeutics1986;9(Suppl C):47‐51. ">Aghababian 1986</a>; <a href="./references#CD013581-bbs2-0005" title="BakshiR , ThumbN , BröllH , KleinG , MayrhoferF , RainerF , et al. Treatment of acute lumbosacral back pain with diclofenac resinate: results of a double‐blind comparative trial versus piroxicam. Drug Investigation1994;8:288‐93. ">Bakshi 1994</a>; <a href="./references#CD013581-bbs2-0007" title="ColbergK , HettichM , SigmundR , DegnerFL . The efficacy and tolerability of an 8‐day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Current Medical Research and Opinion1996;13:363‐77. ">Colberg 1996</a>; <a href="./references#CD013581-bbs2-0008" title="DreiserRL , MartyM , IonescuE , GoldM , LiuJH . Relief of acute low back pain with diclofenac‐K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo‐controlled clinical trial. International Journal of Clinical Pharmacy and Therapeutics2003;41(9):375‐85. ">Dreiser 2003</a>; <a href="./references#CD013581-bbs2-0010" title="HosieGAC . The topical NSAID, felbinac, versus oral ibuprofen: a comparison of efficacy in the treatment of acute lower back injury. British Journal of Clinical Research1993;4:5‐17. ">Hosie 1993</a>; <a href="./references#CD013581-bbs2-0012" title="JaffeG . A double‐blind, between‐patient comparison of alclofenac ('Prinalgin' ) and indomethacin in the treatment of low back pain and sciatica. Current Medical Research and Opinion1974;2:424‐9. ">Jaffe 1974</a>; <a href="./references#CD013581-bbs2-0018" title="PlaplerPG , ScheinbergMA , EcclissatoCC , Bocchi de OliveiraMF , AmazonasRB . Double‐blind, randomized, double‐dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain. Drug Design, Development and Therapy2016;10:1987‐93. ">Plapler 2016</a>; <a href="./references#CD013581-bbs2-0021" title="SchattenkirchnerM , MilachowskiKA . A double‐blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clinical Rheumatology2003;22(2):127‐35. ">Schattenkirchner 2003</a>; <a href="./references#CD013581-bbs2-0023" title="StratzT . Intramuscular etofenamate in the treatment of acute lumbago. Effectiveness and tolerance in comparison with intramuscular diclofenac‐Na. Fortschritte der Medizin1990;108:264‐6. ">Stratz 1990</a>; <a href="./references#CD013581-bbs2-0031" title="YakhnoN , GuekhtA , SkorometsA , SpirinN , StrachunskayaE , TernavskyA , et al. Analgesic efficacy and safety of lornoxicam quick‐release formulation compared with diclofenac potassium: Randomised, double‐blind trial in acute low back pain. Clinical Drug Investigation2006;26(5):267‐77. ">Yakhno 2006</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>). </p> <p><a href="./references#CD013581-bbs2-0001" title="AghababianRV , VolturoGA , HeifetzIN . Comparison of diflunisal and naproxen in the management of acute low back pain. Clinical Therapeutics1986;9(Suppl C):47‐51. ">Aghababian 1986</a> (N = 56) reported no adverse events. </p> <p>Three studies reported a difference in the proportion of participants experiencing adverse events: <a href="./references#CD013581-bbs2-0002" title="AgrifoglioE , BenvenuttiM , GattoP , AlbaneseL , ChrubinoP , MarinoniEC , et al. Aceclofenac: a new NSAID in the treatment of acute lumbago. Multicentre single blind study vs. diclofenac. Acta Therapeutica1994;20:33‐43. ">Agrifoglio 1994</a> (N = 100) reported 2% in the aceclofenac arm versus 12% in the diclofenac arm; <a href="./references#CD013581-bbs2-0004" title="Babej‐DolleR , FreytagS , EckmeyerJ , ZerleG , SchinzelS , SchmeiderG , et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer‐blind multicenter study. International Journal of Clinical Pharmacology and Therapeutics1994;32:204‐9. ">Babej‐Dolle 1994</a> (N = 174) reported 5% in the dipyrone versus 1% in the diclofenac arm; and <a href="./references#CD013581-bbs2-0017" title="OravaS . Medical treatment of acute low back pain. Diflunisal compared with indomethacin in acute lumbago. International Journal of Clinical Research1986;6:45‐51. ">Orava 1986</a> (N = 133) reported 18% in the diflunisal arm versus 31% in the indomethacin arm; this difference was considered both statistically significant and clinically relevant. </p> <p><a href="./references#CD013581-bbs2-0021" title="SchattenkirchnerM , MilachowskiKA . A double‐blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clinical Rheumatology2003;22(2):127‐35. ">Schattenkirchner 2003</a> (N = 227) also evaluated aceclofenac and diclofenac, but found no clear difference. </p> <p>The quality of this evidence is moderate; we downgraded the evidence one level due to risk of bias. </p> </section> <section id="CD013581-sec-0111"> <h6 class="title">Return to work</h6> <p><a href="./references#CD013581-bbs2-0029" title="WieselSW , CucklerJM , DelucaF , JonesF , ZeideMS , RothmanRH . Acute low back pain: an objective analysis of conservative therapy. Spine1980;5:324‐30. ">Wiesel 1980</a> (N = 30) found no clear difference for return to work between those who took aspirin or phenylbutazone. The quality of this evidence is very low; we downgraded the evidence three levels due to risk of bias, indirectness, and imprecision. </p> </section> </section> </section> <section id="CD013581-sec-0112"> <h4 class="title">4. NSAIDs compared to paracetamol</h4> <p>Three studies, with four treatment arms, compared NSAIDs to paracetamol or acetaminophen (<a href="./references#CD013581-bbs2-0015" title="MikiK , IkemotoT , HayashiK , AraiY , SekiguchiM , ShiK , et al. Randomized open‐label non‐inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain. Journal of Orthopaedic Science 2018 Oct 3;23(3):483‐7. [PUBMED: PMID: 30292383] ">Miki 2018</a>; <a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a>; <a href="./references#CD013581-bbs2-0029" title="WieselSW , CucklerJM , DelucaF , JonesF , ZeideMS , RothmanRH . Acute low back pain: an objective analysis of conservative therapy. Spine1980;5:324‐30. ">Wiesel 1980</a>). They respectively compared loxoprofen, ibuprofen, and aspirin or phenylbutazone (two study arms) to paracetamol, all in the form of capsules or tablets. We considered none of the studies at low risk of bias. Follow‐up ranged from four days to four weeks. Treatment duration ranged from two days to four weeks. </p> <section id="CD013581-sec-0113"> <h5 class="title">Primary outcomes</h5> <section id="CD013581-sec-0114"> <h6 class="title">Pain intensity</h6> <p>All studies reported on pain intensity, but not all in comparable formats. <a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a> used a mean change score (NRS scale 0 to 5), and did not directly compare ibuprofen versus acetaminophen; similar to <a href="./references#CD013581-bbs2-0015" title="MikiK , IkemotoT , HayashiK , AraiY , SekiguchiM , ShiK , et al. Randomized open‐label non‐inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain. Journal of Orthopaedic Science 2018 Oct 3;23(3):483‐7. [PUBMED: PMID: 30292383] ">Miki 2018</a>, which reported a pain difference score between the two study arms. We pooled the results from these two studies (N = 289) using the standardised mean difference (SMD), which showed no clear difference between NSAID and paracetamol on short‐term pain relief (SMD ‐0.12, 95% CI ‐0.35 to 0.12; I² 0%; <a href="./references#CD013581-fig-0014" title="">Analysis 3.1</a>). This is comparable with an MD of ‐0.07 (95% CI ‐0.25 to 0.11; I² 0%). </p> <p>The quality of this evidence is low; we downgraded the evidence two levels due to risk of bias and imprecision. </p> <p><a href="./references#CD013581-bbs2-0029" title="WieselSW , CucklerJM , DelucaF , JonesF , ZeideMS , RothmanRH . Acute low back pain: an objective analysis of conservative therapy. Spine1980;5:324‐30. ">Wiesel 1980</a> used pain‐point calculations, a sum score that added ‘points’ each day, depending on the severity of back pain. Therefore, we could not compare their results to the other studies, although results were similar (i.e. no significant differences in pain reduction at follow‐up among two NSAID arms and one paracetamol arm). </p> </section> <section id="CD013581-sec-0115"> <h6 class="title">Disability</h6> <p><a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a> (N = 219) reported no clear difference in the mean change scores in disability for NSAIDs compared to paracetamol after four days. No other studies reported on disability outcomes. The quality of this evidence is low; we downgraded the evidence two levels due to risk of bias and imprecision. </p> </section> <section id="CD013581-sec-0116"> <h6 class="title">Global improvement</h6> <p>There were no data reported on this outcome.</p> </section> <section id="CD013581-sec-0117"> <h6 class="title">Adverse events</h6> <p>Two studies (N = 289) reported on the proportion of participants who experienced adverse events. <a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a> (N = 219) reported 10% in the NSAID arm versus 4% in the paracetamol arm, and no serious side effects. <a href="./references#CD013581-bbs2-0015" title="MikiK , IkemotoT , HayashiK , AraiY , SekiguchiM , ShiK , et al. Randomized open‐label non‐inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain. Journal of Orthopaedic Science 2018 Oct 3;23(3):483‐7. [PUBMED: PMID: 30292383] ">Miki 2018</a> (N = 70) reported 14% in the NSAID arm versus 3% in the paracetamol arm (<a href="./references#CD013581-fig-0015" title="">Analysis 3.2</a>). We did not pool these results because of considerable clinical heterogeneity. Specifically, (i) <a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a> had a short follow‐up duration (four days with two days of treatment), while <a href="./references#CD013581-bbs2-0015" title="MikiK , IkemotoT , HayashiK , AraiY , SekiguchiM , ShiK , et al. Randomized open‐label non‐inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain. Journal of Orthopaedic Science 2018 Oct 3;23(3):483‐7. [PUBMED: PMID: 30292383] ">Miki 2018</a> had a longer follow‐up (four weeks of treatment and follow‐up); and (ii) <a href="./references#CD013581-bbs2-0015" title="MikiK , IkemotoT , HayashiK , AraiY , SekiguchiM , ShiK , et al. Randomized open‐label non‐inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain. Journal of Orthopaedic Science 2018 Oct 3;23(3):483‐7. [PUBMED: PMID: 30292383] ">Miki 2018</a> had high rates of loss to follow‐up for reasons not reported. The quality of this evidence is low; we downgraded the evidence two levels due to risk of bias and imprecision. </p> </section> <section id="CD013581-sec-0118"> <h6 class="title">Return to work</h6> <p><a href="./references#CD013581-bbs2-0029" title="WieselSW , CucklerJM , DelucaF , JonesF , ZeideMS , RothmanRH . Acute low back pain: an objective analysis of conservative therapy. Spine1980;5:324‐30. ">Wiesel 1980</a> (N = 45) reported data on return to work, showing no clear differences among the three arms (three NSAID arms and one paracetamol arm). The quality of this evidence is very low; we downgraded the evidence three levels due to risk of bias, indirectness, and imprecision. </p> </section> </section> <section id="CD013581-sec-0119"> <h5 class="title">Long‐term follow‐up &amp; sensitivity analyses</h5> <p>One study reported data on the pain difference score after four weeks, showing no clear difference between the two study arms (<a href="./references#CD013581-bbs2-0015" title="MikiK , IkemotoT , HayashiK , AraiY , SekiguchiM , ShiK , et al. Randomized open‐label non‐inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain. Journal of Orthopaedic Science 2018 Oct 3;23(3):483‐7. [PUBMED: PMID: 30292383] ">Miki 2018</a>). </p> <p>We did not perform sensitivity analyses for this comparison, since there were no studies at low risk of bias, and none with mixed participant populations. </p> </section> </section> <section id="CD013581-sec-0120"> <h4 class="title">5. NSAIDs compared to other drug treatment</h4> <p>Four studies compared NSAIDs to other drugs (<a href="./references#CD013581-bbs2-0006" title="BrownFL , BodisonS , DixonJ , DavisW , NowoslawskiJ . Comparison of diflunisal and acetaminophen with codeine in the treatment of initial or recurrent acute low back pain. Clinical Therapeutics1986;9(Suppl C):52‐8. ">Brown 1986</a>; <a href="./references#CD013581-bbs2-0011" title="InnesGD , CroskerryP , WorthingtonJ , BeveridgeR , JonesD . Ketorolac versus acetaminophen‐codeine in the emergency department treatment of acute low back pain. Journal of Emergency Medicine1998;16(4):549‐56. ">Innes 1998</a>; <a href="./references#CD013581-bbs2-0014" title="Metscher B. Kubler U. Jahnel‐KrachtH . Dexketoprofen‐trometamol and tramadol in acute lumbago [Dexketoprofen‐Trometamol und Tramadol bei akuter Lumbago]. Fortschritte der Medizin. Originalien2001;118(4):147‐51. ">Metscher 2001</a>; <a href="./references#CD013581-bbs2-0026" title="VidemanT , HeikkilaJ , PartanenT . Double‐blind parallel study of meptazinol versus diflunisal in the treatment of lumbago. Current Medical Research and Opinion1984;9:246‐52. ">Videman 1984</a>). Two of these compared NSAIDs to acetaminophen with codeine (<a href="./references#CD013581-bbs2-0006" title="BrownFL , BodisonS , DixonJ , DavisW , NowoslawskiJ . Comparison of diflunisal and acetaminophen with codeine in the treatment of initial or recurrent acute low back pain. Clinical Therapeutics1986;9(Suppl C):52‐8. ">Brown 1986</a>; <a href="./references#CD013581-bbs2-0011" title="InnesGD , CroskerryP , WorthingtonJ , BeveridgeR , JonesD . Ketorolac versus acetaminophen‐codeine in the emergency department treatment of acute low back pain. Journal of Emergency Medicine1998;16(4):549‐56. ">Innes 1998</a>); <a href="./references#CD013581-bbs2-0014" title="Metscher B. Kubler U. Jahnel‐KrachtH . Dexketoprofen‐trometamol and tramadol in acute lumbago [Dexketoprofen‐Trometamol und Tramadol bei akuter Lumbago]. Fortschritte der Medizin. Originalien2001;118(4):147‐51. ">Metscher 2001</a> compared NSAIDs to tramadol hydrochloride, and <a href="./references#CD013581-bbs2-0026" title="VidemanT , HeikkilaJ , PartanenT . Double‐blind parallel study of meptazinol versus diflunisal in the treatment of lumbago. Current Medical Research and Opinion1984;9:246‐52. ">Videman 1984</a> compared NSAIDs to meptazinol. We considered one study at low risk of bias (<a href="./references#CD013581-bbs2-0011" title="InnesGD , CroskerryP , WorthingtonJ , BeveridgeR , JonesD . Ketorolac versus acetaminophen‐codeine in the emergency department treatment of acute low back pain. Journal of Emergency Medicine1998;16(4):549‐56. ">Innes 1998</a>). Follow‐up ranged from seven days to three weeks. Treatment duration ranged from seven days (or until pain free) to a maximum of three weeks. The studies used either tablets or capsules. </p> <section id="CD013581-sec-0121"> <h5 class="title">Primary outcomes</h5> <section id="CD013581-sec-0122"> <h6 class="title">Pain intensity</h6> <p>All four studies (N = 391) reported on pain intensity, but data were inadequately reported, and therefore, we were unable to conduct a meta‐analysis. <a href="./references#CD013581-bbs2-0011" title="InnesGD , CroskerryP , WorthingtonJ , BeveridgeR , JonesD . Ketorolac versus acetaminophen‐codeine in the emergency department treatment of acute low back pain. Journal of Emergency Medicine1998;16(4):549‐56. ">Innes 1998</a> only reported a mean change score after six hours, and we excluded it from this comparison. <a href="./references#CD013581-bbs2-0006" title="BrownFL , BodisonS , DixonJ , DavisW , NowoslawskiJ . Comparison of diflunisal and acetaminophen with codeine in the treatment of initial or recurrent acute low back pain. Clinical Therapeutics1986;9(Suppl C):52‐8. ">Brown 1986</a> used pain assessments by the participant on a 3‐point ordinal scale, showing a curve of slow improvement over 15 days. <a href="./references#CD013581-bbs2-0014" title="Metscher B. Kubler U. Jahnel‐KrachtH . Dexketoprofen‐trometamol and tramadol in acute lumbago [Dexketoprofen‐Trometamol und Tramadol bei akuter Lumbago]. Fortschritte der Medizin. Originalien2001;118(4):147‐51. ">Metscher 2001</a> found that those who took NSAIDs reported a mean pain change score (VAS 0 to 100 scale) of ‐6 (SD 4) after seven days compared to those who took tramadol hydrochloride, which was statistically significant but not clinically relevant. <a href="./references#CD013581-bbs2-0026" title="VidemanT , HeikkilaJ , PartanenT . Double‐blind parallel study of meptazinol versus diflunisal in the treatment of lumbago. Current Medical Research and Opinion1984;9:246‐52. ">Videman 1984</a> reported a mean pain reduction (VAS 0 to 100 scale) of 45 in the NSAID arm versus 40 in the meptazinol arm (data extracted from graphs), showing no clear difference between study arms. The quality of this evidence is low; we downgraded the evidence two levels due to risk of bias and imprecision. </p> <p><b>Disability</b> </p> <p>There were no data reported on this outcome.</p> </section> <section id="CD013581-sec-0123"> <h6 class="title">Global improvement</h6> <p>We pooled the results of two studies (N = 162) that used the same reference drug as a comparison (acetaminophen with codeine (<a href="./references#CD013581-bbs2-0006" title="BrownFL , BodisonS , DixonJ , DavisW , NowoslawskiJ . Comparison of diflunisal and acetaminophen with codeine in the treatment of initial or recurrent acute low back pain. Clinical Therapeutics1986;9(Suppl C):52‐8. ">Brown 1986</a>; <a href="./references#CD013581-bbs2-0011" title="InnesGD , CroskerryP , WorthingtonJ , BeveridgeR , JonesD . Ketorolac versus acetaminophen‐codeine in the emergency department treatment of acute low back pain. Journal of Emergency Medicine1998;16(4):549‐56. ">Innes 1998</a>)). Both studies reported on the proportion of participants who experienced global improvement within a three‐week follow‐up time frame. The pooled RR was 1.01 (95% CI 0.81 to 1.25; I² 0%; <a href="./references#CD013581-fig-0016" title="">Analysis 4.1</a>). The quality of this evidence is moderate; we downgraded the evidence one level due to imprecision. </p> </section> <section id="CD013581-sec-0124"> <h6 class="title">Adverse events</h6> <p>All four studies (N = 391) comparing NSAIDs to other drug treatments reported on the proportion of participants experiencing adverse events. Clinical heterogeneity was considerable, and therefore, we decided not to pool these data. Those who took NSAIDs were more likely to report adverse events than those who took other drugs (RR ranged from 0.53 to 0.83, 95 % CI ranged from 0.18 to 2.41; <a href="./references#CD013581-fig-0017" title="">Analysis 4.2</a>). The quality of this evidence is low; we downgraded the evidence two levels due to risk of bias and imprecision. </p> </section> <section id="CD013581-sec-0125"> <h6 class="title">Return to work</h6> <p>There were no data reported on this outcome.</p> </section> </section> <section id="CD013581-sec-0126"> <h5 class="title">Long‐term follow‐up &amp; sensitivity analyses</h5> <p>There was no long‐term follow‐up available for this comparison.</p> <p>For global improvement, we performed a sensitivity analysis by removing the study at high risk of bias (<a href="./references#CD013581-bbs2-0006" title="BrownFL , BodisonS , DixonJ , DavisW , NowoslawskiJ . Comparison of diflunisal and acetaminophen with codeine in the treatment of initial or recurrent acute low back pain. Clinical Therapeutics1986;9(Suppl C):52‐8. ">Brown 1986</a>). This did not change the results. We were unable to perform sensitivity analyses for the other outcomes. </p> </section> </section> <section id="CD013581-sec-0127"> <h4 class="title">6. NSAIDs compared to non‐drug treatment</h4> <p>Seven studies compared NSAIDs to non‐drug treatment (<a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a>; <a href="./references#CD013581-bbs2-0020" title="PostacchiniF , FacchiniM , PalieriP . Efficacy of various forms of conservative treatment in low back pain: a comparative study. Neuro‐Orthopedics1988;6:28‐35. ">Postacchini 1988</a>; <a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a>; <a href="./references#CD013581-bbs2-0024" title="SzpalskiM , PotyS , HayezJP , DebaizeJP . Objective assessment of trunk function in patients with acute low back pain treated with Tenoxicam. A prospective controlled study. Neuro‐orthopedics1990;10:41‐7. ">Szpalski 1990</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>; <a href="./references#CD013581-bbs2-0028" title="WaterworthRF , HunterIA . An open study of diflunisal, conservative and manipulative therapy in the management of acute mechanical low back pain. New Zealand Medical Journal1985;May:372‐5. ">Waterworth 1985</a>). Specifically, four studies compared NSAIDs to spinal manipulation (<a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0020" title="PostacchiniF , FacchiniM , PalieriP . Efficacy of various forms of conservative treatment in low back pain: a comparative study. Neuro‐Orthopedics1988;6:28‐35. ">Postacchini 1988</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>; <a href="./references#CD013581-bbs2-0028" title="WaterworthRF , HunterIA . An open study of diflunisal, conservative and manipulative therapy in the management of acute mechanical low back pain. New Zealand Medical Journal1985;May:372‐5. ">Waterworth 1985</a>); two studies compared NSAIDs to physiotherapy (<a href="./references#CD013581-bbs2-0020" title="PostacchiniF , FacchiniM , PalieriP . Efficacy of various forms of conservative treatment in low back pain: a comparative study. Neuro‐Orthopedics1988;6:28‐35. ">Postacchini 1988</a>; <a href="./references#CD013581-bbs2-0028" title="WaterworthRF , HunterIA . An open study of diflunisal, conservative and manipulative therapy in the management of acute mechanical low back pain. New Zealand Medical Journal1985;May:372‐5. ">Waterworth 1985</a>); two studies compared NSAIDs to bedrest (<a href="./references#CD013581-bbs2-0020" title="PostacchiniF , FacchiniM , PalieriP . Efficacy of various forms of conservative treatment in low back pain: a comparative study. Neuro‐Orthopedics1988;6:28‐35. ">Postacchini 1988</a>; <a href="./references#CD013581-bbs2-0024" title="SzpalskiM , PotyS , HayezJP , DebaizeJP . Objective assessment of trunk function in patients with acute low back pain treated with Tenoxicam. A prospective controlled study. Neuro‐orthopedics1990;10:41‐7. ">Szpalski 1990</a>); one to heat wrap (<a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a>); and one to motion style acupuncture treatment (MSAT (<a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a>)). We considered one study at low risk of bias (<a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>). Follow‐up ranged from four days to six months, and treatment duration from one day to four weeks. NSAIDs were generally administered in tablet or capsule form, with the exception of <a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a>, who administered the NSAID as a single intramuscular injection. Due to considerable clinical heterogeneity, we decided not to pool these studies. Analyses are presented below, grouped according to the non‐drug comparison treatment. We were unable to perform the planned sensitivity analyses for this comparison. </p> <section id="CD013581-sec-0128"> <h5 class="title">6a. NSAIDs compared to spinal manipulation or physiotherapy</h5> <section id="CD013581-sec-0129"> <h6 class="title">Pain intensity</h6> <p>Four studies (six treatment arms, N = 353) compared NSAIDs to spinal manipulation, physiotherapy, or both (<a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0020" title="PostacchiniF , FacchiniM , PalieriP . Efficacy of various forms of conservative treatment in low back pain: a comparative study. Neuro‐Orthopedics1988;6:28‐35. ">Postacchini 1988</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>; <a href="./references#CD013581-bbs2-0028" title="WaterworthRF , HunterIA . An open study of diflunisal, conservative and manipulative therapy in the management of acute mechanical low back pain. New Zealand Medical Journal1985;May:372‐5. ">Waterworth 1985</a>). We considered one study at low risk of bias (<a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>). All four studies reported on pain reduction from baseline (VAS 0 to 100 scale) at a relevant time point. The I² statistic was 94%, representing substantial statistical heterogeneity, and consequently, we did not pool the data. </p> <p><a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a> showed no clear difference in pain reduction when NSAIDs were compared with spinal manipulation (MD 0.80, 95% CI ‐7.11 to 8.71; <a href="./references#CD013581-fig-0018" title="">Analysis 5.1</a>). In contrast, <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a> showed that spinal manipulation reduced pain more than NSAIDs (MD 18.31, 95% CI 15.62 to 21.00; <a href="./references#CD013581-fig-0018" title="">Analysis 5.1</a>); this was clinically relevant. </p> <p><a href="./references#CD013581-bbs2-0028" title="WaterworthRF , HunterIA . An open study of diflunisal, conservative and manipulative therapy in the management of acute mechanical low back pain. New Zealand Medical Journal1985;May:372‐5. ">Waterworth 1985</a> presented pain intensity scores on a 4‐point scale, and showed no clear difference after 12 days. <a href="./references#CD013581-bbs2-0020" title="PostacchiniF , FacchiniM , PalieriP . Efficacy of various forms of conservative treatment in low back pain: a comparative study. Neuro‐Orthopedics1988;6:28‐35. ">Postacchini 1988</a> only presented a combination score of improvement in pain, disability, and spinal mobility, and showed no clear difference between NSAIDs and either spinal manipulation or physiotherapy, after three weeks and two months. The quality of this evidence is very low; we downgraded the evidence three levels due to risk of bias, inconsistency, and imprecision. </p> </section> <section id="CD013581-sec-0130"> <h6 class="title">Disability</h6> <p>Two studies (N = 193) reported on short‐term disability (<a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>). <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a> did not report mean baseline data on disability, only median baseline values, and the mean change in disability from baseline. <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a> showed that spinal manipulation reduced disability more than NSAIDs by a statistically significant and clinically relevant difference; <a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a> showed no clear difference in disability reduction. The quality of this evidence is very low; we downgraded the evidence three levels due to risk of bias, inconsistency, and imprecision. </p> </section> <section id="CD013581-sec-0131"> <h6 class="title">Global improvement</h6> <p>Two studies (three treatment arms; N = 180) reported on global improvement (<a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>; <a href="./references#CD013581-bbs2-0028" title="WaterworthRF , HunterIA . An open study of diflunisal, conservative and manipulative therapy in the management of acute mechanical low back pain. New Zealand Medical Journal1985;May:372‐5. ">Waterworth 1985</a>). <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a> showed that those who received spinal manipulation reported global improvement over NSAIDs by a statistically significant and clinically relevant difference; <a href="./references#CD013581-bbs2-0028" title="WaterworthRF , HunterIA . An open study of diflunisal, conservative and manipulative therapy in the management of acute mechanical low back pain. New Zealand Medical Journal1985;May:372‐5. ">Waterworth 1985</a> showed no clear difference between study arms (<a href="./references#CD013581-fig-0019" title="">Analysis 5.2</a>). The quality of this evidence is very low; we downgraded the evidence three levels due to risk of bias, inconsistency, and imprecision. </p> <p><a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a> reported global perceived effect, and found no clear difference between study arms (NSAID, spinal manipulation, and placebo spinal manipulation). </p> </section> <section id="CD013581-sec-0132"> <h6 class="title">Adverse events</h6> <p>Two studies (N = 189) reported data on adverse events, showing no clear difference between treatments (<a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>). <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a> reported no adverse events, therefore the risk ratio was not estimable and the data could not be pooled (<a href="./references#CD013581-fig-0020" title="">Analysis 5.3</a>). The quality of this evidence is very low; we downgraded the evidence three levels due to risk of bias, and imprecision (two levels). </p> <p><a href="./references#CD013581-bbs2-0028" title="WaterworthRF , HunterIA . An open study of diflunisal, conservative and manipulative therapy in the management of acute mechanical low back pain. New Zealand Medical Journal1985;May:372‐5. ">Waterworth 1985</a> reported two adverse events in the NSAID group (indigestion and nausea), but did not measure or evaluate adverse events in the comparison groups. </p> <p><b>Return to work</b> </p> <p>One study reported the number of days off‐work, showing no clear difference between NSAIDs and spinal manipulation (<a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>). The quality of this evidence is low; we downgraded the evidence two levels due to risk of bias and imprecision. </p> </section> <section id="CD013581-sec-0133"> <h6 class="title">Long‐term follow‐up</h6> <p>One study reported long‐term follow‐up data (<a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>). After 12 weeks, there were no clear differences between NSAIDs and spinal manipulation in mean pain score, mean disability score, and mean global perceived effect. </p> </section> </section> <section id="CD013581-sec-0134"> <h5 class="title">6b. NSAIDs compared to bedrest</h5> <p>Two studies (N = 130) compared NSAIDs to bedrest. <a href="./references#CD013581-bbs2-0020" title="PostacchiniF , FacchiniM , PalieriP . Efficacy of various forms of conservative treatment in low back pain: a comparative study. Neuro‐Orthopedics1988;6:28‐35. ">Postacchini 1988</a> presented a combination score of improvement in pain, disability, and spinal mobility, and showed no clear difference between NSAIDs and bedrest after three weeks and two months. <a href="./references#CD013581-bbs2-0024" title="SzpalskiM , PotyS , HayezJP , DebaizeJP . Objective assessment of trunk function in patients with acute low back pain treated with Tenoxicam. A prospective controlled study. Neuro‐orthopedics1990;10:41‐7. ">Szpalski 1990</a> did not present any relevant outcomes, except for adverse events; they reported that two participants in the NSAID group withdrew because of adverse events (1 participant with gastric symptoms,1 participant with gastric symptoms and a skin rash). </p> </section> <section id="CD013581-sec-0135"> <h5 class="title">6c. NSAIDs compared to heat wrap</h5> <p>One study compared NSAIDs to a heat wrap (<a href="./references#CD013581-bbs2-0016" title="NadlerSF , SteinerDJ , ErasalaGN , HengeholdDA , HinkleRT , Beth GoodaleM , et al. Continuous low‐level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine2002;27(10):1012‐7. ">Nadler 2002</a>; N = 371). It showed that a heat wrap relieved pain better than NSAIDs (mean pain relief 2.61 versus 1.68 after four days; NRS (0 to 5); statistically significant and clinically relevant difference), and reduced disability more than NSAIDs (mean disability reduction 4.9 versus 2.7 after four days; RMDQ (0 to 24), but this difference was not large enough to be considered clinically relevant. Global improvement was not mentioned. The number of adverse events was similar among study arms (heat wrap 6%, 7/113; and NSAID 10%, 11/106). There was no long‐term follow‐up. </p> </section> <section id="CD013581-sec-0136"> <h5 class="title">6d. NSAIDs compared to motion style acupuncture treatment (MSAT)</h5> <p>One study compared one intramuscular NSAID injection to one MSAT session (<a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a>; N = 58). It showed that the MSAT session reduced pain (mean (SD) pain intensity reduction from baseline 4.17 (3.05) versus 5.83 (2.61); NRS (0 to 10); and disability (mean (SD) improvement in functional status from baseline 36.34 (29.1) versus 56.41 (24.86); ODI (0 to 50)) more than NSAIDs after two weeks; these differences were statistically significant and clinically relevant. </p> <p>After the first 30 minutes, the selection of treatment was no longer restricted, thus participants were allowed to use any other treatment (medication or otherwise), if they wished. Therefore, results reported after the 30‐minute follow‐up should be interpreted with caution. There were no adverse events. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013581-sec-0137" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013581-sec-0137"></div> <section id="CD013581-sec-0138"> <h3 class="title" id="CD013581-sec-0138">Summary of main results</h3> <p>In this updated Cochrane Review, aimed at assessing the efficacy of non‐steroidal anti‐inflammatory drugs (NSAID) for acute low back pain (LBP), we included 32 trials with a total of 5356 participants, ranging in age from 16 to 78 years old. We included 26 trials from the previous review (<a href="./references#CD013581-bbs2-0135" title="RoelofsPDDM , DeyoRA , KoesBW , ScholtenRJPM , vanTulderMW . Non‐steroidal anti‐inflammatory drugs for low back pain. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD000396.pub3] ">Roelofs 2008</a>), and added six trials from the searches conducted between 2007 and 2020 (<a href="./references#CD013581-bbs2-0009" title="HancockMJ , MaherCG , LatimerJ , McLachlanAJ , CooperCW , DayRO , et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first‐line treatment for acute low back pain: a randomised controlled trial. Lancet2007;370(9599):1638‐43. HancockMJ , MaherCG , LatimerJ , et al. Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskel Dis 2005; 6: 57.2005;6:57. ">Hancock 2007</a>; <a href="./references#CD013581-bbs2-0015" title="MikiK , IkemotoT , HayashiK , AraiY , SekiguchiM , ShiK , et al. Randomized open‐label non‐inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain. Journal of Orthopaedic Science 2018 Oct 3;23(3):483‐7. [PUBMED: PMID: 30292383] ">Miki 2018</a>; <a href="./references#CD013581-bbs2-0018" title="PlaplerPG , ScheinbergMA , EcclissatoCC , Bocchi de OliveiraMF , AmazonasRB . Double‐blind, randomized, double‐dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain. Drug Design, Development and Therapy2016;10:1987‐93. ">Plapler 2016</a>; <a href="./references#CD013581-bbs2-0022" title="ShinJS , HaIH , LeeJ , ChoiY , KimMR , ParkBY , et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain2013;154(7):1030‐7. ShinJS , HaIH , LeeTG , ChoiY , ParkBY , KimMR , LeeMS . Motion style acupuncture treatment (MSAT) for acute low back pain with severe disability: a multicenter, randomized, controlled trial protocol. BMC Complement Altern Med2011;11:127. ">Shin 2013</a>; <a href="./references#CD013581-bbs2-0027" title="VonHeymannWJ , SchloemerP , TimmJ , MuehlbauerB . Spinal high‐velocity low amplitude manipulation in acute nonspecific low back pain: a double‐blinded randomized controlled trial in comparison with diclofenac and placebo. Spine2013;38(7):540‐8. [DOI: 10.1097/BRS.0b013e318275d09c] ">von Heymann 2013</a>; <a href="./references#CD013581-bbs2-0032" title="ZippelH , WagenitzA . A multicentre, randomised, double‐blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.. Clinical Drug Investigation2007;27(8):533‐43. ">Zippel 2007</a>). Follow‐up was usually short (≤ 3 weeks). Almost half of the studies were industry‐funded. The most common biases in the 'Risk of bias' assessment were performance and attrition bias. Often, there was a lack of information on randomisation procedures and allocation concealment, which is a risk for selection bias, and studies were prone to selective reporting bias, since most studies did not register their trials. However, for the latter it is important to realise most studies were published long before trial registries existed (around 2004). Therefore, most of the studies included in this review did not have the possibility yet to register their trials. </p> <p>There is moderate quality evidence that NSAIDs are slightly more effective than placebo for short‐term pain reduction (0 to 100 visual analogue scale (VAS)), with a pooled mean difference (MD) in pain intensity of ‐7.29 (95% confidence interval (CI) ‐10.98 to ‐3.61; I² 35%; 4 RCTs, 5 treatment arms, N = 815), a small difference, which is likely not clinically relevant. There is high quality evidence that NSAIDs are slightly more effective than placebo for short‐term reduction of disability (0 to 24 Roland Morris Disability Questionnaire (RMDQ)), with a pooled MD of ‐2.02 (95% CI ‐2.89 to ‐1.15; I² 0%; 2 RCTs, 3 treatment arms, N = 471), a small difference, which is likely not clinically relevant. There is low quality evidence that NSAIDs may be slightly more effective for short‐term global improvement than placebo, with a pooled risk ratio (RR) for experiencing global improvement of 1.40 (95% CI 1.12 to 1.75; I² = 52%; 5 RCTs, 7 treatment arms, N = 1201). However, there was moderate to substantial heterogeneity between studies, and in a sensitivity analysis in which we removed two studies with a mixed participant population, the result was no longer significant (RR 1.29, 95% CI 0.97 to 1.72; I² = 58%). There is very low quality evidence of no clear difference in the proportion of participants who experienced adverse events between those who used NSAIDs and those who used placebo (RR 0.86, 95% CI 0.63 to 1.18; I² = 52%; 6 RCTs, 8 treatment arms, N = 1394). Data on adverse events are usually better documented in observational studies. Most of the trials in this review studied participants for a relatively short‐term treatment and follow‐up, which is expected given the subject of acute LBP. Consequently, these may not be optimal for answering questions about adverse events. There is very low quality evidence that there is no clear difference between the proportion of participants who could return to work after seven days between those who used NSAIDs and those who used placebo (RR 1.48, 95% CI 0.98 to 2.23; 1 RCT, N = 266). </p> <p>There is low quality evidence that there is no clear difference between selective COX‐2 inhibitor NSAIDs and non‐selective NSAIDs in short‐term pain reduction, with a pooled mean change in pain intensity from baseline of ‐2.60 (95% CI ‐9.23 to 4.03; I² = 57%; 2 RCTs, N = 437). There is moderate quality evidence of conflicting results for short‐term improvement of disability (2 RCTs, N = 437). Low quality evidence from one trial (N = 333) found no clear difference between groups in the proportion of participants experiencing global improvement. Very low quality evidence found no clear difference between groups for adverse events (RR 0.97, 95% CI 0.63 to 1.50; I² = 22%; 2 RCTs, N = 444); or for specific gastrointestinal adverse events (RR 0.60, 95% CI 0.33 to 1.09; I² = 14%; 2 RCTs, N = 444). A sensitivity analysis in which we removed the study with a high risk of bias did not change these results. No data were reported on return to work. </p> </section> <section id="CD013581-sec-0139"> <h3 class="title" id="CD013581-sec-0139">Overall completeness and applicability of evidence</h3> <p>This was an update for the Cochrane Review on NSAIDs for LBP (<a href="./references#CD013581-bbs2-0135" title="RoelofsPDDM , DeyoRA , KoesBW , ScholtenRJPM , vanTulderMW . Non‐steroidal anti‐inflammatory drugs for low back pain. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD000396.pub3] ">Roelofs 2008</a>). In the previous review, we included trials on LBP of all types and duration. This review focused on acute LBP, therefore, we had strict criteria on duration and type of pain. We excluded studies with a mixed population of acute with chronic or recurrent LBP, or with a large percentage of participants with additional sciatic complaints, in order to keep the results clear and specific. Thus, fewer trials met the inclusion criteria for this update, but the results may be more applicable. </p> <p>Study populations were rather diverse and often heterogeneous, including a broad range of participants who varied in age and amount of complaints. Both general practitioner (GP) practices and outpatient clinics were used for the source population. In older studies, the study population was sometimes even admitted to the hospital for inpatient treatment. This makes it complex to draw conclusions that fit all people with acute LBP. Furthermore, various types of NSAIDs were used, with different ways of administration, frequencies, doses, and duration of use; adding to the complexity of our attempt to compare a wide range of NSAIDs. The comparison became too heterogeneous to pool, especially when NSAIDs were compared to other drugs, or a combination of other drugs. These different sources of heterogeneity also limited the feasibility of sensitivity or stratified analyses, for instance, regarding the duration of LBP (acute versus subacute) or the dose, duration of treatment, and the mode of delivery of the NSAID. Lastly, not all outcome measures were equally reported. Work‐related outcomes (e.g. return to work status, number of days off work) and long‐term follow‐up (up to three months) were often unavailable, although these could be relevant outcomes for people and their GPs, to help predict the course and prognosis of an episode. Although, when considering the longer‐term outcomes, it is important to keep in mind that the effect of the (usually) short‐term drug treatment may be less relevant at those time points. Despite this variation in (and sometimes lack of useful) outcome reporting, the results of our review appear to be similar to the previous review, which showed a small effect in the quantitative analysis in favour of NSAIDs compared to placebo on pain intensity and global improvement (<a href="./references#CD013581-bbs2-0135" title="RoelofsPDDM , DeyoRA , KoesBW , ScholtenRJPM , vanTulderMW . Non‐steroidal anti‐inflammatory drugs for low back pain. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD000396.pub3] ">Roelofs 2008</a>). </p> <p>One could argue whether our main findings of a mean difference in pain intensity of ‐7.29 on a 0 to 100 VAS scale and a reduction of 2.02 points on the 0 to 24 RMDQ in favour of NSAIDs over placebo are clinically meaningful differences for an individual. A review of the literature shows this is questionable. International consensus was reached on minimal important change (MIC) values of frequently used participant‐reported outcome measures in the field of LBP to aid practical guidance. Reasonable MIC values are ‐15.00 on a 0 to 100 VAS scale and ‐5.00 for the RMDQ. When measuring change from baseline, a 30% improvement was considered a useful threshold for identifying clinically meaningful improvement for each of these measures (<a href="./references#CD013581-bbs2-0122" title="OsteloRW , DeyoRA , StratfordP , WaddellG , CroftP , vonKorffM , et al. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. Spine (Phila Pa 1976) 2008 Jan 1;33(1):90‐4. [DOI: 10.1097/BRS.0b013e31815e3a10; PUBMED: 18165753] ">Ostelo 2008</a>). However, these are considered to be individual‐level changes. What we consider a minimally important between‐group difference has not yet been established, and is context‐dependent. Other reviews in the field of back pain consider differences in treatment effect of less than 10% of the scale, or 9 points on a 100‐point scale a small effect, and not clinically relevant. Thus, the effect sizes shown in this review do not pass the threshold of clinical relevance, or a clinical meaningful change in an individual. </p> <p>Adverse events rates for NSAIDs are better documented in observational studies. Our review considered NSAIDs for acute LBP, and most studies focused on short‐term use of NSAIDs with a short follow‐up time. Most sample sizes were too small for evaluating adverse events, or not sufficiently powered to detect rare adverse events. It is possible that the proportion of adverse events was underestimated, or that rare or uncommon adverse events were missed. We should refrain from conclusions concerning adverse events and the safety of NSAIDs for longer‐term use. </p> </section> <section id="CD013581-sec-0140"> <h3 class="title" id="CD013581-sec-0140">Quality of the evidence</h3> <p>Sample sizes of the included RCTs differed widely (ranging from 30 to 372) and follow‐up time was usually short. Relevant information was not always mentioned, for instance, the method of randomisation was not reported and allocation concealment was not adequately described. About half of the studies did not report sufficiently on blinding, so we judged them at high risk of bias because of lack of blinding. Most studies did not register their trials in a publicly accessible clinical trial registry, mostly because they were published before these existed. Therefore, reporting bias is often unclear and cannot be excluded. About half of the trials avoided co‐interventions, the others we considered unclear or at high risk. One trial had no treatment restrictions at all after the first 30 minutes. Compliance was often not mentioned or clearly described, and was only reported by a few studies. A main problem for many of the studies was funding. We scored half of the studies at high risk of bias because of funding by a pharmaceutical company, and often there were conflicts of interest for one or more of the authors, or the sponsor was involved in data collection and analysis, sometimes even writing the report. Two studies clearly stated that the sponsor was not involved in data collection and analysis, and had no influence on the report; these we scored at low risk of bias. </p> <p>One of the problems we encountered during data‐extraction was that similar outcomes were presented in very different ways across studies. For example, there was substantial variation in the definition and cutoff points for 'global improvement'. Over the years, trials moved from reporting mainly physiological outcomes that combined Likert scales of pain, disability, and global improvement, to reporting separate outcomes, and pain‐ and disability‐specific measurement tools. However, even more recent studies do not always report their outcome measures in a standard way, which impedes the ability to easily compare studies and pool data. Greater consistency in reporting would facilitate higher quality comparisons of studies on acute LBP. A task force of the NIH (National Institutes of Health) Pain Consortium developed research standards for chronic LBP regarding definitions, a minimal data set, reporting outcomes, and future research (<a href="./references#CD013581-bbs2-0103" title="DeyoRA , DworkinSF , AmtmannD , AnderssonG , BorensteinD , CarrageeE , et al. Report of the NIH Task Force on research standards for chronic low back pain. Journal of Pain2014 Jun;15(6):569‐85. [DOI: 10.1016/j.jpain.2014.03.005; PUBMED: 24787228] ">Deyo 2014</a>). Recently, an international steering committee developed a preliminary core outcome measurement set that specifies instruments to be included in every clinical trial involving people with non‐specific LBP, which will be useful for studies reporting on acute LBP (<a href="./references#CD013581-bbs2-0100" title="ChiarottoA , BoersM , DeyoRA , BuchbinderR , CorbinTP , CostaLOP , et al. Core outcome measurement instruments for clinical trials in non‐specific low back pain. Pain2018;159(3):481–95. [DOI: 10.1097/j.pain.0000000000001117; PUBMED: 29194127] ">Chiarotto 2018</a>). Hopefully, this will further improve the comparability of outcomes in future research in acute LBP, and increase the quality of the body of evidence according to the GRADE criteria. </p> <p>To conclude, there is moderate to high quality evidence that NSAIDs are slightly more effective than placebo in reducing pain and disability, respectively, in the short‐term. We downgraded the evidence for pain intensity because of high risk of bias. The magnitude of the difference was small, and often there were methodological shortcomings. However, when we only included the studies with a low risk of bias in a sensitivity analysis, the results were consistent, and did not change. The present findings regarding the efficacy of NSAIDs for acute LBP seem to be in line with the results of the previous Cochrane Review (<a href="./references#CD013581-bbs2-0135" title="RoelofsPDDM , DeyoRA , KoesBW , ScholtenRJPM , vanTulderMW . Non‐steroidal anti‐inflammatory drugs for low back pain. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD000396.pub3] ">Roelofs 2008</a>). </p> </section> <section id="CD013581-sec-0141"> <h3 class="title" id="CD013581-sec-0141">Potential biases in the review process</h3> <p>We aimed to present a complete overview of the efficacy of NSAIDs for acute LBP, and therefore, the review process was thorough, and we tried to be transparent in all steps taken. We used the current guidelines recommended by the Cochrane Back and Neck Group (CBN) and the <i>Cochrane Handbook for Systematic Reviews of Interventions,</i> and graded the quality of the evidence using the GRADE approach (<a href="./references#CD013581-bbs2-0105" title="FurlanAD , MalmivaaraA , ChouR , MaherCG , DeyoRA , SchoeneM , et al. Editorial Board of the Cochrane Back and Neck Group. 2015 Updated method guideline for systematic reviews in the Cochrane Back and Neck Group. Spine2015;40(21):1660‐73. [DOI: 10.1097/BRS.0000000000001061; PUBMED: 26208232] ">Furlan 2015</a>; <a href="./references#CD013581-bbs2-0107" title="AtkinsD , BestD , BrissPA , EcclesM , Falck‐YtterY , FlottorpS , et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJJune 2004;328(7454):1490. ">GRADE Working Group 2004</a>; <a href="./references#CD013581-bbs2-0110" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [DOI: 10.1136/bmj.39489.470347.AD] ">Guyatt 2008</a>; <a href="./references#CD013581-bbs2-0111" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). The information specialist from the CBN conducted a comprehensive literature search. All abstracts were carefully and independently screened by two review authors. Moreover, we checked the references of all included and possibly relevant studies, and of other reviews published from 2008 onwards. It is still possible that we did not identify all studies (due to publication bias or non‐registered trials), but with extensive searches and checks, we tried to reduce this risk to a minimum. The original review protocol stated that only trials published in English, German or Dutch would be included. To be sure of overall completeness, there were no restrictions on language for this review update. However, we did not re‐screen all foreign language abstracts from prior to 2008, so there is a probability that we missed a foreign language study from before 2008 that could have been included. We also included studies with NSAIDs that were no longer available on the market (e.g. phenylbutazone), aiming to provide a complete overview. A potential drawback could be that the results are less applicable to NSAIDs currently on the market. After analysis, this concerned one study, which could not be included in a meta‐analysis, and did not influence the results or conclusions of this review. </p> <p>We tried to be strict on the inclusion criteria for this review to retrieve results that were as 'clean' and reliable as possible. For instance, we excluded recurrent LBP to prevent possible bias. Our underlying assumption was that people with recurrent LBP are most probably people with chronic LBP, who may have already tried several therapies, unsuccessfully. They may be non‐responsive to therapy, and thus, belong to a different trial population than people with acute LBP. Still, in many of the (mostly) older studies, the inclusion criteria concerning the type and location of LBP were not mentioned in a very specific manner, or not stated clearly. In reality, the eligibility criteria for the study population might not have been too strict at that time. Sometimes, this was not completely clear, and it was up to us, as review authors, to make a decision whether to include or exclude the study. Main considerations to include were a clearly stated majority of people in the study population who suffered from acute LBP, with only a small minority that may have had additional leg pain, for instance. In a sensitivity analysis, we checked if excluding these from the analysis would change the results. We intended to be transparent in this process, and to make understandable and reproducible decisions. However, it may be that someone else would have decided differently. In case of a clearly mixed study population (either type of back pain, e.g. acute, chronic or recurrent, sciatica; or location of back pain, e.g. also upper back or neck), or if it was unclear what type of (low) back pain the study population had, we included the study as 'awaiting classification'. Usually, there was no subgroup analysis, and the reported data were insufficient to use. We contacted trial authors for clarification, with plans to include these data in a future update. The sixteen studies currently awaiting classification could have had an impact on the results of this review. </p> <p>Publication bias was difficult to assess due to the limited number of trials included in the meta‐analysis. Almost half of the included trials were supported by pharmaceutical companies, as stated before. Another 43% did not provide (sufficient) information regarding funding. A recent systematic review showed that sponsorship of drug and device studies by the manufacturing company leads to more favourable efficacy results and conclusions, when compared to non‐industry sponsored studies (e.g. any other source of sponsorship). The review authors suggest the existence of an 'industry bias' that cannot be explained by standard 'Risk of bias' assessments (<a href="./references#CD013581-bbs2-0117" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2017</a>). In other words, a form of publication bias could be likely. </p> </section> <section id="CD013581-sec-0142"> <h3 class="title" id="CD013581-sec-0142">Agreements and disagreements with other studies or reviews</h3> <p>A review on NSAIDs for spinal pain had similar findings (<a href="./references#CD013581-bbs2-0118" title="MachadoGC , MaherCG , FerreiraPH , DayRO , PinheiroMB , FerreiraML . Non‐steroidal anti‐inflammatory drugs for spinal pain: a systematic review and meta‐analysis. Annals of the Rheumatic Diseases2017;76:1269‐78. [DOI: 10.1136/annrheumdis‐2016‐210597] ">Machado 2017</a>). They found moderate quality evidence that NSAIDs were effective in reducing pain and disability in the immediate term (less than 2 weeks) compared to placebo, in participants with acute LBP, but the magnitude of the difference was small, and did not exceed the threshold for a clinically relevant treatment effect. Their findings are consistent with our review. A recently published overview of clinical practice guidelines for non‐specific LBP showed that all eight included guidelines currently recommend NSAIDs for acute LBP, either as a first or second choice medication (<a href="./references#CD013581-bbs2-0129" title="SchreijenbergM , KoesBW , LinCWC . Guideline recommendations on the pharmacological management of non‐specific low back pain in primary care – is there a need to change?. Expert Review of Clinical Pharmacology2019;12(2):145‐57. [DOI: 10.1080/17512433.2019.1565992] ">Schreijenberg 2019</a>). Usually, they recommend to take into consideration potential adverse events or contra‐indications, and to give the lowest effective dose for the shortest possible period of time. Newer guidelines tend to move towards non‐pharmacological treatments, with short‐term use of NSAIDs in addition to usual care, only after careful consideration. </p> <p>If we compare our results with the other two recently published Cochrane Reviews on NSAIDs for different subgroups of LBP, we observe that the quality of most of the evidence is comparable (low to very low (<a href="./references#CD013581-bbs2-0104" title="EnthovenWTM , RoelofsPDDM , DeyoRA , vanTulderMW , KoesBW . Non‐steroidal anti‐inflammatory drugs for chronic low back pain. Cochrane Database of Systematic Reviews2016, Issue 2. [DOI: 10.1002/14651858.CD012087] ">Enthoven 2016</a>; <a href="./references#CD013581-bbs2-0126" title="Rasmussen‐BarrE , HeldU , GrootenWJA , RoelofsPDDM , KoesBW , vanTulderMW , et al. Non‐steroidal anti‐inflammatory drugs for sciatica. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD012382] ">Rasmussen‐Barr 2016</a>)). However, two of our outcomes only contained studies at low risk of bias, with sufficient numbers of participants to be assessed as moderate to high quality evidence. In agreement with the review on chronic LBP, there is moderate to high (respectively low in <a href="./references#CD013581-bbs2-0104" title="EnthovenWTM , RoelofsPDDM , DeyoRA , vanTulderMW , KoesBW . Non‐steroidal anti‐inflammatory drugs for chronic low back pain. Cochrane Database of Systematic Reviews2016, Issue 2. [DOI: 10.1002/14651858.CD012087] ">Enthoven 2016</a>) quality evidence that NSAIDs are slightly more effective than placebo regarding pain intensity and disability, but it is questionable whether this effect is clinically meaningful. There were no differences in efficacy between different types of NSAIDs. This seems in line with our results. According to the review on NSAIDs for sciatica, there was low quality evidence that global improvement was slightly better in participants with NSAIDs, compared to placebo (<a href="./references#CD013581-bbs2-0126" title="Rasmussen‐BarrE , HeldU , GrootenWJA , RoelofsPDDM , KoesBW , vanTulderMW , et al. Non‐steroidal anti‐inflammatory drugs for sciatica. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD012382] ">Rasmussen‐Barr 2016</a>). This is in agreement with our review, although in a sensitivity analysis in which we removed the studies with a mixed participant population, the result was no longer significant. Furthermore, there was very low quality evidence that the efficacy of NSAIDs for pain reduction was not significant, which is in disagreement with our review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013581-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD013581-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/full#CD013581-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013581-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary per domain: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD013581-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary per domain: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/full#CD013581-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013581-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph per domain: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies" data-id="CD013581-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph per domain: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/full#CD013581-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013581-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.1 Pain intensity on 100‐mm VAS. Follow‐up ≤ 3 weeks." data-id="CD013581-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.1 Pain intensity on 100‐mm VAS. Follow‐up ≤ 3 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/full#CD013581-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013581-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.2 Disability (RMDQ 0 to 24). Follow‐up ≤ 3 weeks." data-id="CD013581-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.2 Disability (RMDQ 0 to 24). Follow‐up ≤ 3 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/full#CD013581-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013581-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.3 Proportion of participants experiencing global improvement. Follow‐up ≤ 3 weeks." data-id="CD013581-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.3 Proportion of participants experiencing global improvement. Follow‐up ≤ 3 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/full#CD013581-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013581-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NSAIDs versus placebo, Outcome 1 Pain Intensity on 100‐mm VAS. Follow‐up ≤ 3 weeks." data-id="CD013581-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 NSAIDs versus placebo, Outcome 1 Pain Intensity on 100‐mm VAS. Follow‐up ≤ 3 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/references#CD013581-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013581-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NSAIDs versus placebo, Outcome 2 Disability (RMDQ 0 to 24). Follow‐up ≤ 3 weeks." data-id="CD013581-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 NSAIDs versus placebo, Outcome 2 Disability (RMDQ 0 to 24). Follow‐up ≤ 3 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/references#CD013581-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013581-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NSAIDs versus placebo, Outcome 3 Proportion of participants experiencing global improvement. Follow‐up ≤ 3 weeks." data-id="CD013581-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 NSAIDs versus placebo, Outcome 3 Proportion of participants experiencing global improvement. Follow‐up ≤ 3 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/references#CD013581-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013581-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NSAIDs versus placebo, Outcome 4 Proportion of participants experiencing adverse events." data-id="CD013581-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 NSAIDs versus placebo, Outcome 4 Proportion of participants experiencing adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/references#CD013581-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013581-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Selective COX‐2 inhibitors versus non‐selective NSAIDs, Outcome 1 Change in pain intensity from baseline on 100 mm VAS. Follow‐up ≤ 3 weeks." data-id="CD013581-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Selective COX‐2 inhibitors versus non‐selective NSAIDs, Outcome 1 Change in pain intensity from baseline on 100 mm VAS. Follow‐up ≤ 3 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/references#CD013581-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013581-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Selective COX‐2 inhibitors versus non‐selective NSAIDs, Outcome 2 Proportion of patients experiencing adverse events." data-id="CD013581-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Selective COX‐2 inhibitors versus non‐selective NSAIDs, Outcome 2 Proportion of patients experiencing adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/references#CD013581-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013581-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Selective COX‐2 inhibitors versus non‐selective NSAIDs, Outcome 3 Proportion of patients experiencing gastrointestinal adverse events." data-id="CD013581-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Selective COX‐2 inhibitors versus non‐selective NSAIDs, Outcome 3 Proportion of patients experiencing gastrointestinal adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/references#CD013581-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013581-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 NSAIDs versus paracetamol, Outcome 1 Mean difference in pain intensity on various scales. Follow‐up ≤ 3 weeks." data-id="CD013581-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 NSAIDs versus paracetamol, Outcome 1 Mean difference in pain intensity on various scales. Follow‐up ≤ 3 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/references#CD013581-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013581-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 NSAIDs versus paracetamol, Outcome 2 Proportion of participants experiencing adverse events." data-id="CD013581-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 NSAIDs versus paracetamol, Outcome 2 Proportion of participants experiencing adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/references#CD013581-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013581-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 NSAIDs versus other drug treatment, Outcome 1 Proportion of participants experiencing global improvement. Follow‐up ≤ 3 weeks." data-id="CD013581-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 NSAIDs versus other drug treatment, Outcome 1 Proportion of participants experiencing global improvement. Follow‐up ≤ 3 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/references#CD013581-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013581-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 NSAIDs versus other drug treatment, Outcome 2 Proportion of participants experiencing adverse events." data-id="CD013581-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 NSAIDs versus other drug treatment, Outcome 2 Proportion of participants experiencing adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/references#CD013581-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013581-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 NSAIDs versus non‐drug treatment, Outcome 1 Pain Intensity on 100‐mm VAS. Follow‐up ≤ 3 weeks.." data-id="CD013581-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 NSAIDs versus non‐drug treatment, Outcome 1 Pain Intensity on 100‐mm VAS. Follow‐up ≤ 3 weeks.. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/references#CD013581-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013581-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 NSAIDs versus non‐drug treatment, Outcome 2 Proportion of participants experiencing global improvement. Follow‐up ≤ 3 weeks." data-id="CD013581-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 NSAIDs versus non‐drug treatment, Outcome 2 Proportion of participants experiencing global improvement. Follow‐up ≤ 3 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/references#CD013581-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013581-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/urn:x-wiley:14651858:media:CD013581:CD013581-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_t/tCD013581-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 NSAIDs versus non‐drug treatment, Outcome 3 Proportion of participants experiencing adverse events." data-id="CD013581-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 NSAIDs versus non‐drug treatment, Outcome 3 Proportion of participants experiencing adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013581/references#CD013581-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013581/media/CDSR/CD013581/image_n/nCD013581-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013581-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">NSAIDs compared to placebo in people with acute low back pain</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>NSAIDs compared to placebo in people with acute low back pain</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (≥ 18 years of age) with acute low back pain<br/> <b>Setting:</b> primary and secondary care settings, mainly general practice and outpatient clinics<br/> <b>Intervention:</b> NSAIDs<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NSAIDs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain intensity</b> </p> <p>VAS (0 to 100; lower = better)</p> <p>Follow<b>‐</b>up: ≤ 3 weeks (range 7 to 15 days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain intensity in the placebo group ranged from 7.9 to 33.9</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain intensity in the NSAID group was</p> <p>7.29 lower (10.98 lower to 3.61 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>815<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MID is 10 points on a 0 to 100 scale</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability</b> </p> <p>RMDQ (0 to 24; lower = better)</p> <p>Follow‐up: ≤ 3 weeks (range 7 to 14 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean disability in the placebo group ranged from 6.0 to 7.3</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean disability in the NSAID group was</p> <p>2.02 lower (2.89 lower to 1.15 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>471<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MID is 2.4 points on a 0 to 24 scale</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of participants experiencing global improvement</b> </p> <p>Various dichotomised Likert scales; lower = better</p> <p>Follow‐up ≤ 3 weeks (range 1 to 15 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.40<br/> (1.12 to 1.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1201<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>367 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>514 per 1000<br/> (412 to 643) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of participants experiencing adverse events</b> </p> <p>Follow‐up range 1 day to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/> (0.63 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1394<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,d,e,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000<br/> (70 to 130) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Return to work</b> (%) </p> <p>Follow‐up: 7 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.48</p> <p>(0.98 to 2.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>266</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>212 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>314 per 1000</p> <p>(208 to 473)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>VAS:</b> visual analogue scale; <b>RMDQ:</b> Roland Morris Disability Questionnaire; <b>RR:</b> risk ratio; <b>RCT</b> : randomised controlled trial; <b>MID</b>: minimal important difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty.</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty.</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty.</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty.</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias. More than 25% of the included participants were from studies with a high risk of bias.<br/> <sup>b</sup>Downgraded one level due to inconsistency. There is moderate to substantial heterogeneity with an I² of 52% and a wide variance in point estimates across studies.<br/> <sup>c</sup>Downgraded one level due to indirectness. Two studies (three treatment arms) included a small percentage of participants with additional sciatic complaints (different population). NSAID tablets, capsules or intramuscular injections were used (different intervention). Treatment time and timing of outcome assessments ranged (differences in outcome), which could make the results less generalisable.<br/> <sup>d</sup>Downgraded one level due to inconsistency. On visual inspection, there is a wide variance in point estimates across studies. Follow‐up duration to measure and report adverse events varied greatly, and was probably too short in a few studies to adequately detect all adverse events.<br/> <sup>e</sup>Downgraded one level due to indirectness. Two studies (three treatment arms) included a small percentage of participants with additional sciatic complaints (different population). Most studies had a relatively short follow‐up time (ranging from 1 day to 2 to 3 weeks), except for one study (follow‐up time 12 weeks). Therefore, it is unclear if the follow‐up time frame was sufficient to measure and report all relevant outcomes regarding adverse events.<br/> <sup>f</sup>Downgraded one level due to imprecision. The total number of events was less than 300.<br/> <sup>g</sup>Downgraded two levels due to imprecision. Only one study was included in the comparison, with a total number of events far less than 300. The 95% CI includes both no effect and the threshold of appreciable benefit. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">NSAIDs compared to placebo in people with acute low back pain</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013581/full#CD013581-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013581-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Selective COX‐2 inhibitors compared to non‐selective NSAIDs for acute low back pain</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Selective COX‐2 inhibitors compared to non‐selective NSAIDs for acute low back pain</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (≥ 18 years of age) with acute low back pain (LBP)<br/> <b>Setting:</b> primary and secondary care settings, mainly general practice and outpatient clinics<br/> <b>Intervention:</b> selective COX‐2 inhibitors<br/> <b>Comparison:</b> non‐selective NSAIDs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with non‐selective NSAIDs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with COX‐2 inhibitors</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in pain intensity from baseline</b> </p> <p>VAS (0 to 100; lower = better)</p> <p>Follow‐up ≤ 3 weeks (range 7 to 10 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in pain intensity from baseline in the non‐selective NSAID group ranged from 38 to 41 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in pain intensity from baseline in the COX‐2 inhibitors group was 2.60 lower (9.23 lower to 4.03 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>437<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MID is 10 points on a 0 to 100 scale</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability</b> </p> <p>ODI (0 to 50; lower = better)</p> <p>Follow‐up ≤ 3 weeks (range 7 to 10 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>One trial reported a mean difference in disability score of ‐7.00 (95% CI ‐13.15 to ‐0.85) after 10 days, showing a statistically significant and clinically relevant difference in favour of the nimesulide arm. </p> <p>One trial reported a mean decrease in baseline disability of 32% in both the valdecoxib and diclofenac arm at 1 week follow‐up, showing no clear difference between study arms. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>437<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MID is 5 points on a 0 to 50 scale</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants experiencing global improvement</b> </p> <p>% of dichotomized Likert scale</p> <p>Follow‐up ≤ 3 weeks (7 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>One trial reported the percentage of participants who reported their pain relief as 'a lot better' or 'completely better' at 1 week follow‐up, which was similar in both the valdecoxib (80%) and diclofenac (81%) arm, showing no clear difference between study arms. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>333</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of participants experiencing adverse events</b> </p> <p>Follow‐up range 10 to 37 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.63 to 1.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>444<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>248 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>240 per 1000<br/> (156 to 372) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Return to work</b> (%) </p> <p>Follow‐up: N/A</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>VAS:</b> visual analogue scale; <b>ODI:</b> Oswestry Disability Index; <b>RR:</b> risk ratio; <b>RCT</b> : randomised controlled trial; <b>N/A</b> : not available; <b>MID</b>: minimal important difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty.</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty.</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty.</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty.</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias. More than 25% of the included participants were from a study with high risk of bias.<br/> <sup>b</sup>Downgraded one level due to inconsistency. There is moderate to substantial heterogeneity with an I² of 57%, and a wide variance in point estimates.<br/> <sup>c</sup>Downgraded one level due to imprecision. The total number of events was far less than 300, leading to a wide confidence interval. <br/> <sup>d</sup>Downgraded two levels due to imprecision. The total number of events was far less than 300, leading to a wide confidence interval. The 95% confidence interval includes both no effect and the threshold of appreciable benefit or harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Selective COX‐2 inhibitors compared to non‐selective NSAIDs for acute low back pain</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013581/full#CD013581-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013581-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sources of risk of bias</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias domain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Source of Bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Possible answers</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) Was the method of randomisation adequate?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2) Was the treatment allocation concealed?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(3) Was the participant blinded to the intervention?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(4) Was the careprovider blinded to the intervention?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Detection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(5) Was the outcome assessor blinded to the intervention?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Attrition</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(6) Was the dropout rate described and acceptable?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Attrition</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(7) Were all randomised participants analysed in the group<br/> to which they were allocated? </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reporting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(8) Are reports of the study free of suggestion of selective<br/> outcome reporting? </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(9) Were the groups similar at baseline regarding the most<br/> important prognostic indicators? </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(10) Were co‐interventions avoided or similar?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(11) Was the compliance acceptable in all groups?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Detection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(12) Was the timing of the outcome assessment similar in<br/> all groups? </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(13) Are other sources of potential bias unlikely?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/No/Unsure</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><a href="./references#CD013581-bbs2-0105" title="FurlanAD , MalmivaaraA , ChouR , MaherCG , DeyoRA , SchoeneM , et al. Editorial Board of the Cochrane Back and Neck Group. 2015 Updated method guideline for systematic reviews in the Cochrane Back and Neck Group. Spine2015;40(21):1660‐73. [DOI: 10.1097/BRS.0000000000001061; PUBMED: 26208232] ">Furlan 2015</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sources of risk of bias</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013581/full#CD013581-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013581-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Criteria for a judgement of 'yes' for the sources of risk of bias</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A random (unpredictable) assignment sequence. Examples of adequate methods are coin toss (for studies with 2 groups), rolling a dice (for studies with 2 or more groups), drawing of balls of different colours, drawing of ballots with the study group labels from a dark bag, computer‐generated random sequence, pre‐ordered sealed envelopes, sequentially‐ordered vials, telephone call to a central office, and preordered list of treatment assignments. </p> <p>Examples of inadequate methods are: alternation, birth date, social insurance or social security number, date in which they are invited to participate in the study, and hospital registration number. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assignment generated by an independent person not responsible for determining the eligibility of the participants. This person has no information about the persons included in the trial and has no influence on the assignment sequence or on the decision about eligibility of the participant. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index and control groups are indistinguishable for the participants, or if the success of blinding was tested among the participants and it was successful. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index and control groups are indistinguishable for the careproviders, or if the success of blinding was tested among the careproviders and it was successful. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequacy of blinding should be assessed for each primary outcome separately. This item should be scored 'yes' if the success of blinding was tested among the outcome assessors and it was successful or:<br/> • for participant‐reported outcomes in which the participant is the outcome assessor (e.g. pain, disability): the blinding procedure is adequate for outcome assessors if participant blinding is scored 'yes' </p> <p>• for outcome criteria assessed during scheduled visit and that supposes a contact between participants and outcome assessors (e.g. clinical examination): the blinding procedure is adequate if participants are blinded, and the treatment or adverse effects of the treatment cannot be noticed during clinical examination<br/> • for outcome criteria that do not suppose a contact with participants (e.g. radiography, magnetic resonance imaging): the blinding procedure is adequate if the treatment or adverse effects of the treatment cannot be noticed when assessing the main outcome </p> <p>• for outcome criteria that are clinical or therapeutic events that will be determined by the interaction between participants and careproviders (e.g. co‐interventions, hospitalisation length, treatment failure), in which the careprovider is the outcome assessor: the blinding procedure is adequate for outcome assessors if item '4' (caregivers) is scored 'yes'<br/> • for outcome criteria that are assessed from data from the medical forms: the blinding procedure is adequate if the treatment or adverse effects of the treatment cannot be noticed on the extracted data </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The number of participants who were included in the study but did not complete the observation period or were not included in the analysis must be described and reasons given. If the percentage of withdrawals and dropouts does not exceed 20% for short‐term follow‐up and 30% for long‐term follow‐up, and does not lead to substantial bias, a 'yes' is scored. (N.B. these percentages are arbitrary, not supported by literature). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All randomised participants are reported and analysed in the group to which they were allocated by randomisation for the most important moments of effect measurement (minus missing values) irrespective of non‐compliance and co‐interventions. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All the results from all prespecified outcomes have been adequately reported in the published report of the trial. This information is either obtained by comparing the protocol and the report, or in the absence of a protocol, by assessing that the published report includes enough information to make this judgement. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Groups have to be similar at baseline regarding demographic factors, duration and severity of complaints, percentage of participants with neurological symptoms, and value of main outcome measure(s). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If there were no co‐interventions, or if they were similar between the index and control groups. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The review author determines if the compliance with the interventions is acceptable, based on the reported intensity, duration, number, and frequency of sessions for both the index intervention and control intervention(s). For example, physiotherapy treatment is usually administered for several sessions; therefore, it is necessary to assess how many sessions each participant attended. For single‐session interventions (e.g. surgery), this item is irrelevant. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Timing of outcome assessment should be identical for all intervention groups and for all primary outcome measures. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other types of biases. For example:<br/> • When the outcome measures were not valid. There should be evidence from a previous or present scientific study that the primary outcome can be considered valid in the context of the present. </p> <p>• Industry‐sponsored trials. The conflict of interest (COI) statement should explicitly state that the researchers have had full possession of the trial process from planning to reporting without funders with potential COI having any possibility to interfere in the process. If, for example, the statistical analyses have been done by a funder with a potential COI, usually 'unsure' is scored. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>Published by <a href="./references#CD013581-bbs2-0105" title="FurlanAD , MalmivaaraA , ChouR , MaherCG , DeyoRA , SchoeneM , et al. Editorial Board of the Cochrane Back and Neck Group. 2015 Updated method guideline for systematic reviews in the Cochrane Back and Neck Group. Spine2015;40(21):1660‐73. [DOI: 10.1097/BRS.0000000000001061; PUBMED: 26208232] ">Furlan 2015</a>; these instructions were adapted from <a href="./references#CD013581-bbs2-0133" title="vanTulderM , FurlanA , BombardierC , BouterL . Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine2003;28(12):1290‐9. ">van Tulder 2003</a>, <a href="./references#CD013581-bbs2-0098" title="BoutronI , MoherD , TugwellP , GiraudeauB , PoiraudeauS , NizardR , et al. A checklist to evaluate a report of a non pharmacological trial (CLEAR NPT) was developed using consensus. Journal of Clinical Epidemiology2005;58:1233‐40. ">Boutron 2005</a>, and the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013581-bbs2-0111" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Criteria for a judgement of 'yes' for the sources of risk of bias</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013581/full#CD013581-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013581-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">NSAIDs versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain Intensity on 100‐mm VAS. Follow‐up ≤ 3 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>815</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.29 [‐10.98, ‐3.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Disability (RMDQ 0 to 24). Follow‐up ≤ 3 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.02 [‐2.89, ‐1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Proportion of participants experiencing global improvement. Follow‐up ≤ 3 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.12, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Proportion of participants experiencing adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.63, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">NSAIDs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013581/references#CD013581-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013581-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Selective COX‐2 inhibitors versus non‐selective NSAIDs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in pain intensity from baseline on 100 mm VAS. Follow‐up ≤ 3 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.60 [‐9.23, 4.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion of patients experiencing adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.63, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Proportion of patients experiencing gastrointestinal adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.33, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Selective COX‐2 inhibitors versus non‐selective NSAIDs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013581/references#CD013581-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013581-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">NSAIDs versus paracetamol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mean difference in pain intensity on various scales. Follow‐up ≤ 3 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.35, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion of participants experiencing adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">NSAIDs versus paracetamol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013581/references#CD013581-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013581-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">NSAIDs versus other drug treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Proportion of participants experiencing global improvement. Follow‐up ≤ 3 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.81, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion of participants experiencing adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">NSAIDs versus other drug treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013581/references#CD013581-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013581-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">NSAIDs versus non‐drug treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain Intensity on 100‐mm VAS. Follow‐up ≤ 3 weeks. <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 NSAIDs versus spinal manipulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion of participants experiencing global improvement. Follow‐up ≤ 3 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 NSAIDs versus spinal manipulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Proportion of participants experiencing adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 NSAIDs versus spinal manipulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">NSAIDs versus non‐drug treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013581/references#CD013581-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013581&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013581-note-0010">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013581-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013581-note-0008">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013581-note-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD013581-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013581-note-0009">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD013581-note-0004">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD013581-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD013581-note-0003">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013581-note-0019">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013581-note-0002">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013581\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013581\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013581\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013581"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013581\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013581\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013581\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013581\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013581\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013581"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013581\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013581\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013581\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013581"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013581\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013581\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013581\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013581"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013581&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013581';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013581/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013581/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013581%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715514598"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013581/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715514602"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013581/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d88f4cd7d9374',t:'MTc0MDcxNTUxNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 